

JENNIFER SUSAN SMITH

Curriculum Vitae

PERSONAL

University of North Carolina • Gillings School of Global Public Health
Department of Epidemiology
Campus Box #7435, Chapel Hill, NC 27599
(919) 966 7450 • (919) 593 4091 • JenniferS@unc.edu
<http://www.unc.edu/~jsssmith/>

EDUCATION

PhD	2000	Johns Hopkins University , Baltimore, Maryland School of Hygiene and Public Health Department of Epidemiology Division of Infectious Diseases
MPH	1995	Johns Hopkins University , Baltimore, Maryland Department of Population Dynamics
BA	1991	Amherst College , Amherst, Massachusetts Major in Chemistry and in French 1987, Junior Year Study Abroad Program University of York , York, England Langwith College

PROFESSIONAL EXPERIENCE

2013-present	Associate Professor , Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, North Carolina
2009-2012	Research Associate Professor , Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, North Carolina
2004-2009	Research Assistant Professor , Department of Epidemiology, School of Public Health, University of North Carolina at Chapel Hill, North Carolina
2003	Epidemiologist , Reproductive Health and Research (RHR) Division, World Health Organization, Geneva, Switzerland
1997 to 2003	Epidemiologist, Visiting Scientist , Unit of Field and Intervention Studies, International Agency for Research on Cancer, Lyon, France
1992 to 1997	Family Health International (FHI) Fellow , Research Division, Office of Population, United States Agency for International Development, Washington, D.C.
1996	Research Assistant , Collaborative Cervical Cancer Screening Project, University of Zimbabwe and Johns Hopkins Program in International Education for Gynecology and Obstetrics, Baltimore, Maryland
1995	Fellow , The Population Council, Bangkok, Thailand Research Assistant , Collaborative STD Control Project, Moi

- University and
Johns Hopkins University, Eldoret, Kenya
- 1991 to 1992** **Thomas J. Watson Fellow**, Senegal, la Côte d'Ivoire, Ghana, Togo and Cameroon (O.R.S.T.O.M., Yaoundé); Centre d'Etudes et de Recherches sur les Populations Africaines et Asiatiques, Paris, France
- 1990 to 1991** **Intern**, Hampshire Scientific Research Institute, Alexandria, Virginia
Intern, World Health Organization, Geneva, Switzerland

HONORS

John E. Larsh, Jr. Award, for student mentorship, UNC Gillings School of Global Public Health, 2015
Lineberger Comprehensive Cancer Center Population Sciences Research Award, 2004
Elion Research Award, International Herpes Management Forum, 2002
Jean Coombs Award, Epidemiology Department, Johns Hopkins University, 1999
Chateaubriand Fellowship Recipient, French Embassy, 1998
Delta Omega National Public Health Honors Society, 1995
Jacob Javitz Graduate Fellowship recipient, The United States Department of Education, 1994
Samuel Houston Citizenship Award, 1991
Johnson Fellowship for Social Service Work, 1991
Harvard Traveller's Club Award, 1990
Sigma Xi Scientific Honors Society, 1987

MEMBERSHIPS

UNC/North Carolina Mentor, UNC Cancer Control Education Program, 2011- present
Full Member, UNC Lineberger Comprehensive Cancer Center, University of North Carolina, 2004-present
Member, Center for AIDS Research, University of North Carolina, 2004-present
Member, Center for Women's Health Research, University of North Carolina, 2004-present
Member, North Carolina Public Health Association, 2011-present
Member, Virology in Progress, University of North Carolina, 2006-present

International

Member, International Union Against Sexually Transmitted Infections, North American Branch, 2007-present
Member, Eurogin, 2000-present
Member, European Association for Cancer Research, 1997-present
Member, International Papillomavirus Society, 1996-present
Partner, Cancer Control P.L.A.N.E.T. (Plan, Link, Act, Network with Evidence-based Tools), a Web portal designed to assist in the planning and implementation of evidence-based cancer prevention and control programs, 2013
Honorary President, Sciences TV Au Féminin, Paris, France, 2004-2008

BIBLIOGRAPHY

Book Chapters

1. Lörincz AT, **Smith JS** Sexually transmissible viral pathogens: The human papillomaviruses and herpes viruses. In: Lörincz AT, ed. *Nucleic Acid Testing for Human Disease*. Boca Raton, FL: CRC Press, Taylor & Francis Group; 2006: 243-273.
2. Christine C. Ginocchio, Patti E. Gravitt, and **Jennifer S. Smith**, Human Papillomaviruses, In: Jorgensen JH, and Pfaller, M., ed. *Manual of Clinical Microbiology*. Washington, DC: ASM Press; 2015: 1783-1802.

In press

1. Ting J[±], **Smith JS**, Hudgens M, Psioda M, Kwatampora J, Chitwa M, Patel S, Gakure H, Kimani J, Schoenbach V, Mugo N, Myers ER Impact of uncertainty in relative test performance between cytology, physician-, and self-collected high-risk HPV testing on estimated screening efficiency among high-risk women in Kenya: a simulation. 2014 submission. *Cancer Causes and Control* (20 pages)
2. Burger-Calderon R, **Smith JS**, Ramsey KJ and Webster-Cyriaque J. The association between the history of HIV diagnosis and oral health. 2016 submission. *Journal of Dental Research* (20 pages).

[±] Indicates a graduate or post-graduate primary advisee at UNC

* Indicates a graduate or post-graduate student (non-primary)

Refereed

1. Johnson DC, Lhaki P, Bhatta MP, Kempf MC, **Smith JS**, Bhattarai P, Aryal S, Chamot E, Regmi K, Vermund SH, Shrestha S. Spousal migration and human papillomavirus infection among women in rural western Nepal. *Int Health*. 2016 Apr 4. pii: ihw015. [Epub ahead of print] PMID: 27048288.
2. Moore KR*, **Smith JS**, Cole SR, Schoenbach VJ, Schlusser K, Gaydos CA, Baird DD. Herpes Simplex Virus Type 2 Seroprevalence and Ultrasound-Diagnosed Uterine Fibroids in a Large Population of Young African-American Women. *Am J Epidemiol*. 2016 May 8. pii: kwv313. [Epub ahead of print] PMID:27188945.
3. Johnson DC, Lhaki P, Bhatta MP, Kempf MC, **Smith JS**, Bhattarai P, Aryal S, Chamot E, Regmi K, Vermund SH, Shrestha S. Spousal migration and human papillomavirus infection among women in rural western Nepal. *International health*. 2016. Epub 2016/04/07. PubMed PMID: 27048288.
4. Michelow P, Sherrin A, Rossouw L, Mohaleamolla S, Evans D, Swarts A, Rakhombe N, **Smith JS**, Firnhaber C. Performance of the Cellslide® automated liquid-based cytology system among HIV-positive women with very high cervical abnormality rates. *Afr J Lab Med*. 2016; 5(1), Art. #278, 6 pages.
5. Senkomago V[±], Des Marais AC, Rahangdale L, Vibat CR, Erlander MG, **Smith JS**. Comparison of urine specimen collection times and testing fractions for the detection of high-risk human papillomavirus and high-grade cervical precancer. *J Clin Virol*. 2016 Jan;74:26-31. PMID:26655264.

6. Firnhaber C, Goeieman B, Faesen M, Levin S, Williams S, Rameotshela S, Swarts A, Michelow P, Omar T, Williamson AL, Allan B, Schnippel K, **Smith JS**. Prospective One Year Follow Up of HIV Infected Women Screened for Cervical Cancer Using Visual Inspection with Acetic Acid, Cytology and Human Papillomavirus Testing in Johannesburg South Africa. *PLoS One*. 2016 Jan 5;11(1):e0144905. PMID: 26730710.
7. Lince-Deroche N, Phiri J, Michelow P, **Smith JS**, Firnhaber C; Costs and cost effectiveness of three approaches for cervical cancer screening among HIV-positive women in Johannesburg, South Africa, 2015, Nov; 10(11). *Plos One*. 10(11): e0141969. PMID: 26559487.
8. Colombara DV*, Manhart LE, Carter JJ, Hawes SE, Weiss NS, Hughes JP, Barnett MJ, Goodman GE, Qiao YL, **Smith JS**, Galloway DA Prior Human Polyomavirus and Papillomavirus Infection and Incident Lung Cancer: A Nested Case-Control Study. *Cancer Causes Control*. 2015 Dec;26(12):1835-44. doi: 10.1007/s10552-015-0676-3. Epub 2015 Sep 28. PMID: 26415892
9. Wysham WZ, Campbell S, Garcia K, **Smith J**, Rahangdale L. Predictors of Follow-Up in Women with Cervical Intraepithelial Neoplasia 2-3. *The Journal of reproductive medicine*. 2015;60(11-12):507-12. Epub 2016/01/19. PubMed PMID: 26775459.
10. Boggan JC, Walmer DK, Henderson G, Chakhtoura N, McCarthy SH, Beauvais HJ, **Smith JS**. Vaginal self-sampling for human papillomavirus infection as a primary cervical cancer screening tool in a Haitian population, *Sexually Transmitted Diseases*, 2015 Nov;42(11):655-9. PMID: 26462192.
11. McCullough LE*, Miller EM, Wang Q, Li JY, Liu L, Li H, Zhang J, **Smith JS**. Cross-sectional associations between body size, circulating sex-steroid hormones and IGF components among healthy Chinese women. *Plos One*. 2015 Sep 9;10(9). PMID: 26352264.
12. Demment MM, Peters K, Dykens JA, Dozier A, Nawaz H, McIntosh S, **Smith JS**, Sy A, Irwin T, Fogg TT, Khaliq M, Blumenfeld R, Massoudi M, De Ver Dye T. *PLoS One*. Developing the Evidence Base to Inform Best Practice: A Scoping Study of Breast and Cervical Cancer Reviews in Low- and Middle-Income Countries. 2015 Sep 1;10(9):e0134618. PMID: 26325181.
13. Ting J[±], **Smith JS**, Myers ER. Cost-Effectiveness of High-Risk Human Papillomavirus Testing With Messenger RNA Versus DNA Under United States Guidelines for Cervical Cancer Screening. *J Low Genit Tract Dis*. 2015 Jul 29. PMID: 26225945
14. Wang Q, Liu L, Li H, McCullough L*, Qi Y, Li J, Zhang J, Miller E, Yang C, **Smith JS** Genetic and Dietary Determinants of Insulin-like Growth Factor (IGF)-1 and IGF Binding Protein (BP)-3 Levels among Chinese women, *PlosOne*. 2014 Oct 6;9(10). PMID: 25285521
15. Vielot N[±], Hudgens MG, Mugo N, Chitwa M, Kimani J, **Smith J**. The Role of Chlamydia trachomatis in High-Risk Human Papillomavirus Persistence Among Female Sex Workers in Nairobi, Kenya. *Sex Transm Dis*. 2015 Jun;42(6):305-11. PMID: 25970306
16. Sivasubramaniam PG, Zhang BL, Zhang Q, **Smith JS**, Zhang B, Tang ZH, Chen GJ, Xie XM, Xu XZ, Yang HJ, He JJ, Li H, Li JY, Fan JH, Qiao YL. Breast Cancer Disparities: A Multicenter Comparison of Tumor Diagnosis, Characteristics, and

Surgical Treatment in China and the U.S. *Oncologist*. 2015 Aug 3. 2014-0290. PMID: 26240131

17. Meyerson BE, Zimet GD, Multani G, Levell C, Lawrence CA, **Smith JS**. Increasing Efforts to Reduce Cervical Cancer Through State-Level Comprehensive Cancer Control Planning. *Cancer Prev Res (Phila)*. *Cancer Prev Res (Phila)*. 2015 Jul;8(7):636-41. PMID: 25943743.
18. Zhao YQ, Chang IJ, Zhao FH, Hu SY, **Smith JS**, Zhang X, Li SM, Bai P, Zhang WH, Qiao YL. Distribution of cervical intraepithelial neoplasia on the cervix in Chinese women: pooled analysis of 19 population based screening studies. *BMC Cancer*. 2015 Jun 27;15:485. doi: 10.1186/s12885-015-1494-4. PMID: 26122004
19. Hirth JM, Rahman M, **Smith JS**, Berenson AB. Regional variations in HPV vaccination among 9-17 year old adolescent females from the BRFSS, 2008-2010. *Hum Vaccin Immunother*. 2014;10(12):3475-83. PMID: 25668660.
20. Meyerson BE, Lawrence CA, **Smith JS**. Attend to the “small p” stuff: State policy issues affecting cervical cancer efforts. *OJOG*. June 2014;4(8):455-61.
21. Moore KR[±], Cole SR, Dittmer DP, Schoenbach VJ, **Smith JS**, Baird DD. Self-Reported Reproductive Tract Infections and Ultrasound Diagnosed Uterine Fibroids in African-American Women. *J Womens Health (Larchmt)*. 2015 Apr 22. [Epub ahead of print] PubMed PMID: 25901468.
22. Senkomago V[±], Backes DM[±], Hudgens MG, Poole C, Agot K, Moses S, Snijders PJ, Meijer CJ, Hesselink AT, Schlecht NF, Bailey RC, **Smith JS**. Acquisition and persistence of human papillomavirus 16 (HPV-16) and HPV-18 among men with high-HPV viral load infections in a circumcision trial in Kisumu, Kenya. *J Infect Dis*. 2015 Mar 1;211(5):811-20. PMID: 25261492. PMCID:PMC: 4402376
23. Firnhaber C, Mao L*, Levin S, Faesen M, Lewis DA, Goeieman BJ, Swarts AJ, Rakhombe N, Michelow PM, Williams S, **Smith JS**. Evaluation of a cervicography-based program to ensure quality of visual inspection of the cervix in HIV-infected women in Johannesburg, South Africa. *J Low Genit Tract Dis*. 2015 Jan;19(1):7-11. PMID: 24914887, PMCID: PMC4272220
24. Zhang HY, Fei MD, Jiang Y, Fei QY, Qian H, Xu L, Jin YN, Jiang CQ, Li HX, Tiggelaar SM*, **Smith JS**, Sahasrabudde VV, Qiao YL. The diversity of human papillomavirus infection among human immunodeficiency virus-infected women in Yunnan, China. *Journal of Virology*. 2014 Dec 7;11(1):202. PMID: 25481842, PMCID: PMC4279793
25. McKinnon LR, Nyanga M, Kim CJ, Izulla P, Kwatampora J, Kimani M, Shahabi K, Mugo N, **Smith JS**, Anzala AO, Kimani J, Kaul R. Early HIV-1 infection is associated with reduced frequencies of cervical Th17 cells, *J Acquir Immune Defic Syndr*. 2015 Jan 1; 68(1): 6-12. PMID: 25296095.
26. Galbraith KV, Gilkey MB, **Smith JS**, Richman AR*, Barclay L, Brewer NT. Perceptions of mailed HPV self-testing among women at higher risk for cervical cancer. *Journal of Community Health*. 2014;39(5):849-56. PMID: 25120228, PMCID: PMC4316669
27. Gomih Alakija A[±], Ting J[±], Mugo N, Kwatampora J, Getman D, Chitwa M, Patel S, Gokhale M, Kimani J, Behets FS, **Smith JS**. Clinical characteristics associated with Mycoplasma genitalium among female sex workers in Nairobi, Kenya. *J Clin Microbiol*. 2014 Oct;52(10):3660-6. PMID: 25100823, PMCID: PMC4187795

28. Ting J[±], Rositch AF[±], Taylor S, Rahangdale L, Soeters HM, Sun X, **Smith JS**. Worldwide incidence of cervical lesions: a systematic review and meta-analysis. *Epidemiol Infect.* 2015 Jan;143(2):225-41. PMID: 24877975.
29. Johnson DC, Bhatta MP, **Smith JS**, Kempf MC, Broker TR, Vermund SH, Chamot E, Aryal S, Lhaki P, Shrestha S. Assessment of High-Risk Human Papillomavirus Infections Using Clinician- and Self-Collected Cervical Sampling Methods in Rural Women from Far Western Nepal. *PLoS One.* 2014 Jun 30;9(6). PMID: 24978811, PMCID: PMC4076302
30. Offutt-Powell TN[±], Ojha RP, Brinkman TM, Tota JE, Jackson BE, Singh KP, **Smith JS**. Inequalities in vaccination coverage for young females whose parents are informal caregivers. *Hum Vaccin Immunother.* 2014 May 8;10(8):2454-9. PMID: 24809973.
31. Reiter PL*, Brewer NT, Gilkey MB, Katz ML, Paskett ED, **Smith JS**. Early Adoption of HPV Vaccine among Hispanic Adolescent Males in the United States. *Cancer.* 2014 Oct 15;120(20):3200-7. PMID: 24948439, PMCID: PMC4321105
32. Vidal AC*, **Smith JS**, Iversen E, Valea F, Gradison M, Yarnall K, Ford A, Overcash F, Grant K, Murphy SK, Hoyo C. HPV genotypes and cervical intraepithelial neoplasia in a multiethnic cohort in Southeastern U.S.A. *Cancer Causes Control.* 2014 Aug;25(8):1055-62. PMID: 24928693, PMCID: PMC4082644
33. Hong JN, Berggren EK, Campbell SL, **Smith JS**, Rahangdale L. Abnormal cervical cancer screening in pregnancy and spontaneous preterm birth. *Paediatric & Perinatal Epi.* 2014 Jul;28(4):297-301. PMID: 24891016.
34. **Smith JS**. Prevalence of human papillomavirus infection in adolescent girls before reported sexual debut. *J Infect Dis* 2014 Sep 15;210(6):837-45. PMID: 24740632.
35. Moss JL, Feld AL, O'Malley B, Entzel P, **Smith JS**, Gilkey MB, & Brewer NT. Opportunities for increasing human papillomavirus vaccine provision in school health centers. *Journal of School Health.* 2014 Jun;84(6):370-78. PMID: 24749919, PMCID: PMC4325977
36. Brewer NT, Chung JK*, Baker HM, Rothholz MC, **Smith JS**. Pharmacist authority to provide HPV vaccine: Novel partners in cervical cancer prevention. *Gynecol Oncol.* 2014 Mar;132 Suppl 1:S3-8. PMID: 24361732
37. Kester LM, Shedd-Steele RB, Dotson-Roberts CA, **Smith, JS**, Zimet GD. The effects of a brief educational intervention on human papillomavirus knowledge and intention to initiate HPV vaccination in 18-26 year old young adults. *Gynecol Oncol.* 2014 Mar;132 Suppl 1:S9-12. PMID: 24384459
38. Rahangdale L, Lippmann QK, Garcia K, Budwit D, **Smith JS**, Van Le L. Topical 5-fluorouracil for treatment of cervical intraepithelial neoplasia 2: A randomized controlled trial. *Am J Obstet Gynecol.* 2014 Apr;210(4):314.e1-8. PMID: 24384495
39. Reiter PL*, Gupta K, Brewer NT, Gilkey MB, Katz ML, Paskett ED, **Smith JS**. Provider-Verified HPV Vaccine Coverage among a National Sample of Hispanic Adolescent Females Cancer. *Epidemiol Biomarkers Prev.* 2014 May;23(5):742-54. PMID: 24633142, PMCID: PMC4018302
40. Westreich D, Jamal N, **Smith JS**, Schulze D, Williams S, Michelow P, Levin S, Firnhaber C. Injectable and oral contraception and the incidence and progression of cervical disease in HIV-infected women in South Africa. *Contraception* 2014 Apr; 89(4):286-91. PMID: 24485095, PMCID: PMC3972316

41. Fernandez ME, Savas L, Lipizzi E, **Smith JS**, Vernon S. Cervical cancer control for Hispanic women in Texas: Strategies from research and practice. *Gynecol Oncol.* 2014 Mar;132S1:S26-32. PMID: 24398135, PMCID: PMC4053183
42. Rositch AF[±], Soeters HM, Offutt-Powell TN, Wheeler BS, Taylor SM, **Smith JS**. The incidence of human papillomavirus infection following treatment for cervical neoplasia: A systematic review. *Gynecol Oncol.* 2014 Mar;132(3):767-79. PMID: 24398135
43. Wordlaw-Stinson L, Jones S, Little S, Fish L, Vidal A, **Smith JS**, Hoyo C, Moorman PG. Challenges and recommendations to recruiting women who do not adhere to follow-up gynecological care. *Open J Prev Med.* 2014 Mar 20;4(3):123-8. PMID: 24991485, PMCID: PMC4075769
44. Zhang SK, Ci PW, Velicer C, Kang LN, Liu B, Cui JF, Chen F, Zhang X, Chang IJ*, Roberts CC, **Smith JS**, Chen W, Qiao YL. Comparison of HPV genotypes and viral load between different sites of genital tract: The significance for cervical cancer screening. *Cancer Epidemiol.* 2014 Apr;38(2):168-73. PMID: 24522235
45. Petrick JL, Wyss AB, Butler AM, Cummings C, Sun X, Poole C, **Smith JS**, Olshan AF. Prevalence of human papillomavirus among esophageal squamous cell carcinoma cases: Systematic review and meta-analysis. *Br J Cancer.* 2014 Apr 29; 110(9):2369-77. PMID: 24619077, PMCID: PMC4007246
46. **Smith JS**, Crosby R. Mapping new territory: Emerging challenges in cervical cancer prevention. *Gynecol Oncol.* 2014 Mar;132 Suppl 1:S1-2. PMID: 24630575
47. Stolka K, Ndom P, Hemingway-Foday J, Iriondo-Perez J, Miley W, Labo N, Stella J, Abassora M, Woelk G, Ryder R, Whitby D, **Smith JS**. Risk factors for Kaposi's sarcoma among HIV-positive individuals in a case control study in Cameroon. *Cancer Epidemiol.* 2014 Apr;38(2):137-43. PMID: 24631417, PMCID: PMC4075442
48. Mahomed K, Evans D, Sauls C, Richter K, **Smith JS**, Firnhaber C. Human papillomavirus (HPV) testing on self-collected specimens: perceptions among HIV positive women attending rural and urban clinics in South Africa. *Pan Afr Med J.* 2014 Mar 11;17:189. PMID: 25396015, PMCID: PMC4228994
49. Fish LJ, Moorman PG, Wordlaw-Stintson L, Vidal A, **Smith JS**, Hoyo C. Factors associated with adherence to follow-up colposcopy. *Am J Health Educ.* 2013 June; 44(6):293-8. PMID: 24991653, PMCID: PMC4075768
50. Husaiyin S; Niyazi M; Wang LH; Wang JJ; Wang JB; Simayi A; Wang L; Ainiwaer Z; Ma CH; **Smith JS**. HPV infection among uygur women in a rural area of Hetian prefecture, Xinjiang Uygur autonomous region, China. *Biomed Environ Sci.* 2013 Nov;26(11):934-936. PMID: 24331541
51. Bleecker E, Koehler E, **Smith JS**, Budwit D, Rahangdale L. Outcomes After management of young women with cervical intraepithelial neoplasia 2 with 6 month observation protocol. *J of Lower Gen Tract Dis.* 2014 Jan;18(1):46-9. PMID: 23959297
52. Vidal AC, Henry NM, Murphy SK, Oneko O, Nye M, Bartlett JA, Overcash F, Huang Z, Wang F, Mlay P, Obure J, **Smith JS**, Vasquez B, Swai B, Hernandez B, Hoyo C. PEG1/MEST and IGF2 DNA methylation in CIN and in cervical cancer. *Clin Transl Oncol.* 2014 Mar;16(3):266-72. PMID: 23775149, PMCID: PMC3924020
53. **Smith JS**. A shorter interval between menarche and first sexual intercourse is associated with increased risk of high-grade cervical disease. *Evid Based Nurs.* 2014

Jan;17(1):6-7. PMID: 23708400

54. Chang IJ*, Huang R, He W, Zhang SK, Wang SM, Zhao FH, **Smith JS**, Qiao YL. Effect of an educational intervention of HPV knowledge and vaccine attitudes among urban employed women and female undergraduate students in China: A cross-sectional study. *BMC Public Health*. 2013 Oct 2;13:916. PMID: 24088392, PMCID: PMC3852612
55. Vanderpool RC, Jones MG, Stradtman LR, **Smith JS**, Crosby RA. Self-collecting a cervico-vaginal specimen for cervical cancer screening: An exploratory study of acceptability among medically underserved women in rural Appalachia. *Gynecol Oncol*. 2014 Mar; 132 Suppl 1:S21-5. PMID: 24125753
56. Ludema C*, Cole SR, Poole C, **Smith JS**, Schoenbach VJ, Wilhelmus K. Association between unprotected ultraviolet radiation exposure and recurrence of ocular herpes simplex virus. *Am J Epidemiol*. 2014 Jan 15;179(2): 208-15. PMID: 24142918, PMCID: PMC3873108
57. Rositch AF[±], Mao L*, Hudgens M, Moses S, Agot K, Backes DM[±], Nyagaya E, Snijders PJ, Meijer CJ, Bailey RC, **Smith JS**. Risk of HIV acquisition among circumcised and uncircumcised young men with penile HPV infection. *AIDS*. 2014 Mar 13;28(5):745-52. PMID: 24149088, PMCID: PMC4074250
58. Denslow SA[±], Rositch AF[±], Ting J[±], Firnhaber C, **Smith JS**. Incidence and progression of cervical lesions in women with HIV: a systematic global review. *Int J STD AIDS*. 2014 Mar;25(3):163-77. PMID: 24216030
59. Moore KR[±], **Smith JS**, Laughlin-Tommaso SK, Baird DD. Cervical neoplasia-related factors and decreased prevalence of uterine fibroids among a cohort of African American women. *Fertil Steril*. 2014 Jan;101(1):208-14. PMID: 24268705, PMCID: PMC3880401
60. Soh J, Rositch AF[±], Koutsky L, Guthrie BL, Choi RY, Bosire R, Gatuguta A, **Smith JS**, Kiarie JN, Lohman-Payne B, Farquhar C. Individual and partner risk factors associated with abnormal cervical cytology among women in HIV-discordant relationships. *Int J STD AIDS*. 2014 Apr;25(5):315-24. PMID: 24047885, PMCID: PMC3968186
61. Ting J[±], Mugo N, Kwatampora J, Hill C, Chitwa M, Patel S, Gakure H, Kimani J, Schoenbach VJ, Poole C, **Smith JS**. High-risk human papillomavirus messenger RNA testing in physician- and self-collected specimens for cervical lesion detection in high-risk women, Kenya. *Sex Transm Dis*. 2013 Jul;40(7):584-9. PMID: 23965776
62. Ginocchio CC, Chapin K, **Smith JS**, Snook J, Hill CS, Aslanzadeh J, Gaydos CA. Response to Implications of Trichomonas vaginalis Nucleic Acid Amplification Testing on Medical Training and Practice. *J Clin Microbiol*. 2013 May; 51(5):1651. PMID: 23592857
63. **Smith JS**, Brewer NT, Saslow D, Alexander K, Chernofsky MR, Crosby R, Derting L, Devlin L, Dunton CJ, Engle J, Fernandez M, Fouad M, Huh W, Kinney W, Pierce J, Rios E, Rothholz MC, Shlay JC, Shedd-Steele R, Vernon S, Walker J, Wynn T, Zimet GD, and Casey BR. Recommendations for a National Agenda to Substantially Reduce Cervical Cancer. *Causes and Control*. 2013 Aug;24(8):1583-93. PMID: 23828553
64. Sudenga SL*, Rositch AF[±], Otieno WA, **Smith JS**. Knowledge, Attitudes, Practices,

and Perceived Risk of Cervical Cancer Among Kenyan Women: A brief report. *Int J Gynecol Cancer*. 2013 Jun;23(5):895-9. PMID: 23694983, PMCID: PMC3662490

65. Rositch AF[±], Gravitt, PE and **Smith JS**. Growing evidence that HPV infection is associated with an increase in HIV acquisition: Exploring the issue of HPV vaccination. *Sex Transm Infect*. 2013 Aug;89(5):357. PMID: 23858496
66. Wang SM, Colombara D*, Shi JF, Zhao FH, Li J, Chen F, Chen W, Li SM, Zhang X, Pan QJ, Belinson JL, **Smith JS**, Qiao YL. Six-year regression and progression of cervical lesions of different human papillomavirus viral loads in varied histological diagnoses. *Int J Gynecol Cancer*. 2013 May;23(4):716-23. PMID: 23455757, PMCID: PMC3636161
67. Patel SJ*, Mugo NR, Cohen C, Ting J[±], Nguti R, Kwantampora J, Waweru W, Patnaik P[±], Donders GG, Kenney DL, Kimani J, Kiviat NB, **Smith JS**. Multiple human papillomavirus infections and HIV seropositivity as risk factors for abnormal cervical cytology among female sex workers in Nairobi. *Int J STD AIDS*. 2013 Mar;24(3):221-5. PMID: 23535357
68. Wu EQ, Liu B, Cui JF, Chen W, Wang JB, Lu L, Niyazi M, Zhao C, Ren SD, Li CQ, Gong XZ, **Smith JS**, Belinson JL, Liaw KL, Velicer C, Qiao YL. Prevalence of type-specific human papillomavirus and pap results in Chinese women: a multi-center, population-based cross-sectional study. *Cancer Causes Control*. 2013 Apr;24(4):795-803. PMID: 23397310
69. **Smith JS**, Weiderpass E. Real-world effectiveness of population-based roll-out of human papillomavirus vaccination against rates of genital warts. *J Natl Cancer Inst*. 2013 Apr 3;105(7):449-51. PMID: 23486549
70. Nye MD, Hoyo C, Huang Z, Vidal AC, Wang F, Overcash F, **Smith JS**, Vasquez B, Hernandez B, Swai B, Oneko O, Mlay P, Obure J, Bartlett JA, Murphy SK. Associations between methylation of paternally expressed gene 3 (PEG3), cervical intraepithelial neoplasia and invasive cervical cancer. *Plos One*. 2013;8(2):e56325. PMID: 23418553, PMCID: PMC3571954
71. Firnhaber C, Mayisela N, Mao L*, Williams S, Swarts A, Faesen M, Levin A, Michelow P, Omar T, Hudgens MG, Williamson AL, Allan B, Lewis DA, **Smith JS**. Validation of cervical cancer screening methods in HIV positive women from Johannesburg South Africa. *PLOS One*. 2013;8(1):e53494. PMID: 23326441, PMCID: PMC3543403
72. Hayes KA*, Entzel P, Berger W, Caskey RN, Shlay JC, Stubbs BW, **Smith JS**, Brewer NT. Early lessons learned from extramural vaccination programs that offer HPV vaccine in US schools. *J Sch Health*. 2013 Feb;83(2):119-26. PMID: 23331272
73. Backes DM[±], Snijders PJ, Hudgens MG, Bailey RC, Bogaarts M, Agot K, Agingu W, Moses S, Meijer CJM, **Smith JS**. Sexual behaviour and less frequent bathing are associated with higher human papillomavirus incidence in a cohort study of uncircumcised Kenyan men. *Sex Transm Infect*. 2013 Mar;89(2):148-55. PMID: 22941862, PMCID: PMC3700546
74. Steben M, Saraiya M, Jeronimo J, Markowitz L, Wittet S, **Smith JS**, Jensen C, Ogilvie G, Franceschi S, LaMontagne DS. Upgrading public health programs for HPV prevention and control is possible in low and middle income countries. *Vaccine*. 2012 Nov 20;30 (Suppl 5):F183-91. PMID: 23199962

75. Rositch AF[±], Koshiol J*, Hudgens MG, Poole C, Backes DM[±], Pimenta JM, Franco EL, **Smith JS**. Patterns of persistent genital human papillomavirus infection among women worldwide: A literature review and meta-analysis. *Int J Cancer*. 2013 Sept 15;133(6):1271-85. PMID: 22961444, PMCID: PMC3707974
76. Atashili J*, Miller WC, **Smith JS**, Ndumbe PM, Ikomey GM, Eron J, Rinas AC, Myers E, Adimora AA. Age trends in the prevalence of cervical squamous intraepithelial lesions among HIV-positive women in Cameroon: a cross-sectional study. *BMC Res Notes*. 2012 Oct 29;5(1):590. PMID: 23106940, PMCID: PMC3505154
77. Houlihan CF, Larke NL, Watson-Jones D, Smith-McCune KK, Shiboski S, Gravitt PE, **Smith JS**, Kuhn L, Wang C, Hayes R. HPV infection and increased risk of HIV acquisition. A systematic review and meta-analysis. *AIDS*. 2012 Nov 13;26(17):2211-2. PMID: 22874522, PMCID: PMC3831022
78. Ji J*, Sun HK, **Smith JS**, Wang H, Esser MT, Hu S, Pretorius RG, Chen W, Belinson JL, Qiao YL. Seroprevalence of human papillomavirus types 6, 11, 16 and 18 in Chinese women. *BMC Infect Dis*. 2012 Jun 20;12:137. PMID: 22715915, PMCID: PMC3482566
79. Monsonogo J, Zerat L, Syrjänen K, Zerat JC, **Smith JS**, Halfon P. Prevalence of genotype-specific HPV infection among women in France: Implications for screening and vaccination. *Gynecol Obstet Fertil*. 2013 May;41(5):305-13. PMID: 23647817
80. Song PI*, Liang H, Wei WQ, Jiang YQ, **Smith JS**, Qiao YL. The clinical profile of Merkel cell carcinoma in mainland China. *Int J Dermatol*. 2012 Sep;51(9):1054-9. PMID: 22909358, PMCID: PMC3732818
81. Firnhaber C, Westreich D, Schulz D, Williams S, Siminya M, Michelow P, Levin S, Faesen M, **Smith JS**. Highly active antiretroviral therapy and cervical dysplasia in HIV- positive women in South Africa. *J Int AIDS Soc*. 2012 Jun 7;15(2):17382. PMID: 22713259, PMCID: PMC3499783
82. Rositch AF[±], Gatuguta A, Choi RY, Guthrie BL, Bosire R, Kiarie JN, **Smith JS**, Farquhar C. Knowledge and acceptability of pap smears, self-sampling and HPV vaccination among adult women in Kenya. *PloS One*. 2012;7(7):e40766. PMID: 22808257, PMCID: PMC3393696
83. Kruzikas D, **Smith JS**, Binstock M, Harley C, Buzinec P. Costs associated with management of cervical human papillomavirus-related conditions. *Cancer Epidemiol Biomarkers Prev*. 2012 Sep;21(9):1469-78. PMID: 22781027
84. Ginocchio CC, Chapin K, **Smith JS**, Aslanzadeh J, Snook J, Hill CS, Gaydos CA. Prevalence of *Trichomonas vaginalis* and co-infection with *Chlamydia trachomatis* and *Neisseria gonorrhoea* in the United States as determined by the APTIMA *Trichomonas vaginalis* nucleic acid amplification assay. *J Clin Microbiology*. 2012 Aug;50(8):2601-8. PMID: 22622447, PMCID: PMC3647950
85. Tiggelaar SM*, Lin MJ*, Viscidi RP, Ji J*, **Smith JS**. Age-specific human papillomavirus antibody and DNA prevalence: a global review. *J Adolesc Health*. 2012 Feb;50(2):110-31. PMID: 22265107
86. Zhao FH, Lewkowitz AK*, Hu SY, Chen F, Li LY, Zhang QM, Wu RF, Li CQ, Wei LH, Xu AD, Zhang WH, Pan QJ, Zhang X, Belinson JL, Sellors JW, **Smith JS**, Qiao YL, Franceschi S. Prevalence of human papillomavirus and cervical intraepithelial

- neoplasia in China: A pooled analysis of 17 population-based studies. *Int J Cancer*. 2012 Dec 15;131(12):2929-38. PMID: 22488743, PMCID: PMC3435460
87. Hariri S, Steinau M, Rinas A, Gargano JW, Ludema C*, Unger ER, Carter AL, Grant KL, Bamberg M, McDermott JE, Markowitz LE, Brewer N, **Smith JS**. HPV genotypes in high grade cervical lesions and invasive cervical carcinoma as detected by two commercial DNA assays, North Carolina, 2001-2006. *PLoS One*. 2012;7(3):e34044. PMID: 22479516, PMCID: PMC3315505
 88. Rositch AF[±], Hudgens MG, Backes DM[±], Moses S, Agot K, Nyagaya E, Snijders PJF, Meijer CJLM, Bailey RC, **Smith JS**. Vaccine-relevant HPV infections and future acquisition of high-risk HPV types in men. *J Infect Dis*. 2012 Sep 1;20(5):669-77. PMID: 22711906, PMCID: PMC3491740
 89. Zhang HV, Tiggelaar SM*, Sahasrabudhe VV, **Smith JS**, Jiang C-Q, Mei R-B, Wang XG, Li ZA, Qiao YL. HPV prevalence and cervical intraepithelial neoplasia among HIV- infected women in Yunnan Province, China: A pilot study. *Asian Pac J Cancer Prev*. 2012;13(1):91-6. PMID: 22502720, PMCID: PMC3809115
 90. Denslow SA[±], Knop G, Klaus C, Brewer N, Rao C, **Smith JS**. Burden of invasive cervical cancer in North Carolina. *Prev Med*. 2012 Mar-Apr;54(3-4):270-6. PMID: 22342290
 91. Monsonogo J, Hudgens M, Zerat L, Zerat JC, Syrjanen K, **Smith JS**. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study). *Gynecol Oncol*. 2012 Apr;125(1):175-80. PMID: 22233689
 92. Mingo AM*, Panozzo CA, DiAngi YT, **Smith JS**, Steenhoff AP, Ramogola-Masire D, Brewer NT. Cervical cancer awareness and screening in Botswana. *Int J Gynecol Cancer*. 2012 May;22(4):638-44. PMID: 22367370
 93. Zhao FH, Lewkowitz AK*, Chen F, Lin MJ*, Hu SY, Zhang X, Pan QJ, Niyazi M, Li CQ, Li SM, **Smith JS**, Belinson JL, Qiao YL, Castle PE. Pooled analysis of self-sampling HPV DNA test as a cervical cancer primary screening method *J Natl Cancer Inst*. 2012 Feb 8;104(3):178-88. PMID: 22271765, PMCID: PMC3274511
 94. Tiggelaar SM*, Lin MJ*, Ji J*, Visciti R, **Smith JS**. Age-specific human papillomavirus antibody and deoxyribonucleic acid prevalence: a global review. *J Adolesc Health*. 2012 Feb;50(2):110-31. PMID: 22265107, PMCID: PMC3572199
 95. Rositch AF[±], Poole C, Hudgens MG, Agot K, Nyagaya E, Moses S, Snijders PJ, Meijer CJ, Bailey RC, **Smith JS**. Multiple human papillomavirus infections and type competition in men. *J Infect Dis*. 2012 Jan 1;205(1):72-81. PMID: 22058418, PMCID: PMC3242748
 96. Atashili J*, Adimora AA, Ndumbe PM, Ikomey GM, Rinas AC, Myers E, Eron J, **Smith JS**, Miller WC. High prevalence of cervical squamous intraepithelial lesions in women on antiretroviral therapy in Cameroon: Is targeted screening feasible? *Cancer Epidemiol*. 2012 Jun;36(3):263-9. PMID: 22047636, PMCID: PMC3288586
 97. Backes DM[±], Bleeker MC, Meijer CJ, Hudgens MG, Agot K, Bailey RC, Ndinya-Achola JO, Hayombe J, Hogewoning CJ, Moses S, Snijders PJ, **Smith JS**. Male circumcision is associated with a lower prevalence of human papillomavirus-associated penile lesions among Kenyan men. *Int J Cancer*. 2012 Apr 15;130(8):1888-97. PMID: 21618520, PMCID: PMC3262059

98. **Smith JS**, Belinson JL, Lewkowitz AK*, Ji J*, Hu SY, Chen W, Esser M, Taddeo FJ, Pretorius RG, Qiao YL. Population-based human papillomavirus 16/18/6/11 DNA and seropositivity in Chinese women. *Int J Cancer*. 2012 Sept 15;131(6):1388-95. PMID: 22120998
99. Vidal AC, Murphy SK, Hernandez BY, Vasquez B, Bartlett JA, Oneko O, Mlay P, Obure J, Overcash F, **Smith JS**, van der Kolk M, Hoyo C. Distribution of HPV genotypes in cervical intraepithelial lesions and cervical cancer in Tanzanian women. *Infect Agent Cancer*. 2011 Nov 14;6(1):20. PMID: 22081870, PMCID: PMC3262746
100. Louie KS, Castellsague X, de Sanjose S, Herrero R, Meijer CJ, Shah K, Munoz N, Bosch FX; **International Agency for Research on Cancer Multicenter Cervical Cancer Study Group**. Smoking and passive smoking in cervical cancer risk: pooled analysis of couples from the IARC multicentric case-control studies. *Cancer Epidemiol Biomarkers Prev*. 2011 Jul;20(7):1379-90. PMID: 21610224
101. **Smith JS**, Brewer NT, Chang Y*, Liddon N, Guerry S, Pettigrew E*, Markowitz LE, Gottlieb SL. Acceptability of school requirements for human papillomavirus vaccine. *Hum Vaccine*. 2011 Sep;7(9):952-7. PMID: 22024912, PMCID: PMC3360068
102. Robitz R, Gottlieb SL, De Rosa CJ, Guerry SL, Liddon N, Zaidi A, Walker S, **Smith JS**, Brewer NT, Markowitz LE. Parent attitudes about school requirements for human papillomavirus vaccine in high-risk communities of Los Angeles, California. *Cancer Epidemiol Biomarkers Prev*. 2011 Jul;20(7):1421-9. PMID: 21551243
103. **Smith JS**, Gilbert PA, Melendy A[±], Rana RK, Pimenta JM. Age-specific prevalence of human papillomavirus infection in males: A global review. *J Adolesc Health*. 2011 Jun;48(6):540-52. PMID: 21575812
104. Denslow SA[±], Westreich DJ, Firnhaber C, Michelow P, Williams S, **Smith JS**. Bacterial vaginosis as a risk factor for high-grade cervical lesions and cancer in HIV-seropositive women. *Int J Gynaecol Obstet*. 2011 Sep;114(3):273-7. PMID: 21683359
105. Atashili J*, **Smith JS**, Adimora AA, Eron J, Miller WC, Myers E. Potential impact of antiretroviral therapy and screening on cervical cancer mortality in HIV-positive women in Sub-Saharan Africa: a simulation. *PLoS One*. 2011 Apr 4;6(4):e18527. PMID: 21483701, PMCID: PMC3070738
106. Mitchell CE*, Hudgens MG, King CC, Cu-Uvin S, Lo Y, Rompalo A, Sobel J, **Smith JS**. Discrete-time semi-Markov modeling of HPV persistence. *Stat Med*. 2011 Jul 30;30(17):2160-70. PMID: 21538985, PMCID: PMC3129469
107. Schuler CL[±], Reiter PL*, **Smith JS**, Brewer NT. Human papillomavirus vaccine and behavioural disinhibition. *Sex Transm Infect*. 2011 Jun;87(4):349-53. PMID: 21357601, PMCID: PMC3098300
108. Hoots BE[±], Hudgens MG, Cole SR, King CC, Klein RS, Mayer KH, Rompalo AM, Sobel JD, Jamieson DJ, **Smith JS**. Lack of association of herpes simplex virus type 2 seropositivity with the progression of HIV infection in the HERS Cohort. *Am J Epidemiol*. 2011 Apr 1;173(7):837-44. PMID: 21372062, PMCID: PMC3105280
109. Richman AR*, Brewer NT, Liebman AK*, Rinas AC, **Smith JS**. Optimising human papillomavirus self-testing for high risk women. *Sex Transm Infect*. 2011 Mar;87(2):118-22. PMID: 21115503
110. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjanen K, Halfon P, Ruiz F, **Smith JS**. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-

based cytology in primary cervical cancer screening: The FASE study. *Int J Cancer*. 2011 Aug 1;129(3):691-701. PMID: 20941740

111. Brewer NT, Gottlieb SL, Reiter PL*, McRee AL, Liddon N, Markowitz L, **Smith JS**. Longitudinal predictors of human papillomavirus vaccine initiation among adolescent girls in a high-risk geographic area. *Sex Transm Dis*. 2011 Mar;38(3):197-204. PMID: 20838362, PMCID: PMC3025264
112. Gilbert P*, Brewer NT, Reiter PL*, Ng TW, **Smith JS**. HPV vaccine acceptability in heterosexual, gay, and bisexual men. *Am J Mens Health*. 2011 Jul; 5(4):297-305. PMID: 20798149, PMCID: PMC3083462
113. Salz T*, Gottlieb SL, **Smith JS**, Brewer NT. The association between cervical abnormalities and attitudes toward cervical cancer prevention. *J Womens Health (Larchmt)*. 2010 Nov;19(11):2011-6. PMID: 20846019
114. **Smith JS**, Van Damme K, Randrianjafisamindrakotroka N, Ting J[±], Rabozakandraina T, Randrianasolo BS, Raharinivo M, Zanasaotra S, Hobbs M, Rinas A, Cohen M, Gravitt P, Behets F. Human papillomavirus and cervical neoplasia among female sex workers in Madagascar. *Int J Gynecol Cancer*. 2010 Dec;20(9):1593-6. PMID: 21370602
115. Ting J[±], Kruzikas DT, **Smith JS**. A global review of age-specific and overall prevalence of cervical lesions. *Int J Gynecol Cancer*. 2010 Oct;20(7):1244-49. PMID: 21495248
116. Cates JR, Shafer A, Carpentier FD, Reiter PL*, Brewer NT, McRee AL, **Smith JS**. How parents hear about human papillomavirus vaccine: implications for uptake. *J Adolesc Health*. 2010 Sep;47(3):305-8. PMID: 20708571
117. Becker-Dreps S*, Otieno WA, Brewer NT, Agot K, **Smith JS**. HPV vaccine acceptability among Kenyan women. *Vaccine*. 2010 Jul 12;28(31):4864-7. PMID: 20566394, PMCID: PMC2906622
118. Reiter PL*, Brewer NT, and **Smith JS**. Human papillomavirus knowledge and vaccine acceptability among a national sample of heterosexual men. *Sex Transm Infect*. 2010 Jun;86(3):241-6. PMID: 19951936, PMCID: PMC4028225
119. Reiter PL*, Cates JR, McRee AL, Gottlieb SL, Shafer A, **Smith JS**, Brewer NT. Statewide HPV vaccine initiation among adolescent females in North Carolina. *Sex Transm Dis*. 2010 Sep;37(9):549-56. PMID: 20414146, PMCID: PMC4018582
120. **Smith JS**, Moses S, Hudgens MG, Parker CB, Agot K, Maclean I, Ndinya-Achola JO, Snijders PJ, Meijer CJ, Bailey RC. Increased risk of HIV acquisition among Kenyan men with human papillomavirus infection. *J Infect Dis*. 2010 Jun 1; 201(11):1677-85. PMID: 20415595, PMCID: PMC2873838
121. Vaccarella S, Franceschi S, Snijders PJ, Herrero R, Meijer CJ, Plummer M, **IARC HPV Prevalence Surveys Study Group**. Concurrent infection with multiple human papillomavirus types: Pooled analysis of the IARC HPV Prevalence Surveys. *Cancer Epidemiol Biomarkers Prev*. 2010 Feb;19(2):503-10. PMID: 20142247
122. Belinson JL, Hu S, Niyazi, M, Pretorius RG, Wang H, Wen C, **Smith JS**, Li J, Taddeo FJ, Burchette RJ, Qiao YL. Prevalence of type-specific human papillomavirus in endocervical, upper and lower vaginal, perineal and vaginal self-collected specimens: implications for vaginal self-collection. *Int J Cancer*. 2010 Sep 1;127(5):1151-7. PMID: 20039323

123. Reed AC*, Reiter PL*, **Smith JS**, Palefsky JM, Brewer NT. Gay and bisexual men's willingness to receive anal Papanicolaou testing. *Am J Public Health*. 2010 Jun;100(6):1123-9. PMID: 20395576, PMCID: PMC2866587
124. Reed AC*, Brewer NT, **Smith JS**, Palefsky JM, Reiter PL*. Author reply: Gay and bisexual men's willingness to receive anal Papanicolaou testing. *Am J Public Health*. 2010 Jun;100(6):1123-9. PMID: 20395576
125. Shrestha S, Sudenga SL, **Smith JS**, Bachmann LH, Wilson CM, Kempf MC. The impact of highly active antiretroviral therapy on prevalence and incidence of cervical human papillomavirus infections in HIV-positive adolescents. *BMC Infect Dis*. 2010 Oct 14;10:295. PMID: 20946655, PMCID: PMC2965148
126. Garland SM, **Smith JS**. Human papillomavirus vaccines: current status and future prospects. *Drugs*. 2010 Jun 18;70(9):1079-98. *Invited paper* PMID: 20518577
127. Firnhaber C, Van Le H*, Pettifor A, Schulze D, Michelow P, Sanne IM, Lewis DA, Williamson AL, Allan B, Williams S, Rinas A, Levin S, **Smith JS**. Association between cervical dysplasia and human papillomavirus in HIV seropositive women from Johannesburg South Africa. *Cancer Causes Control* 2010 Mar;21(3):433-43. PMID: 19949850, PMCID: PMC2835728
128. Arama V, Cercel AS, Vladareanu R, Mihai C, Mihailescu R, Rankin J, Goschin S, Filipescu A, Rafila A, Arama S, Hristea A, Malkin JE, Pimenta JM, **Smith JS**. Type-specific herpes simplex virus-1 and herpes simplex virus-2 seroprevalence in Romania: comparison of prevalence and risk factors in women and men. *Int J Infect Dis*. 2010 Sep;14 (Suppl 3): e25-31. PMID: 20106695
129. McRee AL*, Brewer NT, Reiter PL*, Gottlieb S, **Smith JS**. The Carolina HPV immunization attitudes and beliefs scale (CHIAS): scale development and association with intentions to vaccinate. *Sex Transm Dis*. 2010 Apr;37(4):234-239. PMID: 19940807
130. Reiter PL*, Brewer NT, McRee AL*, Gilbert P, **Smith JS**. Acceptability of HPV vaccine among a national sample of gay and bisexual men. *Sex Transm Dis*. 2010 Mar;37(3):197-203. PMID: 20118831, PMCID: PMC4018212
131. **Smith JS**, Backes DM[±], Hudgens MG, Bailey RC, Veronesi G, Bogaarts M, Agot K, Ndinya-Achola JO, Maclean I, Agingu W, Meijer CJ, Moses S, Snijders PJ. Prevalence and risk factors of human papillomavirus infection by penile site in uncircumcised Kenyan men. *Int J Cancer*. 2010 Jan 15;126(2):572-7. PMID: 19626601
132. Louie KS, de Sanjosé S, Diaz M, Castellsagué X, Herrero R, Meijer CJ, Shah K, Franceschi S, Muñoz N, Bosch FX, **International Agency for Research on Cancer Multicenter Cervical Cancer Study Group**. Early age at first sexual intercourse and early pregnancy are risk factors for cervical cancer in developing countries. *Br J Cancer*. 2009 Apr 7;100(7):1191-7. PMID: 19277042, PMCID: PMC2670004
133. Franceschi S, Plummer M, Clifford G, de Sanjose S, Bosch X, Herrero R, Muñoz N, Vaccarella S, International Agency for Research on Cancer Multicentric Cervical Cancer Study Groups, **International Agency for Research on Cancer Human Papillomavirus Prevalence Surveys Study Group**. Differences in the risk of cervical cancer and human papillomavirus infection by education level. *Br J Cancer*. 2009 Sep 1;101(5):865-70. PMID: 19654578, PMCID: PMC2736843

134. Reiter PL*, Brewer NT, Gottlieb SL, McRee AL*, and **Smith JS**. How much will it hurt? HPV vaccine side effects and influence on completion of the three-dose regimen. *Vaccine*. 2009 Nov 16;27(49):6840-4. PMID: 19765398, PMCID: PMC4016947
135. Shi JF*, Belinson JL, Zhao FH, Pretorius RG, Li J, Ma JF, Chen F, Xiang W, Pan QJ, Zhang X, Zhang WH, Qiao YL, **Smith JS**. Human papillomavirus testing for cervical cancer screening: results from a 6-year prospective study in rural China. *Am J Epidemiol*. 2009 Sep 15;170(6):708-16. PMID: 19692327
136. Chen W, Zhang X, Molijn A, Jenkins D, Shi JF, Quint W, Schmidt JE, Wang P, Liu YL, Li LK, Shi H, Liu JH, Xie X, Niyazi M, Yang P, Wei LH, Li LY, Li J, Liu JF, Zhou Q, Hong Y, Li L, Li Q, Zhou HL, Bian ML, Chen J, Qiao YL, **Smith JS**. Human papillomavirus type-distribution in cervical cancer in China: the importance of HPV 16 and 18. *Cancer Causes Control*. 2009 Nov;20(9):1705-13. PMID: 19705288
137. Gottlieb SL, Brewer NT, **Smith JS**, Keating KM*, Markowitz LE. Availability of the human papillomavirus vaccine at medical practices in an area with elevated rates of cervical cancer. *J Adolesc Health*. 2009 Nov;45(5):438-45. PMID: 19837349
138. Gottlieb SL, Brewer NT, Sternberg MR, **Smith JS**, Ziarnowski K, Liddon N, Markowitz LE. Human papillomavirus vaccine initiation in an area with elevated rates of cervical cancer. *J Adolesc Health*. 2009 Nov;45(5):430-7. PMID: 19837348
139. Reiter PL*, Brewer NT, Gottlieb SL, McRee AL*, **Smith JS**. Parents' health beliefs and HPV vaccination of their adolescent daughters. *Soc Sci Med*. 2009 Aug;69(3):475-80. PMID: 19540642
140. Le HV*, Schoenbach VJ, Herrero R, Hoang Pham AT, Nguyen HT, Nguyen TT, Muñoz N, Franceschi S, Vaccarella S, Parkin MD, Snijders PJ, Morrow RA, **Smith JS**. Herpes simplex virus type-2 seropositivity among ever married women in South and north Vietnam: a population-based study. *Sex Transm Dis*. 2009 Oct;36(10):616-20. PMID: 19617867, PMCID: PMC2901908
141. Chang Y*, Brewer NT, Rinas AC, Schmitt K, **Smith JS**. Evaluating the impact of human papillomavirus vaccines. *Vaccine*. 2009;27(32):4355-62. PMID: 19515467
142. **Smith JS**, Backes DM[±], Hoots BE[±], Kurman RJ, Pimenta JM. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors. *Obstet Gynecol* 2009;113(4):917-24. PMID: 19305339
143. Backes DM[±], Kurman RJ, Pimenta JM, **Smith JS**. Systematic review of human papillomavirus prevalence in invasive penile cancer. *Cancer Causes Control*. 2009;20(4):449-57. PMID: 19082746
144. **Smith JS**, Bailey RC, Westreich DJ, Maclean I, Agot K, Ndinya-Achola JO, Hogrefe W, Morrow RA, Moses S. Herpes simplex virus type 2 antibody detection performance in Kisumu, Kenya, using the Herpesselect ELISA, Kalon ELISA, Western blot and inhibition testing. *Sex Transm Infect*. 2009 Apr;85(2): 92-6. PMID: 18955387, PMCID: PMC2857340
145. Cates JR, Brewer NT, Fazekas KI, Mitchell CE*, **Smith JS**. Racial differences in HPV knowledge, HPV vaccine acceptability, and related beliefs among rural, southern women. *J Rural Health*. 2009 Winter;25(1):93-7. PMID: 19166567, PMCID: PMC2928162
146. Hughes J*, Cates J, Liddon N, **Smith JS**, Gottlieb SL, Brewer NT. Disparities in how parents are learning about the human papillomavirus vaccine. *Cancer Epidemiol*

Biomarkers Prev. 2009 Feb;18(2):363-72. PMID: 19190161

147. Hoots BE[±], Palefsky JF, Pimenta JM, **Smith JS**. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions. *Int J Cancer.* 2009 May 15;124(10):2375-83. PMID: 19189402
148. Shi JF*, Qiao YL, **Smith JS**, Dondog B, Bao YP, Dai M, Clifford GM, Franceschi S. Epidemiology and prevention of human papillomavirus and cervical cancer in China and Mongolia. *Vaccine.* 2008 Aug 19;26(Suppl 12):M53-9. PMID: 18945414
149. Saraiya M, Watson M, Wu X, King JB, Chen VW, **Smith JS**, Giuliano AR. Incidence of in situ and invasive vulvar cancer in the US, 1998-2003. *Cancer.* 2008 Nov 15;113(10 Suppl):2865-72. PMID: 18980209
150. Garland S, Park SN, Ngan HY, Frazer I, Tay EH, Chen CJ, Bhatla N, Pitts M, Shin HR, Konno R, **Smith JS**, Pagliusi S, Park JS. The need for public education on HPV and cervical cancer prevention in Asia. Opinions of experts at the AOGIN conference. *Vaccine.* 2008 Oct 9;26(43):5435-40. PMID: 18706952
151. Moscicki AB, **Smith JS**. Issues in human papillomavirus vaccination in adolescents. *Journal of Adolescent Health.* 2008 Oct;43(Suppl 4):S1-4. PMID: 18809142
152. **Smith JS**, Kumlin U, Nyberg F, Fortes C, Zaridze D, Ahrens W, Bruske-Hohlfeld I, Constantinescu V, Ting J[±], Benhamou S, Simonato L, Boman J, Gaborieau V, Boffetta P. Benhamou S, Simonato L, Gaborieau V, Boffetta P. Lack of association between serum antibodies of Chlamydia pneumoniae infection and the risk of lung cancer. *Int J Cancer.* 2008 Nov 15;123(10):2469-71. PMID: 18720403
153. Keating K *, Brewer NT, Gottlieb SL, Liddon N, Ludema C*, **Smith JS** Potential barriers to HPV vaccine provision among medical practices in an area with high rates of cervical cancer. *J Adolesc Health.* 2008 Oct;43(Suppl 4):S61-7. PMID: 18809147
154. Belinson S*, **Smith JS**, Myers E, Olshan A, Belinson J, Pretorius R, Qiao Y, Hartmann K. Descriptive evidence that risk profiles for cervical intraepithelial neoplasia 1, 2, and 3 are unique. *Cancer Epidemiol Biomarkers Prev.* 2008 Sep;17(9):2350-5. PMID: 18768503
155. Suarez E, **Smith JS**, Bosch FX, Nieminen P, Chen CJ, Torvinen S, Demarteau N, Standaert B. Cost-effectiveness of vaccination against cervical cancer: a multi-regional analysis assessing the impact of vaccine characteristics and alternative vaccination scenarios. *Vaccine.* 2008 Sep 15;26(Suppl 5):F29-45. PMID: 18992380
156. **Smith JS**, Melendy A[±], Rana RK, Pimenta JM. Age-specific prevalence of human papillomavirus infection in females: a global review. *J Adolesc Health.* 2008 Oct;43 (Suppl 4):S5-25, S25.e1-41. PMID: 18809145
157. Ragoza R, Ferko N, Bentley J, Meijer CJ, Berkof H, Wang KL, Downs L, **Smith JS**, Franco E. Optimization of primary and secondary cervical cancer prevention strategies in an era of cervical cancer vaccination: a multi-regional health economic analysis. *Vaccine.* 2008 Sep 15;26(suppl 5):F46-58. PMID: 18992382
158. Herzog TJ, Vallerie A, **Smith JS**, Wright JD. Clinical indications for human papillomavirus vaccination. *Clinical Ovarian Cancer.* 2008;1(1):36-9.
159. **Smith JS**. Ethnic disparities in cervical cancer illness burden and subsequent care: a prospective view in managed care. *American J Manag Care.* 2008 Jun;14(6 Suppl 1):S193-9. PMID: 18611087

160. Atashili J*, Poole C, Ndumbe PM, Adimora AA, **Smith JS**. Bacterial vaginosis and HIV acquisition: a meta-analysis of published studies. *AIDS*. 2008 Jul 31;22(12):1493-501. PMID: 18614873, PMCID: PMC2788489
161. Myers E, Huh WK, Wright JD, **Smith JS**. The current and future role of screening in the era of HPV vaccination. *Gynecol Oncol*. 2008 May;109(2 Suppl):S31-9. PMID: 18482556
162. Herzog TJ, Huh WK, Downs LS, **Smith JS**, Monk BJ. Initial lessons learned in HPV vaccination. *Gynecol Oncol*. 2008 May;109(2 Suppl): S4-11. PMID: 18482557
163. Wright TC, Huh WK, Monk BJ, **Smith JS**, Ault K, Herzog T. Age considerations when vaccinating against HPV. *Gynecol Oncol*. 2008 May;109(2 Suppl):S40-7. PMID: 18482558
164. Downs L, **Smith JS**, Denny L, Parham GP, Scarinci I, Flowers L. The disparity of cervical cancer in diverse populations. *Gynecol Oncol*. 2008 May;109(2 Suppl):S22-30. PMID: 18482555
165. Koshiol J*, Lindsay L, Pimenta JM, Poole C, Jenkins D, **Smith JS**. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. *Am J Epidemiol*. 2008 Jul 15;168(2):123-37. PMID: 18483125, PMCID: PMC2878094
166. Papadogeorgakis H, Caroni C, Katsambas A, Pimenta JM, Avdeliodi C, Kotrotsou T, Frangoulis E, **Smith JS**. Herpes simplex virus seroprevalence among children, adolescents and adults in Greece. *Int J STD AIDS*. 2008 Apr;19(4): 272-78. PMID: 18482949
167. Fazekas KI*, Brewer NT, **Smith JS**. HPV vaccine acceptability in a rural Southern area. *J Womens Health (Larchmt)*. 2008 May;17(4):539-48. PMID: 18370586
168. Sperber NR*, Brewer NT, **Smith JS**. Influence of parent characteristics and disease outcome framing on HPV vaccine acceptability among rural, Southern women. *Cancer Causes Control*. 2008 Feb;19(1):115-8. PMID: 17952620
169. De Vuyst H, Lillo F, Broutet N, **Smith JS**. HIV, human papillomavirus, and cervical neoplasia and cancer in the era of highly active antiretroviral therapy. *Eur J Cancer Prev*. 2008 Nov;17(6):545-54. PMID: 18941376
170. Kinoshita-Moleka R*, **Smith JS**, Atibu J, Tshefu A, Hemingway-Foday J, Hobbs M, Bartz J, Koch MA, Rimoin AW, Ryder RW. Low prevalence of HIV and other selected sexually transmitted infections in 2004 in pregnant women from Kinshasa, the Democratic Republic of the Congo. *Epidemiol Infect*. 2008 Sep;136(9):1290-6. PMID: 18028581, PMCID: PMC2870915
171. Bao YP*, Li N, **Smith JS**, Qiao YL. Human papillomavirus type distribution in women from Asia: a meta-analysis. *Int J Gynecol Cancer*. 2008 Jan-Feb;18(1):71-9. PMID: 17466054
172. **Smith JS**, Qiao Y. HPV type-specific prevalence in invasive cervical cancer in China: an update of the global literature. *HPV Today*. 2007;13:4.
173. Chen XS, Yin YP, Chen LP, Yu YH, Wei WH, Thuy NT, **Smith JS**. Herpes simplex virus 2 infection in women attending an antenatal clinic in Fuzhou, China. *Sex Transm Infect*. 2007 Aug;83(5):369-70. PMID: 17475682, PMCID: PMC2659029
174. Franceschi S, **Smith JS**, van den Brule A, Herrero R, Arslan A, Anh PT, Bosch FX,

- Hieu NT, Matos E, Posso H, Qiao YL, Shin HR, Sukvirach S, Thomas JO, Snijders PJ, Muñoz N, Meijer CJ. Cervical infection with *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in women from ten areas in four continents: a cross-sectional study. *Sex Transm Dis*. 2007 Aug;34(8):563-9. PMID: 17417132
175. Pretorius RG, Bao YP, Belinson JL, Burchette RJ, **Smith JS**, Qiao YL. Inappropriate gold standard bias in cervical cancer screening studies. *Int J Cancer*. 2007 Nov 15;121(10):2218-24. PMID: 17657715
176. Patnaik P[±], R. Herrero, Morrow RA, Muñoz N, Bosch FX, Bayo S, El Gueddari B, Caceres E, Chichareon SB, Castellsaque X, Meijer CJ, Snijders PJ, **Smith JS**. Type-specific seroprevalence of herpes simplex virus type 2 and associated risk factors in middle-aged women from 6 countries: the IARC multicentric study. *Sex Transm Dis*. 2007 Dec;34(12):1019-24. PMID: 18080353
177. **Smith JS**, Moses S, Hudgens MG, Agot K, Franceschi S, Maclean IW, Ndinya-Achola JO, Parker CB, Pugh N, Meijer CJ, Snijders PJ, Bailey RC. Human papillomavirus detection by penile site in young men from Kenya. *Sex Transm Dis*. 2007 Nov;34(11):928-34. PMID: 17621251, PMCID: PMC2519883
178. **Smith JS**, Lindsay L, Hoots B[±], Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. *Int J Cancer*. 2007 Aug 1;121(3):621-32. PMID: 17405118
179. Akers AY*, Newmann SJ, **Smith JS**. Factors underlying disparities in cervical cancer incidence, screening, and treatment in the United States. *Curr Probl Cancer*. 2007 May-Jun;31(3):157-81. PMID: 17543946
180. Vaccarella S, Herrero R, Dai M, Snijders PJ, Meijer CJ, Thomas JO, Hoang Anh PT, Ferreccio C, Matos E, Posso H, de Sanjosé S, Shin HR, Sukvirach S, Lazcano-Ponce E, Ronco G, Rajkumar R, Qiao YL, Muñoz N, Franceschi S., the **International Agency for Research on Cancer Multicenter Cervical Cancer Study Group**. Reproductive factors, oral contraceptive use, and human papillomavirus infection: pooled analysis of the IARC HPV prevalence surveys. *Cancer Epidemiol Biomarkers Prev*. 2006 Nov;15(11):2148-53. PMID: 17119039
181. Franceschi S, Herrero R, Clifford GM, Snijders PJ, Arslan A, Anh PT, Bosch FX, Ferreccio C, Hieu NT, Lazcano-Ponce E, Matos E, Molano M, Qiao YL, Rajkumar R, Ronco G, de Sanjosé S, Shin HR, Sukvirach S, Thomas JO, Meijer CJ, Muñoz N, **International Agency for Research on Cancer Multicenter Cervical Cancer Study Group**. Variations in the age-specific curves of human papillomavirus prevalence in women worldwide. *Int J Cancer*. 2006 Dec 1;119(11):2677-84. PMID: 16991121
182. Koshiol J*, Schroeder J, Jamieson DJ, Marshall SW, Duerr A, Heilig CM, Shah KV, Klein RS, Cu-Uvin S, Schuman S, Celentano D, **Smith JS**. Time to clearance of human papillomavirus infection by type in human immunodeficiency virus serostatus. *Int J Cancer*. 2006 Oct 1;119(7):1623-29. PMID: 16646070
183. Koshiol J*, Schroeder J, Jamieson DJ, Marshall SW, Duerr A, Heilig CM, Shah K, Klein RS, Cu-Uvin S, Schuman S, Celentano D, **Smith JS**. Smoking and time to clearance of human papillomavirus infection in HIV-seropositive and HIV-seronegative women. *Am J Epidemiol*. 2006 Jul 15;164(2):176-83. PMID: 16775041
184. **Smith JS**, Rosińska M, Trzcińska A, Pimenta JM, Litwińska B, Siennicka J. Type

specific seroprevalence of HSV-1 and HSV-2 in four geographical regions of Poland. *Sex Transm Infect.* 2006 Apr;82(2):159-63. PMID: 16581747, PMCID: PMC2564693

185. Castellsagué X, Díaz M, de Sanjosé S, Muñoz N, Herrero R, Franceschi S, Peeling RW, Ashley R, **Smith JS**, Snijders PJ, Meijer CJ, Bosch FX, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Worldwide human papillomavirus etiology of cervical adenocarcinoma and its cofactors: implications for screening and prevention. *J Natl Cancer Inst.* 2006 Mar 1;98(5):303-15. PMID: 16507827
186. Vaccarella S, Franceschi S, Herrero R, Muñoz N, Snijders PJ, Clifford GM, **Smith JS**, Lazcano-Ponce E, Sukvirach S, Shin HR, de Sanjosé S, Molano M, Matos E, Ferreccio C, Anh PT, Thomas JO, Meijer CM, IARC Prevalence Surveys Study Group. Sexual behavior, condom use and human papillomavirus: pooled analysis of the IARC human papillomavirus prevalence surveys. *Cancer Epidemiol Biomarkers Prev.* 2006 Feb;15(2):326-33. PMID: 16492924
187. Aguilar LV, Lazcano-Ponce E, Vaccarella S, Cruz A, Hernández P, **Smith JS**, Muñoz N, Kornegay JR, Hernández M, Franceschi S. Human papillomavirus in men: comparison of different genital sites. *Sex Transm Infect.* 2006 Feb; 82(1):31-3. PMID: 16461598, PMCID: PMC2563819
188. Escobar PF, Rojas-Espaillet L, Tisci S, Enerson C, Brainard J, De La Rosa V, Romero W, **Smith JS**, Tresser NJ, Feldchtein FI, Rojas LB, Belinson JL. Optical coherence tomography as a diagnostic adjunct to visual inspection and colposcopy for preinvasive and invasive cervical cancer of the uterine cervix. *Int J Gynecol Cancer.* 2006 Sep-Oct;16(5):1815-22. PMID: 17009977
189. Hernández-Girón C*, **Smith JS**, Lazcano-Ponce E, Hernández-Avila M, Salmerón J. Prevalencia de infección por virus de papiloma humano (VPH) de alto riesgo y factores asociados en embarazadas derechohabientes del IMSS en el estado de Morelos. *Salud Pública Mex.* 2005 Nov-Dec;47(6):423-9. PMID: 16983987
190. Hernandez-Giron C*, **Smith JS**, Lorincz A, Lazcano E, Hernández-Avila, Salmeron J. High-risk human papillomavirus detection and related risk factors among pregnant and nonpregnant women in Mexico. *Sex Transm Dis.* 2005 Oct;32(10):613-8. PMID: 16205302
191. Clifford GM, Gallus S, Herrero R, Muñoz N, Snijders PJ, Vaccarella S, Anh PT, Ferreccio C, Hieu NT, Matos E, Molano M, Rajkumar R, Ronco G, de Sanjosé S, Shin HR, Sukvirach S, Thomas JO, Tunsakul S, Meijer CJ, Franceschi S, **IARC HPV Prevalence Surveys Study Group**. Worldwide distribution of human papillomavirus types in cytologically normal women in the International Agency for Research on Cancer HPV prevalence surveys: a pooled analysis. *Lancet.* 2005 Sep 17-23;366(9490):991-8. PMID: 16168781
192. Castellsagué X, Peeling RW, Franceschi S, de Sanjosé S, **Smith JS**, Albero G, Díaz M, Herrero R, Muñoz N, Bosch FX, IARC Multicenter Cervical Cancer Study Group. Chlamydia trachomatis infection in female partners of circumcised and uncircumcised adult men. *Am J Epidemiol.* 2005 Nov 1;162(9):907-16. PMID: 16177149
193. Clifford GM, Rana RK, Franceschi S, **Smith JS**, Gough G, Pimenta JM. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. *Cancer Epidemiol Biomarkers Prev.* 2005 Mar;14(5):1157-64. PMID: 15894666

194. Golijow CD*, Pérez LO, **Smith JS**, Abba MC. Human papillomavirus DNA detection and typing in male urine samples from a high-risk population from Argentina. *J Virol Methods*. 2005 Mar;124(1-2):217-20. PMID: 15664072
195. Golijow CD*, Abba MC, Mourón SA, Laguens RM, Dulout FN, **Smith JS**. Chlamydia trachomatis and human papillomavirus infections in cervical disease in Argentine women. *Gynecol Oncol*. 2005 Jan;96(1):181-6. PMID: 15589598
196. Drain PK*, **Smith JS**, Hughes JP, Halperin DT, Holmes KK. Correlates of national HIV seroprevalence: an ecologic analysis of 122 developing countries *J Acquir Immune Defic Syndr*. 2004 Apr;35(4):407-20. PMID: 15097158
197. **Smith JS**, Bosetti C, Muñoz N, Herrero R, Bosch FX, Eluf-Neto J, Meijer CJ, Van Den Brule AJ, Francheschi S, Peeling RW, IARC multicentric case-control study. Chlamydia trachomatis and invasive cervical cancer: a pooled analysis of the IARC multicentric case-control study. *Int J Cancer*. 2004 Sep 1;111(3):431-9. PMID: 15221973
198. Ashley-Morrow R, Nollkamper J, Robinson NJ, Bishop N, **Smith JS**. Performance of focus ELISA tests for herpes simplex virus type 1 (HSV-1) and HSV-2 antibodies among women in ten diverse geographical locations. *Clin Microbiol Infect*. 2004 Jun;10(6):530-6. PMID: 15191381
199. Thomas JO, Herrero R Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A, Oladepo O, **Smith JS**, Arslan A, Muñoz N, Snijders PJ, Meijer CJ, Franceschi S. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. *Br J Cancer*. 2004 Feb;90(3):638-45. PMID: 14760378, PMCID: PMC2409602
200. Vineis P, Alavanja, Buffler P, Fontham E, Franceschi S, Gao YT, Gupta PC, Hackshaw A, Matos E, Samet J, Sitas F, **Smith JS**, Stayner L, Straif K, Thun MJ, Wichmann HE, Wu AH, Zaridze D, Peto R, Doll R. Tobacco and cancer: recent epidemiological evidence. *J Natl Cancer Inst*. 2004 Jan 21;96(2):99-106. PMID: 14734699
201. Plummer M, Herrero R, Franceschi S, Meijer CJ, Snijders P, Bosch FX, de Sanjosé S, Muñoz N, **IARC Multi-centre Cervical Cancer Study Group**. Smoking and cervical cancer: pooled analysis of the IARC multi-centric case-control study. *Cancer Causes Control*. 2003 Nov;14(9):805-14. PMID: 14682438
202. Rodriguez AC, Castle PE, **Smith JS**, Bratti C, Hildesheim A, Schiffman M, Viscidi R, Burk RD, Ashley RL, Castellsagué X, Herrero R. A population based study of herpes simplex virus 2 seroprevalence in rural Costa Rica. *Sex Transm Infect*. 2003 Dec;79(6):460-5. PMID: 14663121, PMCID: PMC1744764
203. Altieri A, Franceschi S, Ferlay J, **Smith JS**, La Vecchia C. Epidemiology and aetiology of gestational trophoblastic diseases. *Lancet Oncol*. 2003 Nov;4(11):670-82. PMID: 14602247
204. Conde-González CJ, Lazcano-Ponce E, Hernández-Girón C, Juárez-Figueroa L, **Smith JS**, Hernández-Avila M. Seroprevalencia de la infección por el virus herpes simplex tipo 2 en tres grupos poblacionales de la Ciudad de Mexico. *Salud Publica Mex*. 2003;45(Suppl 5):S608-16. PMID: 14974271
205. **Smith JS**, Green J, Berrington de Gonzalez A, Appleby P, Peto J, Plummer M, Franceschi S, Beral V. Cervical cancer and use of hormonal contraceptives: a systematic review. *Lancet*. 2003 Apr 5;36(9364):1159-67. PMID: 12686037

206. Green J, Berrington de Gonzalez A, **Smith JS**, Franceschi S, Appleby P, Plummer M, Beral V. Human papillomavirus infection and use of oral contraceptives. *Br J Cancer*. 2003 Jun 2;88(1):1713-20. PMID: 12771986, PMCID: PMC2377143
207. Clifford GM, **Smith JS**, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. *Br J Cancer*. 2003 Jul 7;89(1):101-5. PMID: 12838308, PMCID: PMC2394204
208. Sukvirach S, **Smith JS**, Tunsakul S, Muñoz N, Kesararat V, Opasatian O, Chichareon S, Kaenploy V, Ashley R, Meijer CJ, Snijders PJ, Coursaget P, Franceschi S, Herrero R. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand. *J Infect Dis*. 2003 Apr 15;187(8):1246-56. PMID: 12696004
209. Pham TH, Nguyen TH, Herrero R, Vaccarella S, **Smith JS**, Nguyen Thuy TT, Nguyen HN, Nguyen BD, Ashley R, Snijders PJ, Meijer CJ, Muñoz N, Parkin DM, Franceschi S. Human papillomavirus infection among women in South and North Vietnam. *Int J Cancer*. 2003 Mar 20;104(2):213-20. PMID: 12569577
210. Clifford GM, **Smith JS**, Plummer M, Muñoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. *Br J Cancer*. 2003 Jan 13;88(1):63-73. PMID: 12556961, PMCID: PMC2376782
211. Shin HR, Lee DH, Herrero R, **Smith JS**, Vaccarella S, Hong SH, Jung KY, Kim HH, Park UD, Cha HS, Park S, Touzé A, Muñoz N, Snijders PJ, Meijer CJ, Coursaget P, Franceschi S. Prevalence of human papillomavirus infection in women in Busan, South Korea. *Int J Cancer*. 2003 Jan 20;103(3):413-21. PMID: 12471626
212. Muñoz N, Bosch FX, de Sanjosé S, Herrero R, Castellsagué X, Shah KV, Snijders PJ, Meijer CJ, **International Agency for Research on Cancer Multicenter Cervical Cancer Study Group**. Epidemiologic classification of human papillomavirus types associated with cervical cancer. *N Engl J Med*. 2003 Feb 6;348(6):518-27. PMID: 12571259
213. **Smith JS**, Herrero R, Bosetti C, Muñoz N, Bosch FX, Eluf-Neto J, Castellsagué X, Meijer CJ, Van den Brule AJ, Franceschi S, Ashley R, IARC Multicentric Cervical Cancer Study Group. Herpes simplex virus-2 as a human papillomavirus cofactor in the etiology of invasive cervical cancer. *J Natl Cancer Inst*. 2002 Nov 6;94(21):1604-13. PMID: 12419786
214. **Smith JS**, Robinson NJ. Age-specific prevalence of infection with herpes simplex virus types 2 and 1: a global review *J Infect Dis* 2002; 186 (Suppl 1): S3-28. PMID: 12353183
215. **Smith JS**, Muñoz N, Herrero R, Eluf-Neto J, Ngelangel C, Franceschi S, Bosch FX, Walboomers JM, Peeling RW. Evidence for Chlamydia trachomatis as a human papillomavirus cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. *J Infect Dis*. 2002 Feb 1;185(3):324-31. PMID: 11807714
216. Muñoz N, Franceschi S, Bosetti C, Moreno V, Herrero R, **Smith JS**, Shah KV, Meijer CJ, Bosch FX, International Agency for Research on Cancer Multicentric Cervical Cancer Study Group. Role of parity and human papillomavirus in cervical cancer: the IARC multicentric case-control study. *Lancet*. 2002 Mar 30; 359(9312):1093-101. PMID: 11943256
217. Castellsagué X, Bosch FX, Muñoz N, Meijer CJ, Shah KV, de Sanjosé S, Eluf-Neto J, Ngelangel C, Chichareon S, **Smith JS**, Herrero R, Moreno V, Franceschi S,

International Agency for Research on Cancer Multicentric Cervical Cancer Study Group. Male circumcision, penile human papillomavirus infection, and cervical cancer in female partners. *N Eng J Med*. 2002 Apr 11;346(15):1105-12. PMID: 11948269

218. Franceschi S, Castellsagué X, Dal Maso L, **Smith JS**, Plummer M, Ngelangel C, Chichareon S, Eluf-Neto J, Shah KV, Snijders PJ, Meijer CJ, Bosch FX, Muñoz N. Prevalence and determinants of human papillomavirus genital infection in men. *Br J Cancer* 2002; 86: 705-11. PMID: 11875730, PMCID: PMC2375316
219. Moreno V, Bosch FX, Muñoz N, Meijer CJ, Shah KV, Walboomers JM, Herrero R, Franceschi S; **International Agency for Research on Cancer Multicentric Cervical Cancer Study Group**. Effect of oral contraceptives on risk of cervical cancer in women with human papillomavirus infection: the IARC multicentric case-control study *Lancet* 2002; 359: 1085-92 PMID: 11943255
220. **Smith JS**, Muñoz N, Franceschi S, Eluf-Neto J, Herrero R, Peeling RW. Letter concerning Anttila et al. Chlamydia trachomatis and cervical squamous cell carcinoma *JAMA* 2001; 285 (13): 1704-6 doi:10.1001/jama.285.13.1703 PMID: 11277820
221. Lazcano-Ponce E, **Smith JS**, Muñoz N, Conde-Glez CJ, Juárez-Figueroa L, Cruz A, Hernández M. High prevalence of antibodies to herpes simplex virus type 2 among middle-aged women in Mexico City, Mexico: a population-based study *Sex Transm Dis* 2001; 28: 270-6. PMID: 11354265
222. **Smith JS**, Herrero R, Erles K, Grimm D, Muñoz N, Bosch FX, Tafur L, Shah KV, Schlehofer JR. Adeno-associated virus seropositivity and HPV-induced cervical cancer in Spain and Colombia *Int J Cancer* 2001; 94: 520-6. PMID: 11745438
223. **Smith JS**, Herrero R, Muñoz N, Eluf-Neto J, Ngelangel C, Ashley RL, Bosch FX. Prevalence and risk factors for herpes simplex virus type 2 infection among middle-age women in Brazil and the Philippines *Sex Transm Dis* 2001; 28: 187-94. PMID: 11318248
224. Rolón PA, **Smith JS**, Muñoz N, Klug SJ, Herrero R, Bosch X, Llamosas F, Meijer CJ, Walboomers JM. Human papillomavirus infection and invasive cervical cancer in Paraguay *Int J Cancer* 2000; 85: 469-91. PMID: 10699919
225. **Smith JS**, Nalagoda F, Wawer MJ, Serwadda D, Sewankambo N, Konde-Lule J, Lutalo T, Li C, Gray RH. Education attainment as a predictor of HIV risk in rural Uganda: results from a population-based study *Int J STD AIDS* 1999; 10: 452-9. PMID: 10454180

Non-Refereed Publications

1. Curtis K, Bright T, and **Smith JS**, editors Recommendations for updating practices in contraceptive use: Results from a technical meeting. *Volume 1: Combined oral contraceptives, progestin-only injectables, NORPLANT(R) implants, and copper-bearing intrauterine devices*. Technical Guidance Working Group, U.S. Cooperating Agency Working Group, November 1994
2. **Smith JS**. *Maternal and child health care: An inquiry of infant weaning practices and the knowledge, attitudes, and practices of contraception in Awing, Cameroon*. Office de la Recherche Scientifique et Technique d'Outre-Mer. Paris, July 1992

Submitted for Publication

1. Wheeler BS*, Rositch AF[±], **Smith JS**. Worldwide incidence of human papillomavirus infection in women: a systematic review and meta-analysis. 2015 submission. *International Journal of Epidemiology*. (29 pages). Under revisions.
2. Hunter K Holt*, Li Zhang, Fang Hui Zhao, Shangying Hu, Lian Xue Zhao, Xun Zhang, Qin Jing Pan, Wen Hua Zhang, Jennifer S Smith, You-Lin Qiao, Evaluation of multiple primary and combination screening strategies in postmenopausal women for detection of cervical cancer in developing countries, *Int J Cancer* (13 pages).

Published Abstracts

*Indicates student collaboration

1. Busola Sanusi, Sara B Smith, Jenny S. Myers, Beth Meadows, Yinghao Pan, and **Jennifer S. Smith**. Overcoming Barriers To Adolescent Vaccination: Champions' Perspective. Poster Presentation. Eurogin 2016 Conference, June 15 - 18, 2016, Salzburg, Austria.
2. Des Marais AC, Shapiro L, Brewer NT, Barclay L, **Smith JS**. Dissemination of at-home self-collection for HPV testing: Improving access to cervical cancer screening among under-screened Latina women. Oral presentation. 143rd Annual Meeting and Expo of the American Public Health Association; Oct 31-Nov 3, 2015; Chicago, IL.
3. Des Marais AC, Shapiro L, Barclay L, **Smith JS**. Assessing self-collection for HPV testing in a high-risk Latina population. International Papillomavirus Congress; Poster presentation. September 17-21, 2015; Lisbon, Portugal.
4. Islam JY[±], Gruber JF, Lockhart A*, Kunwar M, Wilson S, Oh EY, Smith SB, **Smith JS**. Opportunities and challenges associated with administering HPV and other adolescent vaccinations within pharmacies. Poster Presentation. 30th International Papillomavirus Conference; September 17-21, 2015; Lisbon, Portugal. .
5. Dizon AM*, Di Bona V, Smith SB, Levitz LG, Ramos S, Morgan K, Kim CJ, Richter K, de Sanjose S, **Smith JS**. Adolescent providers' knowledge of human papillomavirus vaccination recommendations in five countries. Poster Presentation. 30th International Papillomavirus Conference; Lisbon, Portugal; September 17-21, 2015.
6. Vielot NA[±], Smith SB, Zimet G, McDonald MA, Ramos S, Morgan K, Kim CJ, Richter K, Peris M, Whaley KJ, **Smith JS**. Acceptance of multipurpose HPV vaccines among providers and mothers of adolescent girls: A mixed-methods study in five countries. Poster Presentation. 30th International Papillomavirus Conference; September 17-21, 2015; Lisbon, Portugal.
7. Sanusi B*, **Smith JS**, Swarts A, Faesen M, Levin S, Goeieman B, Ramotshela S, Rakhombe N, Williamson AL, Michelow P, Omar T, Hudgens M and Firnhaber C. A randomized trial comparing cervical dysplasia treatment modalities in HIV-seropositive women from Johannesburg, South Africa. Oral Presentation. HPV2015 30th International Papillomavirus Conference; September 17 - 21, 2015; Lisbon, Portugal.
8. Moore KR[±], Cole SR, Dittmer DP, Schoenbach VJ, **Smith JS**, Baird DD. Self-Reported Reproductive Tract Infections and Ultrasound Diagnosed Uterine Fibroids: Poster Presentation. Triangle Consortium for Reproductive Biology 24th Annual Meeting; March 14, 2015; Research Triangle Park, NC.
9. Moore KR[±], Cole SR, Dittmer DP, Schoenbach VJ, **Smith JS**, Baird DD. Self-Reported Reproductive Tract Infections and Ultrasound Diagnosed Uterine Fibroids: Poster Presentation, Society for Epidemiologic Research 48th Annual Meeting; June 16-19th, 2015;

- Denver, Colorado. **Accepted.**
10. Moore KR[±], Cole SR, Dittmer DP, Schoenbach VJ, **Smith JS**, Baird DD. Self-Reported Reproductive Tract Infections and Ultrasound Diagnosed Uterine Fibroids: Poster Presentation, Society for Pediatric and Perinatal Epidemiologic Research 28th Annual Meeting; June 15-16th, 2015; Denver, Colorado. **Accepted.**
 11. Des Marais AC, Shapiro L, Brewer NT, Barclay L **Smith JS**. Dissemination of at-home self-collection for HPV testing: Improving access to cervical cancer screening among under-screened Latina women. 143rd Annual Meeting and Expo of the American Public Health Association; October 31-November 3, 2015; Chicago, IL. Submitted.
 12. Vielot N[±], Hudgens MG, Mugo N, Kwatampora J, Chitwa M, Gakure H, Kimani J, **Smith J**. Infection with *C.trachomatis* increases high-risk human papillomavirus infection duration among female sex worker in Kenya. Oral presentation. EUROGIN 2015 International Multidisciplinary Congress; February 4-7, 2015; Seville, Spain.
 13. Smith SB, Landi SN, Ramos S, Morgan K, Kim CJ, Richter K, de Sanjose S, Butera N, Senkemago V, **Smith JS**. Preference for 2- compared to 3-dose HPV vaccine in a global sample of adolescent vaccine providers. Oral presentation. Eurogin conference; February 4 - 7, 2015; Sevilla, Spain.
 14. Manguro GO, Mochache VO, Adala LA, Deya RW, Mandaliya K, McClelland RS, **Smith JS**. Feasibility of self-collection and dry specimen storage for HPV mRNA testing to detect cervical lesions in high-risk women, oral presentation, Eurogin conference, Sevilla, Spain, February 4-7, 2015.
 15. Ting J[±], **Smith JS**, Myers ER. Cost-effectiveness of HPV DNA versus HPV mRNA testing under current United States guidelines for cervical cancer screening, poster presentation, Eurogin conference, Sevilla, Spain, February 4-7, 2015.
 16. Islam JY[±], Smith SB, Ramos S, Morgan K, Kim CJ, Richter K, Tuser MP, **Smith JS**. Provider insight into strategies to increase HPV vaccine uptake: a multi-site study. Poster Presentation. Eurogin; February 4 - 7, 2015; Sevilla, Spain.
 17. Reiter PL*, Brewer NT, Gilkey MB, Katz ML, Paskett ED, **Smith JS**. HPV vaccination among Hispanic females in the United States: results from the National Immunization Survey-Teen. Poster to be presented at the American Public Health Association Annual Meeting; November 2014; New Orleans, LA.
 18. Shen GC*, **Smith JS**, Qiao YL, Kang LN, Xie K, Liu GG. High striker: An examination of public hospital reform in China. Third Global Symposium on Health Systems Research; September 30-October 3, 2014; Cape Town, South Africa.
 19. Senkomago V[±], Ting J, Mugo N, Kwatampora J, Hill C, **Smith JS**. HPV-RNA Screening with Physician- and Self- Collected Samples and Co-testing with Cytology for Detection of Cervical Lesions over 24 Months in Female Sex Workers in Kenya. International Papillomavirus (IPV) Conference; August 21-25 2014; Seattle, WA.
 20. Senkomago V[±], Backes DM, Hudgens MG, Poole C, Meshnick SR, Kawango A, Moses S, Meijer CJLM, Hesselink AT, Schlecht NF, Bailey RC, Snijders PJF, **Smith JS**. HPV16 and 18 Penile Viral Load and Subsequent HPV Clearance in Uncircumcised Kenyan Men. International Papillomavirus (IPV) Conference; August 21-25 2014; Seattle, WA.
 21. Senkomago V[±], Des Marais A, Rahangdale L, Nunez ER, Muniz-Fernandez A, Vibat CR, **Smith JS**. A Comparison of Urine Collection Times for the Detection of High-Risk HPV Infection in Women. International Papillomavirus (IPV) Conference; August 21-25 2014; Seattle, WA.
 22. Johnson D, Bhatta MP, Aryal S, **Smith JS**, Kempf M-C, Broker T, Vermund S, Chamot E, Lhaki P, Shrestha S. Risk Factors Associated with Testing Positive for

- High-risk HPV and Increasing Cervical Cytology Severity. International Papillomavirus (IPV) Conference; August 21-25 2014; Seattle, WA.
23. Zhang H, Senkomago V[±], Min Y*, Chen W, Qiao Y, **Smith JS**. High-risk HPV Prevalence and Screening for the Detection of Cervical Lesions in HIV-Positive Women in Yunnan Province, China. International Papillomavirus (IPV) Conference; August 21-25 2014; Seattle, WA.
 24. Cameron JE, Rositch AF, Gilliland A, Senkomago V, Mugo N, Hagensee ME, **Smith JS**. Cervical HPV, Epstein-Barr Virus, and abnormal cytology in high-risk women from Nairobi, Kenya. International Papillomavirus (IPV) Conference; August 21-25 2014. Seattle, WA.
 25. Hsieh E*, Wang Q, Zhang RZ, Li J, Fraenkel L, Bradley EH, **Smith JS**, Qiao YL, Zhou CW, Zhang P. Risk and Prevalence of Vertebral Fractures Among Breast Cancer Survivors in China. Consortium of Universities for Global Health 5th Annual Meeting; May 10-12, 2014; Washington, D.C.
 26. **Smith JS** and Senkomago V[±]. Addressing Issues of Screening and Treatment of HIV-Infected Women in Resource Limited Settings. Asia-Oceania Research Organization in Genital Infection and Neoplasia (AOGIN) Conference; April 25-27, 2014; Beijing, China.
 27. Goeieman B, Firnhaber C, Michelow P, Swarts A, **Smith JS**, Wilkin T. Prevalence of Anal Dysplasia in HIV- infected Women from Johannesburg South Africa, Poster presentation at The 21st Conference for Retroviruses and Opportunistic Infections (CROI), 2014; March 3-6 2014; Boston, Massachusetts, USA.
 28. Des Marais AC, Brewer NT, Knight S, **Smith JS**. Perceived advantages and disadvantages of self-collection for HPV testing among underscreened, medically underserved women. International Papillomavirus Congress; August 21-25, 2014; Seattle, WA.
 29. Des Marais AC, Senkomago V, Brewer NT, Barclay L, Hobbs MM, **Smith JS**. Home-based self-collection for the detection of sexually transmitted infections in high-risk women in North Carolina. Oral presentation. 2014 CDC STD Prevention Conference; June 9-12, 2014; Atlanta, GA.
 30. Des Marais AC, Brewer NT, Barclay L, Brooks XR, **Smith JS**. Demographic differences in uptake of a mailed self-collection device for oncogenic HPV mRNA laboratory testing. Oral presentation. International Papillomavirus Congress; August 21-25, 2014; Seattle, WA.
 31. Williams I*, Des Marais AC, Jolly D, **Smith JS**. Trust in the accuracy of HPV self-collection by age, race, and educational level. Annual Biomedical Research Conference for Minority Students; November 2013; Nashville, TN.
 32. Ting J[±], Mugo N, Kwatampora J, Hill C, Chitwa M, Patel S, Gakure H, KLimani J, and **Smith JS**. HPV infection and cervical lesions over 18 months in physician and self- collected specimens in female sex workers, Kenya. Oral presentation. Eurogin meeting; November 3-6, 2013; Florence, Italy.
 33. Des Marais AC, Brewer NT, Perez-Heydrich C, Pfaff A, Williams I, Johnson M, Brooks XR, Smith SB, Barclay L, **Smith JS**. Mailed self-sampling intervention project among underscreened women in the United States. Oral presentation. Eurogin; November 3-6, 2013; Florence, Italy.
 34. Des Marais AC, Brewer NT, Perez-Heydrich C, Brooks XR, Pfaff A, Smith SB, Barclay L, **Smith JS**. Evaluation of a mailed self-collection device for oncogenic HPV mRNA laboratory testing in under-screened women in the United States. Poster presentation. 29th Annual Clinical Virology Symposium; April 2013;

- Daytona, Florida.
35. Des Marais AC, Brewer NT, Perez-Heydrich C, Pfaff A, Williams I, Johnson M, Brooks XR, Smith SB, Barclay L, **Smith JS**. Evaluation of a mailed self-collection device to screen for high-risk HPV infection in under-screened women in North Carolina. Oral presentation. American Public Health Association; November 2-6, 2013; Boston, MA.
 36. Gomih A[±], Mugo N, Ting J, Kwatampora J, Hill C, Chitwa M, Patel S, Gakure H, Kimani J, **Smith JS**. Risk factors for Mycoplasma genitalium among female sex workers in Nairobi, Kenya, Poster Presentation. STI & AIDS World Congress 2013 (Joint Meeting of the 20th ISSTD and 14th IUSTI Meeting); July 14-17, 2013; Vienna, Austria.
 37. Chang IJ*, Zhao Y-Q, Zhao F-H, Hu S-Y, **Smith JS**, Qiao Y-L. Surface distribution frequency and severity of cervical intraepithelial neoplasia in Chinese women, submitted to Eurogin; November 3-6, 2013; Florence, Italy.
 38. Ludema C*, Cole SR, Poole C, **Smith JS**, Schoenbach VJ, Wilhelmus KR. Association between unprotected UV exposure and ocular herpes simplex virus (HSV) recurrence. 46th Annual Society for Epidemiologic Research Meeting. Abstract 529-S. June 2013; Boston, MA.
 39. Williams I*, Des Marais AC, Jolly D, **Smith JS**. Trust in the accuracy of HPV self-collection by age, race, and educational level. Fayetteville State University Student Research Conference; April 2013; Fayetteville, NC.
 40. Gilkey MB, Galbraith KV, **Smith JS**, Brewer NT. Racial disparities in knowledge and attitudes related to HPV self-testing among women at risk for cervical cancer. Talk accepted for presentation at the 2013 Annual Meeting of the American Society of Preventive Oncology; March 2013; Memphis, TN.
 41. Brooks XR, Des Marais AC, Pfaff A, Qi Z, Brewer NT, **Smith JS**. Maximizing recruitment of under-screening, uninsured women to cervical cancer studies. International Papillomavirus Congress 2012; November 30-December 6, 2012; San Juan, Puerto Rico.
 42. Sudenga SL, Rositch AF, Otieno WA, **Smith JS**. Factors influencing cervical cancer risk perception among women of reproductive age in Kenya. International Papillomavirus Congress; November 30-December 6, 2012; San Juan, Puerto Rico.
 43. Backes DM[±], Hudgens MG, Fokar A, Agot K, Opiyo F, Maclean I, Moses S, Meijer CJLM, Bailey RC, Snijders PJF, **Smith JS**. Incidence and clearance of penile HPV infection among recently circumcised Kenyan men. International Papillomavirus Congress; November 30-December 6, 2012; San Juan, Puerto Rico.
 44. Backes DM[±], Hudgens MG, Chakraborty H, Agot K, Opiyo F, Maclean I, Moses S, Meijer CJLM, Bailey RC, Snijders PJF, **Smith JS**. Risk factors of HPV incidence and clearance among Kenyan men. International Papillomavirus Congress; November 30- December 6, 2012; San Juan, Puerto Rico.
 45. Des Marais AC, Brewer NT, Brooks XR, Pfaff A, Smith SB, Barclay L, **Smith JS**. Evaluation of a mailed self-collection device for oncogenic HPV mRNA laboratory testing in under-screened women in the United States. International Papillomavirus Congress; November 30-December 6, 2012; San Juan, Puerto Rico.
 46. Ting J[±], **Smith JS**, Mugo N, Kwatampora J, Chitwa M, Patel S, Gakure H, Kimani J, Myers ER. Impact of uncertainty in relative test performance between cytology, physician-, and self-collected high-risk HPV mRNA testing on estimated screening efficiency in Kenya: a simulation. International Papillomavirus Congress; November 30- Dec 6, 2012; San Juan, Puerto Rico.

47. Offutt-Powell TN[±], Rositch AF, Taylor SM, Soeters HM, **Smith JS**. The incidence of human papillomavirus following treatment for cervical neoplasia: a systematic review. International Papillomavirus Congress, November 30-December 6, 2012, San Juan, Puerto Rico.
48. Cooper JA, Rositch AF[±], Guthrie BL, Bosire R, Choi R, Kiarie J, Farquhar C, **Smith JS**. HPV and high-grade lesions in HIV-seropositive women from HIV-discordant couples. International Papillomavirus Congress; November 30-December 6, 2012; San Juan, Puerto Rico.
49. **Smith JS**, Casey B, Fernandez M, Fouad M, Robinson S, Shedd-Steele R, Simpson R, Vernon S, Zimet G, Brewer NT. Cervical Cancer-Free America: Moving from evidence to action. International Papillomavirus Congress; November 30-December 6, 2012; San Juan, Puerto Rico.
50. Senkomago V[±], Backes DM, Hudgens MG, Agot K, Maclean I, Mfalila C, Moses S, Meijer CJLM, Schlecht NF, Bailey RC, Snijders PJF, and **Smith JS**. Male circumcision reduces the risk of acquisition of high viral load HPV infections in Kenyan Men. International Papillomavirus Congress; November 30-December 6, 2012; San Juan, Puerto Rico.
51. Des Marais AC, Brewer NT, Perez-Heydrich C, Rinas A, Kamradt M, Ricchetti K, Murphy K, Smith SB, Richman A*, Yen-Lieberman B, Barclay L, Belinson JL, **Smith JS**. Mailed HPV self-sampling with Pap smear referral among high-risk women: the My Body, My Test study. American Public Health Association; October 27-31, 2012; San Francisco, CA.
52. Stolka K[±], Ndom P, Hemingway-Foday J; Abassora M, Iriundo-Perez J, Mupang L, Njiki Bikoi J, Miley W, **Smith JS**, Whitby D. Sociodemographic and behavioral risk factors associated with Kaposi's Sarcoma (KS) status and Kaposi's Sarcoma Herpesvirus (KSHV) seropositivity among HIV+ cases and controls in Cameroon. Oral presentation. International Congress on Oncogenic Herpesviruses and Associated Diseases; August 2012; Philadelphia, PA.
53. Hong JN, Berggren EK, Campbell SL, **Smith JS**, Rahangdale L. HPV Infection in pregnancy and spontaneous preterm birth. Infectious Disease Society for Obstetrics and Gynecology 39th Annual Meeting; August 11, 2012; Whistler, British Columbia, Canada.
54. Ting J[±], **Smith JS**. High-risk human papillomavirus mRNA testing in physician- and self-collected specimens for cervical lesion detection in high-risk women in Kenya. Eurogin; July 8-11, 2012; Prague, Czech Republic.
55. Firnhaber C, Mayisela N, Mao L*, Williams S, Swarts A, Faesen M, Levin S, Michelow P, Omar T, Hudgens MG, Williamson AL, Allan B, Lewis DA, **Smith JS**. Validation of cervical cancer screening methods in HIV positive women from Johannesburg South Africa. Eurogin; July 8-11, 2012; Prague, Czech Republic.
56. Chung J*; Brewer NT, **Smith JS**. Pharmacist vaccination authority of the human papillomavirus vaccine: a state-by-state analysis of the United States of America. Oral presentation. Eurogin; July 2012; Prague, Czech Republic.
57. Gaydos CA, Ginocchio CC, Chapin K, **Smith JS**, Aslanzadeh J, Snook J, Hill CS. Risk factors associated with *Trichomonas vaginalis* infection as measured with a nucleic acid amplification test in women in the United States. National STD Prevention Conference, CDC; March 12-15 2012; Minneapolis, MN.
58. **Smith JS**, Brewer NT, Rinas A, Kamradt M, Liebman A, Riccetti K, Larson R, Murphy K, Nghiem V, Richman A*, Zentz S, Yen-Lieberman B, Barclay L, Belinson J. Implementation of HPV self-sampling with Pap smear referral among high-risk women. Oral presentation. 27th International Papillomavirus Conference;

- September 2011; Berlin, Germany.
59. Rositch AF[±], Hudgens MG, Backes D, Agot K, Maclean I, Moses S, Snijders PJF, Meijer CJLM, Bailey RC, **Smith JS**. Acquisition of high-risk HPV among men with prevalent HPV infections. 27th International Papillomavirus Conference; September 2011; Berlin, Germany.
 60. Backes DM[±], Snijders PJF, Hudgens MG, Bailey RC, Bogaarts M, Agot K, Agungu W, Moses S, Meijer CJLM, **Smith JS**. HPV incidence and risk factors among uncircumcised Kenyan men. 27th International Papillomavirus Conference; September 2011; Berlin, Germany.
 61. Zhao FH, Lewkowitz AK*, Chen F, Lin MJ*, Hu Sy, Pan QJ, Ma JF, Niyazi M, Li CQ, Li SM, **Smith JS**, Belinson JL, Qiao YL, Castle PE. A pooled analysis of HPV DNA testing performance using self-collected cervicovaginal. specimens as a primary screening test for cervical cancer in rural China. 27th International Papillomavirus Conference; September 2011; Berlin, Germany.
 62. Ting J[±], Mugo N, Kwatampora J, Hill C, Schroeder A, Chitwa M, Patel S, Gakure H, Kimani J, **Smith JS**. HPV-mRNA testing of self-collected specimens to detect cervical lesions, Kenya. 27th International Papillomavirus Conference; September 2011; Berlin, Germany.
 63. Mugo N, Ting J[±], Kwatampora J, Hill C, Schroeder A, Chitwa M, Patel S, Gakure H, Kimani J, **Smith JS**. Determinants of HPV-mRNA positivity in self- and physician- collected specimens, Kenya. 27th International Papillomavirus Conference; September 2011; Berlin, Germany.
 64. Stolka KB[±], Woelk GB, Ndom P, Hemingway-Foday JJ, Newman JE, **Smith JS**, Iriondo Perez J, Abassora M, Atibu J, Ryder R. Risk factors for Kaposi's Sarcoma(KS) and HHV8 prevalence among HIV+ and HIV- patients in Cameroon. 13th International Workshop on Adverse Drug Reactions and Co-morbidities in HIV; July 2011; Rome, Italy.
 65. Ginocchio CC, Chapin K, **Smith JS**, Aslanzadeh J, Snook J, Hill CS, Gaydos CA. Prevalence of Trichomonas vaginalis and co-Infection with Chlamydia trachomatis and Neisseria gonorrhoea in the United States as determined by the APTIMA Trichomonas vaginalis Nucleic Acid Amplification Assay. Oral presentation. International Society for Sexually Transmitted Diseases Research; July 2011; Quebec, Canada.
 66. Kwatampora J, Senkomango V[±], Mugo N, Ting J*, Chitwa M, Patel S*, Gakure H, Kimani J, **Smith JS**. Self-collection versus physician-collection for the detection of Chlamydia Trachomatis, Gonorrhoea, Trichomonas and Mycoplasma Genitalia. Oral presentation. International Society for Sexually Transmitted Diseases Research; July 2011; Quebec, Canada.
 67. **Smith JS**. Burden of HPV associated precancers and cancers. Oral presentation. Eurogin; May 2011; Lisbon, Portugal.
 68. **Smith JS**. Prevalence of HPV infection in HIV-seropositive women. Oral presentation. Eurogin; May 2011; Lisbon, Portugal.
 69. **Smith JS**. HPV infection in men. Oral presentation. Eurogin; May 2011; Lisbon, Portugal.
 70. Song PI*, Liang H, Wei WQ, Jiang YQ, **Smith JS**, Qiao YL. The clinical profile of Merkel cell carcinoma in mainland China". Oral presentation. World Congress of Dermatology; May 2011; Seoul, Korea.
 71. Richman AR*, Brewer NT, Liebman A, Rinas AC, **Smith JS**. Optimizing human papillomavirus (HPV) self-testing for high risk women. Oral presentation. American Public Health Association 138th Annual Conference; November 2010; Denver, CO.

72. Song PI*, Liang H, Wei WQ, Jiang YQ, **Smith JS**, Qiao YL. The clinical profile of Merkel cell carcinoma in mainland China. Asian and Pacific American Medical Student's Association National conference; October 2010; Baltimore, MD.
73. Cantrell LA, Rossi E, Denslow S, **Smith JS**, Van le L*. Surrogate opportunities for detection of cervical cancer. Society of Gynecologic Oncology; 2010; Tampa, Florida.
74. **Smith JS**, Backes DM, Bailey RC, Moses M, Agot K, Maclean I, Ndinya-Achola JO, Hudgens M, Meijer CJLM, Snijders PJF. The effect of male circumcision on incident and persistent penile HPV infections in men from Kenya. Oral presentation. 26th International Papillomavirus Conference; July 2010; Montreal, Canada.
75. Wheeler BS*, Rositch AF, **Smith JS**. Worldwide incidence of human papillomavirus infection in women: a systematic review and meta-analysis. 26th International Papillomavirus Conference; July 2010; Montreal, Canada.
76. Sanchez DM*, Layman A, Olshan A, Conway-Dorsey K, **Smith JS**. Prognosis of human papillomavirus (HPV)-positive versus HPV-negative head and neck cancers: a systematic literature review. 26th International Papillomavirus Conference; July 2010; Montreal, Canada.
77. Monsonego J, Hudgens MG, Zerat L, Zerat JC, Syrjänen K, Halfon P, Ruiz F, **Smith JS**. Evaluation of oncogenic human papillomavirus RNA and DNA tests with liquid-based cytology in primary cervical cancer screening (the FASE study). 26th International Papillomavirus Conference; July 2010; Montreal, Canada.
78. Lin MJ*, Ji J*, Viscidi R, **Smith JS**. Age-specific human papillomavirus antibody prevalence: a global review. 26th International Papillomavirus Conference; July 2010; Montreal, Canada.
79. Backes DM[±], Bleeker MCG, Snijders PJF, Bailey RC, Hudgens MG, Agot K, Hayombe J, Moses S, Meijer CJLM, **Smith JS**. Risk factors associated with colposcopy-detected penile lesions in Kenyan men. 26th International Papillomavirus Conference; July 2010; Montreal, Canada.
80. Patel SJ*, Mugo NR, Ting J, Cohen C, Nguti R, Kwantampora J, Patnaik P, Kenney DL, Kiviat NB, **Smith JS**. Concurrent infection with multiple high risk human papillomavirus types among female sex workers in Kenya. 26th International Papillomavirus Conference; July 2010; Montreal, Canada.
81. Rositch AF[±], Soh J, Bosire R, Kiarie JN, Farquhar C, **Smith JS**. Male HIV infection and sexual characteristics as risk factors for cervical precancerous lesions among female partners. 26th International Papillomavirus Conference; July 2010; Montreal, Canada.
82. Mugo NR, Ting J, Patel SJ, Cohen C, Nguti R, Kwantampora J, Patnaik P, Kenney DL, Kiviat NB, **Smith JS**. "Human papillomavirus; cervical neoplasia and impact of HIV-1 infection among female sex workers in Kenya", 26th International Papillomavirus Conference; July 2010; Montreal, Canada.
83. Firnhaber C, Westreich D, Schulz D, Williams S, Michelow P, Faesen M, Levin S, **Smith JS**. Progression of cervical neoplasia in HIV seropositive women with and without antiretroviral therapy in Johannesburg, South Africa. Oral presentation. 12th International Conference on Malignancies in AIDS and Other Acquired Immunodeficiencies; April 2010; Bethesda, Maryland.
84. **Smith JS**, Song P*, Ting J. The burden of HPV-associated cancers. Oral presentation. Eurogin; February 17-20, 2010; Monte Carlo, Monaco.
85. **Smith JS**. HPV in adolescence and young adulthood. Oral presentation. Eurogin; February 17-20, 2010; Monte Carlo, Monaco.

86. Song P*, **Smith JS**. The distribution of HPV types in anogenital HPV-associated cancers. Eurogin; February 17-20, 2010; Monte Carlo, Monaco.
87. Backes DM[±], Bleeker MCG, Bailey RC, Hudgens MG, Agot K, Ndinya-Achola JO, Pittchar T, Onyango R, Hogewoning CJA, Maclean IW, Meijer CJLM, Snijders PJF, Moses S, **Smith JS**. Risk factors associated with colposcopy-detected penile lesions in Kenyan men. Oral presentation. University of Nairobi STD/HIV Collaborative Group Annual Meeting; January 25-29, 2010; Nairobi, Kenya.
88. Rositch AF[±], Soh J, Bosire R, **Smith JS**, Farquhar C. (Couples Against Transmission study) Prevalence and correlates of cervical precancerous lesions among women in HIV- 1 discordant couple relationships in Nairobi, Kenya. Oral presentation. University of Nairobi STD/HIV Collaborative Group Annual Meeting; January 25-29, 2010; Nairobi, Kenya.
89. McRee AL*, Brewer NT, Reiter PL*, Gottlieb S, **Smith JS**. Development of the Carolina HPV Immunization Attitudes Scale (CHIAS). Oral presentation. American Public Health Association 137th Annual Meeting and Exposition: Women's Caucus; November 2009; Philadelphia, PA.
90. Reiter PL*, Brewer NT, **Smith JS**, McRee AL, Gottlieb S. How much will it hurt? HPV vaccine side effects compared to other adolescent vaccines. Oral presentation. The American Public Health Association 137th Annual Meeting and Exposition: Women's Caucus; November 2009; Philadelphia, PA.
91. McRee AL*, Brewer NT, Reiter PL*, Gottlieb S, **Smith JS**. Mother-daughter communication about HPV vaccination. American Public Health Association 137th Annual Meeting and Exposition: Population, Family Planning, and Reproductive Health Section; November 2009; Philadelphia, PA.
92. Reiter PL*, Brewer NT, McRee AL, **Smith JS**. Acceptability of HPV vaccine among gay and bisexual men. American Public Health Association 139th Annual Meeting and Exposition: Lesbian, Gay, Bisexual, and Transgender Caucus of Public Health Workers; November 2009; Philadelphia, PA.
93. Brewer NT, Gottlieb S, Reiter PL*, McRee AL, Liddon N, Markowitz L, **Smith JS**. Longitudinal predictors of HPV vaccine uptake. Oral presentation. American Public Health Association 137th Annual Meeting and Exposition: Women's Caucus; November 2009; Philadelphia, PA.
94. **Smith JS**, Brewer NT, Chang Y*, Guerry S, Pettigrew EM, Liddon N, Markowitz L, Gottlieb SL. Acceptability of school requirements for human papillomavirus vaccine. Oral presentation. American Public Health Association 137th Annual Meeting and Exposition: Women's Caucus; November 2009; Philadelphia, PA.
95. Gilbert PA*, Brewer NT, Reiter PL*, **Smith JS**. HPV vaccine acceptability in heterosexual and gay/bisexual men. American Public Health Association 139th Annual Meeting and Exposition: Lesbian, Gay, Bisexual, and Transgender Caucus of Public Health Workers; November 2009; Philadelphia, PA.
96. Ng T*, McRee AL, Reiter PL*, **Smith JS**, Brewer NT. Men's beliefs about HPV-related disease. American Public Health Association 139th Annual Meeting and Exposition: Lesbian, Gay, Bisexual, and Transgender Caucus of Public Health Workers; November 2009; Philadelphia, PA.
97. **Smith JS**, Moses S, Hudgens MG, Parker CB, Agot K, Maclean I, Ndinya-Achola JO, Snijders PJF, Meijer CJLM, Bailey RC. Risk of HIV acquisition among men with and without human papillomavirus infection in Kisumu, Kenya. Presented as late breaker. 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22 2009; Capetown, South Africa.

98. Atashili J*, Adimora AA, Ndumbe PM, Ikomey GM, Myers E, Eron J, **Smith JS**, Miller WC. High prevalence of cervical squamous intraepithelial lesions in women on antiretroviral therapy in Cameroon: is targeted screening feasible? 5th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; July 19-22 2009; Capetown, South Africa.
99. PJF, Meijer CJLM, Bailey RC, **Smith JS**. Risk of HIV acquisition among men with and without human papillomavirus infection in Kisumu, Kenya. Oral presentation. International Society for Sexually Transmitted Diseases Research; June 2009; London, England.
100. **Smith JS**, Belinson JL, Ji J*, Hu S, Chen W, Esser M, Taddeo FJ, Pretorius RG, Qiao YL. Population-based Human Papillomavirus 16/18/6/11 DNA and Seropositivity in Chinese Women. 25th International Papillomavirus Conference; May 2009; Malmö, Sweden.
101. Hu S*, **Smith JS**, Chen W, Ji J*, Pretorius RG, Esser M, Taddeo FJ, Belinson JL, Qiao YL. HPV16/18 high in precancer, low in normal cytology in China. 25th International Papillomavirus Conference; May 2009; Malmö, Sweden.
102. Ji J*, Wang H, Chen W, Hu S, Esser M, Velicher C, Belinson JL, Pretorius RG, **Smith JS**, Qiao YL. Population-based seroprevalence of human papillomavirus in Chinese women. Oral presentation. 25th International Papillomavirus Conference; May 2009; Malmö, Sweden.
103. Ji J*, Chang Y*, **Smith JS**. Age-specific prevalence of human papillomavirus DNA and antibody: systematic review. 25th International Papillomavirus Conference; May 2009; Malmö, Sweden.
104. Backes DM[±], Bleeker MCG, Snijders PJF, Bailey RC, Hudgens MG, Agot K, Ndinya- Achola JO, T. Pittchar, Onyango R, Hogewoning CJA, Maclean IW, Moses S, Meijer CJLM, **Smith JS**. Prevalence of colposcopy-detected penile lesions in Kenyan men. 25th International Papillomavirus Conference; May 2009; Malmö, Sweden.
105. Ting J[±], Kruzikas DT, **Smith JS**. Age-specific prevalence of precancerous lesions on the cervix: a global review. Oral presentation. 25th International Papillomavirus Conference; May 2009; Malmö, Sweden.
106. Pretorius RG, Qiao YL, Belinson JL, Hu S, Wang H, Li J, **Smith JS**, Burchette RJ. Type-specific human papillomavirus (HPV) stratified by endocervical and vaginal self- test HR-HPV by Hybrid Capture 2® (HC-2). Oral presentation. 25th International Papillomavirus Conference; May 2009; Malmö, Sweden.
107. Belinson JL, Qiao YL, Pretorius RG, Hu S, Wang H, Li J, **Smith JS**, Burchette RJ. Prevalence of type-specific human papillomavirus (HPV) in the endocervix, upper vagina, lower vagina, perineum, and vaginal self-test. 25th International Papillomavirus Conference; May 2009; Malmö, Sweden.
108. Reiter PL*, Brewer NT, Gottlieb S, McRee AL*, **Smith JS**. Caregiver health beliefs and HPV vaccine uptake of adolescent girls: racial and rural/urban differences. Society of Behavioral Medicine Annual Meeting; April 22-25, 2009; Montreal, Quebec.
109. McRee AL*, Brewer NT, **Smith JS**, Reiter PL*, Gottlieb S. Development of a scale to assess caregiver attitudes about HPV vaccination. Society of Behavioral Medicine Annual Meeting; April 22-25, 2009; Montreal, Quebec.
110. Atashili J*, Adimora AA, Ndumbe PM, Ikomey GM, **Smith JS**, Miller WC. High prevalence of cervical squamous intra-epithelial lesions in HIV-positive women in Cameroon. Women's Health Research Day; April 2009; Chapel Hill, North

Carolina.

111. **Smith JS**, Rinas A, Monsonogo J, Robin H, Muller W, Mendoza A, Rao J. Performance of the Aptima HPV assay in ASC-US specimens. Oral presentation. Eurogin; November 2008; Nice, France.
112. **Smith JS**, Ting J*. Worldwide distribution of HPV 16-18-6-11 in various pathologies of the female and male anogenital tracts. Oral presentation. Eurogin; November 2008; Nice, France.
113. **Smith JS**, Bleeker M, Veronesi G, Bailey RC, Hudgens MG, Moses M, Agot K, Maclean I, Ndinya-Achola JO, Snijders PJF, Meijer CJLM. Penile HPV infection and the effect of male circumcision on HPV-associated penile lesions in men from Kenya. Oral presentation. Eurogin; November 2008; Nice, France.
114. Fortino A[±], Koshiol J[±], Franco E, Pimenta J, Poole C, **Smith JS**. Human papillomavirus persistence patterns in women worldwide. Oral presentation. Eurogin; November 2008; Nice, France.
115. **Smith JS**. Interactions between HPV and HIV: STIs and HIV shedding, regulation of HPV by HIV, and HPV VLP influence upon HIV. Oral Presentation. HPV and HIV Disease, Infection and Vaccination; October 2008; Les Pensières, France.
116. Brewer NT, Ziarnowski K*, **Smith JS**, Gottlieb SL. The debate over HPV vaccination and sexual disinhibition. Oral presentation. European Health Psychology annual meeting; September 2008; Bath, England.
117. Brewer NT, Ziarnowski K*, **Smith JS**, Gottlieb SL. Antecedents of anticipated regret related to HPV vaccination. European Health Psychology annual meeting; September 2008; Bath, England.
118. Hughes J*, Cates J, Liddon N, **Smith JS**, Gottlieb S, Brewer NT. How are parents of adolescent girls learning about the HPV vaccine? 2nd Annual National Conference on Health Communication, Marketing and Media; August 12-14, 2008; Atlanta, Georgia.
119. Ziarnowski KL*, Brewer NT, **Smith JS**, Gottlieb SL. Paradoxical effects of anticipated regret on HPV vaccination. Annual Conference of the Society of Behavioral Medicine; March 26-29, 2008; San Diego, CA.
120. Keating KM*, Brewer NT, Chang Y*, **Smith JS**, Liddon N, Gottlieb S. HPV vaccine provision and concerns among medical practices in the rural South. Annual Conference of the Society of Behavioral Medicine; March 26-29, 2008; San Diego, CA.
121. Ziarnowski KL*, Brewer NT, **Smith JS**, Gottlieb SL. Paradoxical effects of anticipated regret on HPV vaccination. Annual Conference of the Society of Behavioral Medicine; March 26-29, 2008; San Diego, CA.
122. **Smith JS**, Bleeker M, Bailey RC, Moses M, Atashilli J*, Hudgens M, Agot K, Maclean I, Ndinya-Achola JO, Parker CB, Snijders PJF, Meijer CJLM. A randomized controlled trial of male circumcision to reduce HPV incidence and persistence in Kisumu, Kenya: progress to date. Oral presentation. 24th International Papillomavirus Conference; November 3-9, 2007; Beijing, China.
123. Backes DM[±], Kurman RJ, **Smith JS**. Systematic review of HPV prevalence in penile cancer and penile intraepithelial neoplasia. 24th International Papillomavirus Conference; November 3-9, 2007; Beijing, China.
124. Hoots B[±], Kurman R, **Smith JS**. Human papillomavirus type distribution in vaginal and vulvar cancers and their precursors: a meta-analysis. Oral presentation. 24th International Papillomavirus Conference; November 3-9, 2007; Beijing, China.
125. Hoots B[±], Palefsky J, Raman S, **Smith JS**. Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions: a meta-analysis. 24th International

- Papillomavirus Conference; November 3-9, 2007; Beijing, China.
126. Firnhaber C, Le HV*, Pettifor A, Schulze D, Williams S, Michelow P, Sanne I, Lewis D, William B, Williamson A, Allan B, Williams S, van der Horst C, **Smith JS**. Effect of antiretroviral therapy on cervical lesions among HIV seropositive women in Johannesburg, South Africa. Oral presentation. 24th International Papillomavirus Conference; November 3-9, 2007; Beijing, China.
 127. Fortino AE[±], Backes D[±], **Smith JS**. Systematic review of human papillomavirus persistence patterns in women worldwide. 24th International Papillomavirus Conference; November 3-9, 2007; Beijing, China.
 128. Fazekas KI*, Brewer NT, **Smith JS**. HPV vaccine acceptability in the rural, southern United States. 24th International Papillomavirus Conference; November 3-9, 2007; Beijing, China.
 129. **Smith JS**, Wang H, Belinson JL, Chen W, Pretorius RG, Li J, Qiao YL. Constant prevalence of human papillomavirus DNA by age in five distinct geographical areas of China. Oral presentation. 24th International Papillomavirus Conference; November 3-9, 2007; Beijing, China.
 130. Belinson JL, Xu AD, Pretorius RG, Wei LH, **Smith JS**, Wu YP, Taddeo FJ, Liaw KL, Qiao YL. Prevalence of HPV DNA in women, stratified by location of sampling in the genital tract (cervix, lower and upper vagina, perineum): implications for self-sampling. 24th International Papillomavirus Conference; November 3-9, 2007; Beijing, China.
 131. Pretorius RG, Ren SD, Belinson JL, Li CQ, Yan GB, Nuer M, Qiao YL, **Smith JS**. Correlation of cervical intra-epithelial neoplasia 2 or worse with type-specific human papillomavirus from self-collected vaginal specimens and physician-collected endocervical specimens. Oral presentation. 24th International Papillomavirus Conference; November 3-9, 2007; Beijing, China.
 132. Chen W, **Smith JS**, Zhang X, Molijn A, Schmidt JE, Shi JF, Quint W, Jenkins D, Qiao YL. Chinese HPV Typing Group. HPV type-distribution in cervical cancer in China: a hospital-based multi-center study. Oral presentation. 24th International Papillomavirus Conference; November 3-9, 2007; Beijing, China.
 133. Pretorius RG, Bao YP, Belinson JL, Burchette RJ, **Smith JS**, Qiao YL. Inappropriate gold standard bias in cervical cancer screening studies. Oral presentation. 24th International Papillomavirus Conference; November 3-9, 2007; Beijing, China.
 134. Arama V, **Smith JS**, Streinu-Cercel A, Benea O, Vladareanu R, Hristea A, Sandu R, Iosipenco M, Mihai C, Iancu S, Ionescu E, Molagic V. Type-specific HSV-1 and HSV-2 seroprevalence in Romania. 23rd Conference of the International Union Against Sexually Transmitted Infections –Europe on Sexually Transmitted Infections; October 11-14, 2007; Dubrovnik, Croatia.
 135. Patnaik P*, Bosetti C, Franceschi S, Herrero R, Muñoz N, Bosch FX, Bayo S, Chaouki N, Caceres E, Chichareon S, Walboomers JMM, Ashley R, Castellsagué X, **Smith JS**. Type-specific herpes simplex virus type 2 (HSV-2) seroprevalence and associated risk factors in cytologically normal, middle-age women from six countries: the IARC multicentric study. Oral presentation. International Society for Sexually Transmitted Disease Research; July 2007; Seattle, WA.
 136. Cates JR, Brewer NT, Fazekas KI*, Mitchell C*, **Smith JS**. Race-related differences in knowledge and attitudes about the HPV vaccine in the Rural United States. International Society for Sexually Transmitted Disease Research; July 2007; Seattle, WA.
 137. Atashili J*, Schmidt G, **Smith JS**. Age-specific prevalence of infection with

- Chlamydia trachomatis infection: a global review. Oral presentation. International Society for Sexually Transmitted Disease Research; July 2007; Seattle, WA.
138. Lee H*, Schoenbach V, Herrero R, Anh PTH, Nguyen TH, Nguyen TT, Nguyen HN, Nguyen BD, Munoz N, Franceschi S, Ashley R, **Smith JS**. Type-specific herpes simplex virus positivity among population-based samples of women in North and South and Vietnam. International Society for Sexually Transmitted Disease Research; July 2007; Seattle, WA.
 139. Makumi AN, Nguti R, Mugo NR, Cohen C, **Smith JS**. Correlates of Neisseria gonorrhoeae and Chlamydia trachomatis infections in a cohort of female sex workers in Nairobi, Kenya. International Society for Sexually Transmitted Disease Research; July 2007; Seattle, WA.
 140. Backes DM[±], Koshiol JE[±], Pimenta JM, **Smith JS**. Systematic review of HPV infection persistence and cervical lesion progression UNC Women's Health Research Day; April 3, 2007; Chapel Hill, NC.
 141. Sperber N*, Brewer NT, Fazekas K, **Smith JS**. HPV vaccination among rural U.S. women: the modifying effect of age. Annual Conference of the Society of Behavioral Medicine; 2007; Washington, DC.
 142. Arama V, Streinu-Cercel A, Benea O, Vladareanu R, Iosipenco M, Sandu R, Patruleasa M, Hristea A, Negoita A, Molagic V, Bohaltea R, Iancu S, Ionescu E, **Smith JS**, Malkin J, Mihai C. Herpes simplex virus-1 and -2 seroprevalence among pregnant women in Romania. International Society for Sexually Transmitted Disease Research; October 2006, Rhodes, Greece.
 143. Papadogeorgakis H, **Smith JS**, Caroni C, Pimenta J, Avdeliodi K, Kotrotsou T, Frangouli E, Katsambas A. Seroprevalence of herpes simplex virus infections in Greece, 2004-2005. Oral presentation. 15th Congress of the European Academy of Dermatology and Venereology; October 2006; Rhodes, Greece.
 144. **Smith JS**, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, Clifford GM. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Oral presentation. International Papillomavirus Conference; September 2006; Prague, Czech Republic.
 145. **Smith JS**, Moses S, Hudgens MG, Agot K, Franceschi S, Maclean I, Ndinya-Achola JO, Parker C, Meijers C, Snijders P, Bailey R. Optimum sampling for penile human papillomavirus detection in young men from Kenya. International Papillomavirus Conference; September 2006; Prague, Czech Republic.
 146. **Smith JS**, Rana RK, Pimenta JM. Global review of age-specific prevalence of human papillomavirus (Types 16/18/Overall). Oral presentation. International Papillomavirus Conference; September 2006; Prague, Czech Republic.
 147. Backes DM[±], Koshiol JE[±], Pimenta JM, **Smith JS**. Systematic review of HPV infection persistence and cervical lesion progression. Oral presentation. International Papillomavirus Conference; September 2006; Prague, Czech Republic.
 148. Koshiol JE[±], Lindsay L, Pimenta JM, Poole CL, Jenkins D, **Smith JS**. A systematic review of human papillomavirus persistence and cervical neoplasia. Oral presentation. International Papillomavirus Conference; September 2006; Prague, Czech Republic.
 149. **Smith JS**. Spectrum of HPV related burden of disease. Oral presentation. Eurogin; April 2006; Paris, France.
 150. **Smith JS**, Hoots B[±]. Sexually transmitted infections: role as HPV cofactors in the etiology of cervical cancer. Eurogin; April 2006; Paris, France.
 151. Patnaik P[±], Mugo N, Cohen C, Kwatampora J, Nguti R, Ngugi E, Donders G, Kiviat N, **Smith JS**. High prevalence of cervical neoplasia, HIV and HPV infection in

- female sex workers in Kenya. Eurogin; April 2006; Paris, France.
152. Atashili J*, **Smith JS**, Adimora AA. Quantifying the correlation between gender inequality and HIV prevalence. Oral presentation. International Conference of Women and Infectious Diseases; March 16-18, 2006; Atlanta, GA.
 153. Kwatampora J, Mugo N, Cohen C, Kiviat N, **Smith JS**. HIV infection is related to a high prevalence of cervical neoplasia and HPV infection in female sex workers in Nairobi. Oral presentation. University of Nairobi STDs/AIDS Collaborative Group; January 24, 2006; Nairobi, Kenya.
 154. Deak J, Kozinszky Z, Pal A, Nyari T, Zadori J, **Smith JS**. Herpes simplex virus-2 and -1 seroprevalence in select population groups in Hungary. International Herpes Management Forum Meeting; October 28-30, 2005; Lisbon, Portugal 1st Central European Forum for Microbiology; October 26-28, 2005; Keszthely, Hungary Annual meeting of Hungarian STD Society and Alp-Danube-Adria XI. STD Workshop; November 4-5, 2005; Hungary.
 155. **Smith JS**, Moses S, Ashley-Morrow R, Maclean I, Agot K, Ndinya-Achola JO, Bailey RC. Validation study comparing herpes simplex virus (HSV)-2 antibody detection using the Focus Diagnostics ELISA, Kalon Elisa, Western Blot, and Inhibition test. Oral presentation. International Herpes Management Forum Meeting; October 28-30, 2005; Lisbon, Portugal.
 156. **Smith JS**. Cervical cancer: epidemiology, HPV typing and oncogenicity. Oral presentation. 14th International Meeting of the European Society of Gynecological Oncology; September 2005; Istanbul, Turkey.
 157. Grainge MJ, **Smith JS**, Myles P, Koshiol J*, Pimenta J, Lindsay L, Jenkins D. A systematic review of the natural history of high-risk human papillomavirus among middle-aged women. European Cancer Organization; September 2005; Istanbul, Turkey.
 158. Atashili J*, Ndumbe PM, Poole C, Adimora AA, **Smith JS**. Is bacterial vaginosis a risk factor for HIV infection? A meta-analysis of published studies. Oral presentation. International Congress on Sexually Transmitted Infections; July 10-13, 2005; Amsterdam, the Netherlands.
 159. Mugo N, Cohen C, Nguti R, Katampora J, Kiviat N, **Smith JS**. Prevalence of human papillomavirus (HPV) in high-risk women in Nairobi, Kenya. International Congress on Sexually Transmitted Infections; July 10-13, 2005; Amsterdam, the Netherlands.
 160. Rojas-Espallat L, Escobar P, Belinson J, Tisci S*, Brainard J, de la Roase V, Romero W, **Smith JS**, Feldchtein F. Optical coherence tomography as a diagnostic adjunct to visual inspection and colposcopy for pre-invasive and invasive cervical cancer of the uterine cervix. 22nd International Papillomavirus Conference and Clinical Workshop; April 30 -May 6, 2005; Vancouver, Canada.
 161. Aguilar LV, Lazcano-Ponce E, Vaccarella S, Cruz A, Hernández P, **Smith JS**, Muñoz N, Kornegay JR, Hernandez M, Franceschi S. Human papillomavirus detection in men: comparison of different sampling sites. 22nd International Papillomavirus Conference and Clinical Workshop; April 30 - May 6, 2005; Vancouver, Canada.
 162. Koshiol J[±], Schroeder J, Marshall S, Helig C, Jamieson D, Olshan A, **Smith JS**. Smoking and time to clearance of human papillomavirus infection in HIV-positive and at risk women. Oral presentation. 22nd International Papillomavirus Conference and Clinical Workshop; April 30-May 6, 2005; Vancouver, Canada.
 163. Randrianjafisamindrakotroka N, Van Damme K, Behets F, Rabozakandraina TOO, Randrianasolo BS, Rabenja NL, Zanasatra RS, Hobbs M, Rinas A, Cohen M,

- Gravitt P, **Smith JS**. Human papillomavirus prevalence in high-risk women and invasive cancer cases in Madagascar. Oral presentation. 22nd International Papillomavirus Conference and Clinical Workshop; April 30-May 6, 2005; Vancouver, Canada.
164. Koshiol JE[±], Lindsay LL, Pimenta JM, Poole CL, Jenkins DD, **Smith JS**. A systematic review of human papillomavirus persistence and cervical neoplasia. University Research Day; March 31, 2005; Chapel Hill, North Carolina Women's Health Research Day, March 23, 2005; Chapel Hill, North Carolina. UNC Lineberger Comprehensive Cancer Center Retreat; March 21, 2005; Chapel Hill, North Carolina.
165. Kinoshita R*, **Smith JS**, Tshefu A, Atibu J, Mpanya G, Onyamboko M, Mwandagaliwa K, Mbuyi B, Matendo R, Hemingway-Foday J, Bartz J, Koch MA, Ryder RW. Stable HIV prevalence in pregnant women as evidenced by the low prevalence of selected STDs in Kinshasa, Democratic Republic of the Congo. Oral presentation. 1st Democratic Republic Congo HIV/STD Conference; February 2005; Kinshasa, DRC.
166. Siennicka J, Rosińska M, Trzcińska A, Pimenta J, Litwińska B, **Smith JS**. A recent estimate of seroprevalence of HSV-1 and HSV-2 in Poland. International Union Against Sexually Transmitted Infections Conference on Sexually Transmitted Infections; October 8-10, 2004.
167. Berrington de González A, **Smith JS**, Green J, Appleby P, Peto J, Plummer M, Franceschi S, Beral V. Cervical cancer, HPV infection and use of hormonal contraceptives: a systematic review. 21st International Papillomavirus Conference and Clinical Workshop; February 20-26, 2004; Mexico City, Mexico.
168. Aguilar Morales LV, Lazcano Ponce CE, Vaccarella S, Cruz A, Hernández P, **Smith JS**, Munoz N, Hernandez M, Franceschi S. Human papillomavirus detection in men: comparison of different sampling sites. 21st International Papillomavirus Conference and Clinical Workshop; February 20-26, 2004; Mexico City, Mexico.
169. Thomas JO, Herrero R, Omigbodun AA, Ojemakinde K, Ajayi IO, Fawole A, Oladepo O, **Smith JS**, Arslan A, Munoz N, Snijders PJF, Meijer CJLM, Franceschi S. Prevalence of papillomavirus infection in women in Ibadan, Nigeria: a population-based study. 21st International Papillomavirus Conference and Clinical Workshop; February 20-26, 2004; Mexico City, Mexico.
170. **Smith JS**, Robinson NJ. Epidemiology of herpes simplex virus in Europe and the United States. 5th International Eurogin Conference; April 13-16, 2003; Paris, France.
171. **Smith JS**, Herrero R, Munoz S, Hussain S, Matos E, Shin H, Lazcano E, de Sanjose S, Sukvirach S, Ahn PTH, Castle P, Hieu NT, Franceschi S, Ashley R. Herpes simplex virus seroprevalence and risk factors in women. 18th Congress on Sexually Transmitted Infections, September 12-14, 2002; Vienna, Austria. Annual Conference at the Institute of Public Health; March 5-6, 2003; Cuernavaca, Mexico.
172. **Smith JS**, Munoz N, Herrero R, Bosetti C, Bosch FX, Eluf-Neto J, Meijer CJLM, Peeling R, Ashley R, Franceschi S. Herpes simplex virus-2 and Chlamydia trachomatis as HPV cofactors in the etiology of invasive cervical cancer. 18th Congress on Sexually Transmitted Infections; September 12-14, 2002; Vienna, Austria Oral presentation. Annual Conference at the Institute of Public Health; March 5-6, 2003; Cuernavaca, Mexico.
173. **Smith JS**, Herrero R, Muñoz N, Matos E, Shin H, Lazcano E, de Sanjosé S, Sukvirach S, Ahn PTH, Hieu NT, Franceschi S, Ashley R. Population-based herpes

- seroprevalence in seven countries. International Society for Sexually Transmitted Diseases; June 24-27th, 2001; Berlin, Germany Oral presentation International Herpes Management Forum Meeting; February 27-March 2, 2003; Paris, France.
174. **Smith JS**, Franceschi S. The natural history of human papillomavirus infection and evidence for HPV cofactors in the etiology of invasive cervical cancer. Oral presentation. 6th National Cancer Institute Cancer and Genetics Conference; December 3-4, 2001; Bangkok, Thailand.
 175. Franceschi S, **Smith JS**. HPV vaccines for cervical cancer prevention. Oral presentation. 6th National Cancer Institute Cancer and Genetics Conference; December 3-4, 2001; Bangkok, Thailand.
 176. Sukvirach S, **Smith JS**, Tunsakul S, Kesararat W, Opasatian O, Kaenploy V, Chicharoen S, Meijer CJLM, Snijders PJF, Munoz N, Franceschi S, Herrero R. Population-based human papillomavirus prevalence in Lampang and Songkla, Thailand Oral presentation. 6th National Cancer Institute Cancer and Genetics Conference; December 3-4, 2001; Bangkok, Thailand.
 177. **Smith JS**, Muñoz N, Bosetti C, Herrero R, Bosch FX, Eluf-Neto J, Van den Brule AJC, Franceschi S, Peeling RW. Chlamydia trachomatis as an HPV cofactor in the etiology of invasive cervical cancer. Oral presentation. 19th International Papillomavirus Conference; September 2001; Florianopolis, Brazil.
 178. **Smith JS**, Herrero R, Muñoz N, Bosetti C, Herrero R, Bosch FX, Eluf-Neto J, Van den Brule AJC, Franceschi S, Peeling RW. Herpes simplex virus-2 as an HPV cofactor in the etiology of invasive cervical cancer. Oral presentation. 19th International Papillomavirus Conference; September 2001; Florianopolis, Brazil.
 179. **Smith JS**, Bosetti C, Franceschi S, Herrero R, Muñoz N, Bosch FX, Chaouki N, Caceres E, Chichareon S, Walboomers J, Ashley R. Herpes simplex virus seroprevalence and associated HSV-2 risk-factors: An analysis of three countries. Oral presentation. International Herpes Management Forum; November 9-11, 2000; Malta.
 180. **Smith JS**, Muñoz N, Herrero R, Bosch FX, Eluf-Neto J, Ngelangel C, Meijer CJLM, Walboomers JMM, Peeling RW. Evidence for Chlamydia trachomatis as an HPV cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. 18th International Papillomavirus Conference; July 2000; Barcelona, Spain Oral presentation. International Chlamydia Meeting; August 2000; Helsinki, Finland.
 181. **Smith JS**, Herrero R, Muñoz N, Bosch FX, Eluf-Neto J, Ngelangel C, Meijer CJLM, Walboomers JMM, Ashley R. Investigating herpes simplex virus-2 as an HPV cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines. 18th International Papillomavirus Conference; July 2000; Barcelona, Spain.
 182. **Smith JS**, Herrero R, Muñoz N, Bosch FX, Ngelangel C, Eluf-Neto J, Muñoz N. Prevalence and risk factors for herpes simplex virus II among middle-aged women in Brazil and the Philippines. Oral presentation. 13th Meeting of the International Society for Sexually Transmitted Diseases; July 1999; Denver, Colorado.
 183. **Smith JS**, Bosch FX, Erles K, Herrero R, Schlehofer J, Tafur L, Shah K, Muñoz N. Are adeno-associated viruses protective factors for HPV-induced cervical cancer? Oral presentation. 17th International Papillomavirus Conference; January 1999; Charleston, South Carolina.
 184. **Smith JS**, Rolón P, Herrero R, Klug S, Walboomers J, Jacobs M, Muñoz N.

- Paraguay: human papillomavirus and invasive cervical cancer. Oral presentation. 17th International Papillomavirus Conference; January 1999; Charleston, South Carolina.
185. Bentley M, **Smith JS**. Behavioral research of microbicide products: a woman's decision- making for pregnancy and STD/HIV prevention. Oral presentation. International Aids Conference; July 1996; Vancouver, Canada.
186. Ayuku D, Bentley M, Egessa O, Maman S, Sweat M, Moss W, Nyarang'o P, Chemtai A, Halsey N, **Moi-JHU Collaborative team**. Factors that facilitate and impede STD Control in Western Kenya. International Aids Conference; July 1996; Vancouver, Canada.

Conference Presentations

1. "Mailed self-sampling intervention project among underscreened women in the United States". Eurogin, Florence, Italy, November 3-6, 2013
2. "HPV infection and cervical lesions over 18 months in physician and self-collected specimens in female sex workers, Kenya". Eurogin meeting, November 2013, Florence, Italy.
3. "Cancer-Free America: Moving from evidence to action". International Papillomavirus Congress, San Juan, Puerto Rico, November 30-December 6, 2012.
4. "Risk of HIV acquisition among men with and without human papillomavirus infection in Kisumu, Kenya." AIDS meeting, Capetown, South Africa, presented as late breaker, July 19-22, 2009; STD/AIDS Collaborative Research Group Annual Meeting 2011; January 20, 2011
5. "The effect of male circumcision on incident and persistent penile HPV infections in men from Kenya." 26th International Papillomavirus Conference, Montreal, Canada, July 2010
6. "Acceptability of school requirements for human papillomavirus vaccine." American Public Health Association 137th Annual Meeting and Exposition: Women's Caucus, Philadelphia, PA, November 2009
7. "Performance of the Aptima HPV Assay in ASC-US Specimens." Eurogin, Nice, France, November 2008
8. "Penile HPV infection and the effect of male circumcision on HPV-associated penile lesions in men from Kenya." Eurogin, Nice, France, November 2008
9. "A randomized controlled trial of male circumcision to reduce HPV incidence and persistence in Kisumu, Kenya: progress to date." 24th International Papillomavirus Conference, Beijing, China, November 3-9, 2007
10. "Constant Prevalence of Human Papillomavirus DNA by Age in Five Distinct Geographical Areas of China." 24th International Papillomavirus Conference, Beijing, China, November 3-9, 2007
11. "HPV type-distribution in cervical cancer in China: a hospital-based multi-center study." 24th International Papillomavirus Conference, Beijing, China, November 3-9, 2007
12. "Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update." International Papillomavirus Conference,

Prague, September 2006

13. "Global Review of Age-specific Prevalence of Human Papillomavirus (Types 16/18/ Overall)." International Papillomavirus Conference, Prague, September 2006
14. "Validation Study Comparing Herpes Simplex Virus (HSV)-2 Antibody Detection Using the Focus Diagnostics ELISA, Kalon ELISA, Western Blot, and Inhibition Text." International Herpes Management Forum, Lisbon, Portugal, October, 28-30, 2005
15. "Herpes Simplex Virus Type-2 as a cofactor acting in conjunction with Human Papillomavirus to cause cervical cancer," International Herpes Management Forum Meeting, Paris, France, February 22-March 2, 2003
16. "Human Papillomavirus in the Etiology of Invasive Cervical Cancer: Future Vaccine Initiatives." University of Baltimore, Baltimore, Maryland, February 24, 2003
17. "Herpes simplex virus seroprevalence and risk factors in women." 18th Congress on Sexually Transmitted Infections, Vienna, Austria, September 12-14, 2002
18. "Herpes simplex virus-2 and Chlamydia trachomatis as HPV cofactors in the etiology of invasive cervical cancer." 18th Congress on Sexually Transmitted Infections, Vienna, Austria, September 12-14, 2002
19. "Chlamydia trachomatis as an HPV cofactor in the etiology of invasive cervical cancer." 19th International Papillomavirus Conference, Florianopolis, Brazil, September 2001
20. "Herpes simplex virus-2 as an HPV cofactor in the etiology of invasive cervical cancer." 19th International Papillomavirus Conference, Florianopolis, Brazil, September 2001
21. "Population-based herpes seroprevalence in seven countries." International Society for Sexually Transmitted Diseases, Berlin, Germany, June 24-27, 2001
22. "Evidence for Chlamydia trachomatis as an HPV cofactor in the etiology of invasive cervical cancer in Brazil and the Philippines." 18th International Papillomavirus Conference, Barcelona, Spain, July 2000
23. "Prevalence and Risk Factors For Herpes Simplex Virus II Among Middle-Aged Women in Brazil and the Philippines." 13th Meeting of the International Society for Sexually Transmitted Diseases, Denver, Colorado, July 11-14, 1999; International Herpes Management Forum, Seville, Spain, December 3-5, 1999
24. "Are Adeno-Associated Viruses Protective Factors for HPV-Induced Cervical Cancer?" 17th International HPV Conference, Charleston, South Carolina, January 9-15, 1999

Invited Oral Presentations

1. "Envisioning a World Free of Cancer- One Cancer at a time", May 28, 2016, Amherst College, Amherst, Massachusetts.
2. "WHO Position and worldwide action on cervical cancer prevention" Roundtable Discussion on Cervical Cancer In China, April 24, 2016, Beijing China.

3. “HPV E6/E7 mRNA test in prevention practice of cervical cancer and the FASE Study, The 14th Annual Meeting of National Cervical Cancer Consortium And Symposium of Cervical Cancer Prevention in China, Cancer Foundation of China April 23, 2016, Beijing China.
4. "Global Cancer Prevention and Control", The 2nd Annual Rochester Global Health Symposium, The Global and Territorial Health Research Network and the UNYTE Translational Research Network and UNYTE Scientific Session, April 21, 2016, Rochester, New York.
5. “Improving Testing, Triage, and Follow up for Cervical Cancer Screening in Medically Underserved Women”, NCCU-UNC U54 collaboration, February 17, 2016, Durham, North Carolina.
6. “Cervical Cancer-Free America: Improved Health through Education and Innovation”, Second Summit of Cervical Cancer-Free South Carolina, Friday, January 8, 2016, Greenville, South Carolina
7. “HPV Cancer Prevention”, 11th Annual Cancer Symposium, October 28th, 2016, Area L North Carolina Health Education Centers (AHEC), Rocky Mount, North Carolina.
8. “Understanding the work of an epidemiologist and population-based surveys”, November 17, 2015, Barretos Hospital, Barretos, Sao Paulo State, Brazil
9. “Alternative Samples for HPV testing: Urine is a Feasible Way?” HPV2015 30th International Papillomavirus Conference; September 18, 2015; Lisbon, Portugal.
10. “Lessons Learned from Media Reports of Adverse Events and National Programs Vaccination Answers”, International Papillomavirus Conference, HPV 2015 30th International Papillomavirus Conference; September 17, 2015; Lisbon, Portugal.
11. “The Evaluation of Screening, Treatment and Vaccination of HIV-infected women”, World Sexually Transmitted Infections and HIV Conference, September 15, 2015, Brisbane, Australia.
12. “International Collaboration and Providing Technical Support, Training and Education for Cervical Cancer Prevention Programs”, September 02, 2015, Intrah Health, Chapel Hill, North Carolina.
13. “Epidemiology of Oral HPV/HIV Infections”, International Consultation Meeting, HPV-Associated Oropharyngeal Cancer: Implications for Research, Education, and Public Health Policy in the Americas, Washington, D.C. , July 27, 2015.
14. “International Collaboration and Providing Technical support, training and education for Cervical Cancer Prevention Programs”, 9TH Stop Cervical, Breast and Prostate Cancer in Africa Conference (SCCA) Theme: Investing to Save Lives: The Role of Public & Private Sector Partnerships, Nairobi, Kenya, July 13, 2015.
15. “Accelerating the implementation of screening and treatment: a critical key to global cervical cancer prevention”, The 1st Annual Rochester Global Health Symposium, Rochester, New York, June 15, 2015
16. "Interface Between Science and Policy for Global Cervical Cancer Control", Global Cancer Day, NCI, Washington, DC, May 08, 2015

17. “HPV and Cervical Cancer Prevention in HIV-Seropositive Women”. Eurogin 2015, Sevilla, Spain, February 7, 2015
18. “Helping community groups with their communication activities”. Eurogin 2015, Sevilla, Spain, February 4, 2015
19. “Identifying and Engaging Key Stakeholders”. NCI CCSG Meeting. Moffitt Cancer Center, Tampa, Florida, January 15, 2015
20. "Cervical Cancer-Free America", NCI HPV Administrative Supplements Teleconference, Wednesday, December 17, 2014
21. “HPV and Cervical Cancer Prevention in HIV-Seropositive Women”. CFAR, New York, New York, December 9, 2014
22. “Global cancer”, NCI Provocative Questions Workshops in India All Saints College, Trivandrum, India, November 5, 2014
23. “Human Papillomavirus Infection, Associated diseases and Vaccination for Cervical Cancer Prevention”. Vaccine Renaissance Conference, Providence, Rhode Island, October 14, 2014
24. "HPV epidemiology, pathogenesis and prevention", Cancer Epidemiology Seminar, UNC Department of Epidemiology, September 26, 2014
25. “Global cancer”, The Global Burden of Non-communicable Diseases conference, UNC William and Ida Friday Center, September 15, 2014
26. “Human Papillomavirus Infection”, Associated Diseases and Vaccination for Cervical Cancer Prevention, Institut Pasteur, Paris, France, September 13, 2014
27. “Cervical cancer prevention among HIV-seropositive women: Some highlights and research gaps”, NCI Center for Global Health (CGH) and the Office of HIV and AIDS Malignancy (OHAM) Satellite Meeting HPV-related Disease in HIV-infected Individuals, Seattle, Washington, August 21, 2014
28. “Urine Fractionation Study”, IPV 2014 meeting, Seattle, Washington, August 2014
29. “MyBodyMytest: A Self-Sampling Approach to Address Cervical Cancer Disparities in North Carolina”, Pache Conference, Washington, DC, July 28, 2014
30. “Human papillomavirus (HPV)-related cancers and vaccines”, UNC-South China STI/HIV Research Training Center Conference, Guangzhou, China, July 14, 2014
31. “Addressing Issues of Screening and Treatment of HIV-Infected Women in Resource Limited Settings”. Asia-Oceania Research Organization in Genital Infection and Neoplasia (AOGIN) Conference. Beijing, China. April 25-27, 2014
32. The President’s Cancer Panel Report, “Accelerating HPV Vaccine Uptake: Urgency for Action to Prevent Cancer”, AACR meeting, San Diego, California, April 05, 2014.
33. “Human Papillomavirus Vaccines and Diagnostics for Cervical Cancer Prevention”, UNC School of Medicine, March 26, 2014
34. “The Women’s Commitment: The Women Against Cervical Cancer (WACC) Foundation Efforts”, Oral presentation. Eurogin; Florence, Italy; November 3-6, 2013
35. “Human Papillomavirus Vaccines and Diagnostics for Cervical Cancer Prevention”,

NCCU, November 2013

36. “HPV Vaccination, Data, Implementation and Controversy”, Cancer Epidemiology Series, October 25th, 2013
37. “HPV and Cervical Cancer: The way forward to prevention through implementation”, Global Cancer - Gillings Global Health, October 23rd, 2013
38. “HPV Vaccination and Methods to measure vaccine coverage and impact”, UNC Department of Epidemiology, Pharmacoepidemiology Division, October 21st, 2013
39. “Global Cervical Cancer Prevention”, South-UNC STI Conference, Guangzhou, China, June 26, 2013
40. “The Importance of Genotype Specific Information”, ACOG meeting, New Orleans, Louisiana, May 9, 2013
41. “Global Epidemiology of HPV Infections and Related Diseases”, President’s Cancer Panel, Miami, Florida, April 23, 2013
42. “How to Talk with Patients about HPV and Cervical Cancer Screening in the Primary Care Setting”, Dialogue for Cancer Screening, Prevent Cancer Foundation, Baltimore, Maryland, March 21, 2013
43. “Cervical cancer symposium: Addressing Issues of Screening and Treatment of HIV- infected Women in Resource Limited Settings, Consortium of Universities for Global Health”, Washington D.C., March 15, 2013
44. “Cervical cancer prevention in HIV-seropositive women”, Annual Review Meeting 2013 University of Nairobi STD/AIDS Collaborative Group, Mayfair Court Southern Sun, Nairobi, Kenya, January 22, 2013
45. “Clinical Performance of Molecular Diagnostic Assays for Detection of Cervical Disease.” Satellite Symposium, American Social Health Association and American STD Association, Melbourne, Australia, October 15, 2012
46. “Global Cervical Cancer Prevention – What are the Challenges?” University of South Carolina, Charleston, South Carolina, September 14, 2012
47. “HPV associated cancers in the United States.” President’s Panel on Cancer, San Francisco, CA, July 23, 2012
48. “Clinical Performance of the APTIMA HPV Assay for Detection of Cervical Disease”, Conference of Asia Oceania Research Organization on Genital Infections and Neoplasia, Hong Kong, July 13, 2012
49. “Evaluation Of HPV RNA And DNA Tests In Primary Cervical Cancer Screening: The FASE Study.” Eurogin, Prague, Czech Republic, July 8-11, 2012
50. “High-risk human papillomavirus mRNA testing in physician- and self-collected specimens for cervical lesion detection in high-risk women in Kenya.” Eurogin 2012, Prague, Czech Republic, July 8-11, 2012
51. “HPV infection and increased risk of HIV acquisition: a systematic review and meta- analysis.” Eurogin 2012, Prague, Czech Republic, July 8-11, 2012
52. “HPV and cervical cancer prevention among high-risk women in China.” 1st UNC- South China STI Research Training Course, Guangzhou, China, May 27, 2012
53. “HPV vaccines to prevent cervical cancer.” The 6th National STD Conference,

Shenzhen, China, May 25, 2012

54. "Clinical Performance of the APTIMA HPV Assay for Detection of Cervical Disease." CDC National STD Conference, Minneapolis, Minnesota, March 14, 2012
55. "The Cervical Cancer-Free America Initiative." Emory OBGYN Grand Rounds, Atlanta, Georgia, February 29, 2012
56. "A Call to Action." HPV/Cervical Cancer Forum, Gynecologic Cancer Awareness Movement (GCAM), November 5, 2011
57. "Update on HPV and Cervical Cancer Vaccines." Healthcare Reform Task Force and 12th Annual Southern Regional Conference, October 14, 2011
58. "Cervical Cancer-Free America: A multi-state initiative." Women in Government: Oncology Task Force, HPV & Related Cancers, Minneapolis, MN, July 2011
59. "Cervical Cancer-Free America: A multi-state initiative." National Women's Political Caucus 40th Anniversary and 20th Biennial Convention – Health Care Forum, Washington, DC, July 2011
60. "Human Papillomavirus Vaccines and Diagnostics for Cervical Cancer Prevention: Current Status and Future Prospects." Jamaica Cancer Center Annual Dr. J. St. Elmo Hall Lecture, Kingston, Jamaica, April 20, 2011
61. "Cervical Cancer Free North Carolina." North Carolina Obstetrics and Gynecology meeting, Asheville, North Carolina, April 15, 2011
62. "Cervical Cancer Studies." Researcher's lunch with Dean Rimer, University of North Carolina, Chapel Hill, NC, 2011
63. "Cervical Cancer-Free America: Changing the Dialogue, Changing Policy." Cervical Cancer Free Indiana Launch Meeting, Indianapolis, Indiana, March 18, 2011
64. "HPV testing and genotyping –The present and the future." Society for Gynecological Oncology, Orlando, Florida, March 8, 2011
65. "Human Papillomavirus Vaccines: Current Status, and Future Prospects for HIV Prevention?" Fogarty International Scholars Program, webcast, February 18, 2011
66. "The effect of HIV on HPV and cervical precancerous lesions in South Africa and Kenya." The First UNC Lineberger-CFAR AIDS Malignancy Retreat, Chapel Hill, NC, December 13, 2010
67. "Oncogenic human papillomavirus, the cause of cervical cancer: Epidemiology, Immunology, Vaccinology, and Case Reports." Speakers Training, February 27, 2010; Philadelphia, PA, March 2, 2010
68. "Why are cervical cancer and HPV diseases still running today?" Eurogin, Women Against Cervical Cancer Forum Plenary Session Eurogin, Monaco, February 18, 2010
69. "The Burden of HPV-associated cancers." Eurogin, Monaco, February 18, 2010
70. "HPV in adolescence and young adulthood." Eurogin, Monaco, February 18, 2010
71. "Current Status on Human Papillomavirus Vaccines and Diagnostics for Cervical Cancer Prevention." University of North Carolina, School of Medicine, Obstetrics and Gynecology Grand Rounds, December 9, 2009

72. "Epidemiology of Trichomonas vaginalis." Expert Panel Meeting, Del Mar, California, November 2-4, 2009
73. "Oncogenic Human Papillomavirus: The Cause of Cervical Cancer." Speaker Training, San Diego, California, October 23-25, 2009
74. "Human Papillomavirus Vaccines: Current Status, and Future Prospects for HIV Prevention?" Physician's Research Network, New York City, NY, October 20, 2009
75. "Cervical Cancer Free Initiative." Partnership Against Cervical Cancer, Washington D.C, October 7, 2009
76. "Human papillomavirus vaccines for cervical cancer: Will prevention fulfill the promise?" Gaitherburg, Maryland, September 30, 2009
77. "Public Health Innovations for the Early Detection of HPV Infections and Cervical Neoplasia-Liquid Based Cytology" and "Primary prevention of HPV by Prophylactic Vaccination." lectures video webcasted to the International Congress on Cervical Cancer Prevention in Porto Alegre, Brazil, September 3-5, 2009
78. "The HPV Vaccine: Considering Context." 30th Annual Minority Health Conference, Chapel Hill, North Carolina, February 27, 2009
79. "Human papillomavirus vaccines for cervical cancer: Will prevention fulfill the promise?" Triangle Virology meeting December 22, 2008, North Carolina Biotechnology Center, Research Triangle Park, NC; Cancer Epidemiology Seminar, February 20, 2009
80. "Penile HPV infection and the effect of male circumcision on HPV-associated penile lesions in men from Kenya." Eurogin, Nice, France, November 2008
81. "Performance of the Aptima HPV Assay in ASC-US Specimens." Eurogin, Nice, France, November 2008
82. "Worldwide Distribution of HPV 16-18-6-11 in Various Pathologies of the Female and Male Anogenital Tracts." Eurogin, Nice, France, November 2008
83. "Interactions between HPV and HIV: STIs and HIV shedding, regulation of HPV by HIV, and HPV VLP influence upon HIV." HPV and HIV Disease, Infection and Vaccination, Annecy, France, October 19-21, 2008
84. "HPV Vaccines in Less-Developed Countries: The Promise and Problems." UNC Global Health committee for American Medical Student Association, UNC Chapel Hill, Chapel Hill, NC, April 23, 2008
85. "Vaccination anti-HPV." Scientific Day of Internet, Medical and Pharmacy of Casablanca, presentation given in French, March 14, 2008
86. "Human papillomavirus and Cervical Cancer: Current Ongoing and Planned Research." Virology in Progress, October 19, 2007
87. "Burden of Disease: Epidemiology of Cervical Cancer", GlaxoSmithKline Health Economics Special Issues Board for Cervical Cancer. Atlanta, Georgia, September 29, 2007
88. "Updating current management strategies: the role of genotyping and molecular markers" and "Expected Impact on the Reduction of Cervical Cancer after HPV Vaccination Programs." International Experts Congress on Lower Genital Tract Diseases and Colposcopy, Porto Alegre, Brazil, August 30-31, 2007

89. "Epidemiology of Cervical Cancer." Cervical Cancer Working Expert Panel, Dallas, Texas, June 7-8, 2007
90. "Epidemiology of Cervical Cancer and Burden of Illness – The Economic Impact of Cervical Cancer." Economic Working Expert Panel, Boston, MA, April 26, 2007
91. "HPV Questions and Answers: The HPV Vaccine, Women's Health Week 2007, Many Cultures, Common Grounds." University of North Carolina, Chapel Hill, NC, March 27, 2007
92. "The HPV Vaccine, Cervical Cancer Prevention and the Pap Smear." North Carolina Society of Cytology/Wake Medical Center, Spring 2007 Cytology Seminar, Wake Medical Center, NC, March 24, 2007
93. "Global and regional epidemiology of cervical cancer in Northern Africa and the Middle East." First Annual Oncology Conference, Cairo, Egypt, February 2, 2007; Arab Health Conference, Dubai, United Arab Emirates, January 29, 2007
94. "Cervical Cancer and HPV Vaccine: Global Perspective." Annual Review Meeting 2007, University of Nairobi STD/AIDs Collaborative Group, Nairobi, Kenya, January 24, 2007; University of Nairobi Grand Rounds, January 26, 2007
95. "Rationale and Significance of Human Papillomavirus Typing Study in China." Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China, January 20, 2007
96. "Cervical Cancer: Epidemiology, HPV Oncogenicity, and Global Prevention by Vaccination." UNC Pathology Grand Rounds, Chapel Hill, North Carolina, January 11, 2007
97. "Human Papillomavirus: Global Epidemiology, Typing and Oncogenicity." Gen-Probe, San Diego, CA, December 18, 2006
98. "Cervical Cancer Worldwide: How will HPV Vaccines Play a Role in Prevention?" Cancer Institute, Chinese Academy of Medical Sciences (CICAMS), Beijing, China, November 17, 2006
99. "HPV Vaccines: Overview of Key Research and Implications for Developing Countries" Family Health International, Research Triangle Park, NC, October 25, 2006
100. "Putting on an epidemiologist's hat: a focus on population-based surveys." Cleveland Clinic, Cleveland, Ohio, October 23, 2006
101. "Global Prevention of Cervical Cancer by Vaccination – Will Vaccines Substitute Other Methods of Cervical Cancer Control?" and "Molecular Markers to Improve the Diagnosis of Cervical Carcinogenesis." International Congress of Experts for the Treatment of Genital Tract Infections and Colposcopy, Porto Alegre, Brazil, October 4-6, 2006
102. "Global impact of chlamydia trachomatis infection." 40th Brazilian Congress of Clinical Pathology and Laboratory Medicine, Curitiba, Brazil, September 18, 2006
103. "Introduction to the species of chlamydia, and the clinical significance and epidemiology of Chlamydia Pneumoniae: Introdução às espécies de clamídias, and significância clínica e epidemiologia da Cl. Pneumoniae." Clinical Pre-congress course, 40th Brazilian Congress of Clinical Pathology and Laboratory Medicine, Curitiba, Brazil, September 18, 2006

104. "Human papillomavirus: How do I get infected and how can I protect myself?" Open forum on cervical cancer prevention, International Papillomavirus Conference, Prague, September 7, 2006
105. "A Systematic Review of Human Papillomavirus Persistence and Cervical Neoplasia: Application for clinical endpoints for HPV vaccine clinical trials." World Health Organization, Meeting on the Clinical Outcome and Laboratory Issues related to HPV vaccines, Geneva, Switzerland, August 28-30, 2006
106. "Epidemiology of Human Papillomavirus and Cervical Cancer: Implications for future provision of HPV prophylactic vaccines." Cervical Cancer Working Group for Egypt, Saudi Arabia, Libya and Gulf and Near East Countries, Dubai, June 14-15, 2006; Advisory board for Turkey, June 22, 2006, Istanbul, Turkey; HPV expert Panel for Africa, August 3, 2006
107. "Update on HPV prophylactic vaccines." Center of Disease Control, Kisumu, Kenya office, Kisumu, Kenya, May 18, 2006
108. "Spectrum of HPV related burden of disease." Eurogin 2006, Paris, France, April 2006
109. "Sexually Transmitted Infections: Role as HPV Cofactors in the Etiology of Cervical Cancer." Eurogin 2006, Paris, France, April 2006
110. "Vaccination against Human Papillomavirus." West African College of Surgeons; College Ouest African Des Chirurgiens." 46th Annual Conference, Accra, Ghana, February 4-11, 2006
111. "Epidémiologie des infections à Papilloma Virus Humain (HPV) et cancer du col de l'utérus." University of Washington and GlaxoSmithKline collaborative meeting for future HPV vaccine bridging studies in Hospital Fann, Dakar, Senegal, January 17, 2006
112. "Epidemiology of Human Papillomavirus Infection in Africa." Presentation in French, African Regional Cancer Conference, Dakar, Senegal, November 2005
113. "Epidemiology of HSV-2 and HIV acquisition and transmission." Presentation in French, L'Institut Pasteur, Paris, France, October 26, 2005
114. "Cervical cancer: Epidemiology, HPV typing and oncogenicity." Symposium on Vaccination, a New Tool for Gynecologists for the Prevention of Cervical Cancer 14th International Meeting of the European Society of Gynaecological Oncology." Istanbul, Turkey, September 25-29, 2005
115. "Strategies for HPV vaccine introduction to Africa." Internal Glaxo Smith Kline meeting, Rixensart, Belgium, September 27, 2005
116. "Cervical Cancer - Epidemiology, HPV Typing & Oncogenicity." GSK Cervical Cancer Ad Board, Chicago, Illinois, August 26-28, 2005
117. "Update on HPV prophylactic vaccines." University of Nairobi STDs/AIDS Collaborative Group, Nairobi, Kenya, January 31st, 2005; Department of Clinical Microbiology, University of Szeged, Hungary, June 16, 2005
118. "Current Issues in the Seroindentification and Seroepidemiology of Herpes Simplex Virus Infections." 15th European Congress of Clinical Microbiology and Infectious Diseases, Copenhagen, April 2-5, 2005. Focus Technologies Webex Presentation, Infectious Disease Continuing Education For Laboratory Scientists, May 12, 2005

119. "Current Issues in the Seroidentification and Seroepidemiology of Herpes Simplex Virus Infections." International Union Against Sexually Transmitted Infections, Conference on Sexually Transmitted Infections, Mikonos, Greece, October 8, 2004
120. "Viral Sexually Transmitted Infections: Human Papillomavirus and Herpes Simplex Virus: What's the catch? Women's work in progress meeting." University of North Carolina, Center for Women's Health Research, Chapel Hill, NC, August 3, 2004
121. "HPV and other cofactors in the etiology of invasive cervical cancer." Colegio de Médicos de la Provincia de Buenos Aires Distrito, Conferencia Sobre Cancer Cervical, presentation in Spanish, December 11, 2003
122. "Global Patterns of Herpes Simplex Virus Infections." 8th World STI/AIDS Congress, 40th International Union Against Sexually Transmitted Infections World General Assembly, Punte del Este, Uruguay, December 2-5, 2003
123. "Combined Oral Contraceptives and known cervical intraepithelial lesions." WHO Expert Working Group Meeting to update the Medical Eligibility Criteria for Contraceptive Use, October 22, 2003
124. "The Etiology of Invasive Cervical Cancer: An International Perspective." University of Geneva, Conference sur la Santé reproductive dans les pays en voie de développement, September 18, 2003
125. "Invasive Cervical Cancer, Human Papillomavirus and other Cofactors." University of North Carolina, Chapel Hill, North Carolina, May 23, 2003; Family Health International, May 21, 2003
126. "Epidemiology of Herpes Simplex Virus in Europe and the United States." HSV Symposium: HSV- Looking into the Future, 5th International Eurogin Conference, 2003, Paris, France, April 13-16, 2003
127. "Herpes Simplex Virus Type-2 and Chlamydia Trachomatis Infections as Cofactors in the Etiology of Invasive Cervical Cancer." University of Nairobi STDs/AIDS Collaborative Group, Nairobi, Kenya, January 27, 2003
128. "Human Papillomavirus in Adolescence." Department of Pediatrics, University of California San Francisco, San Francisco, CA, January 16, 2003
129. "Human Papillomavirus and Associated Cofactors in the Etiology of Invasive Cervical Cancer." New York Academy of Medicine, New York, NY, January 9, 2003
130. "Human Papillomavirus Clinical Epidemiology." 12th International Union against Sexually Transmitted Infections, Beijing, China, October 24-27, 2002
131. "Chlamydia, Herpes Simplex Virus, HIV and other Sexually Transmitted Diseases as HPV cofactors in the Etiology of Cervical Cancer." Advisory Group Meeting on Cervical Cancer Studies in EPIC, Barcelona, Spain, May 14-15, 2002
132. "HPV and uterine cervical cancer: prevention prospectives." XXVI Reunion du Groupe pour l'Epidemiologie et L'Enregistrement du Cancer dans les Pays de Langue Latine, presentation given in French, Naples, Italy, May 8, 2002
133. "HPV infection and men: Potential protective effect of male circumcision." National Cancer Institute, Cuernavaca, Mexico, April 11, 2002
134. "Oral contraceptives and cervical cancer: Methods for a Systematic Literature

Review.” Cancer Epidemiology Unit, University of Oxford, Oxford, England, February 25, 2002

135. “Human Papillomavirus Infection in Men: a Potential Protective Effect of Male Circumcision?” University of Nairobi STDs/AIDS Collaborative Group, Nairobi, Kenya, January 30, 2002
136. “The Natural History of Human Papillomavirus Infection and Evidence for HPV Cofactors in the Etiology of Invasive Cervical Cancer.” 6th National Cancer Institute Hospital K, National Cancer Institute, Hanoi, December 8, 2002; Cancer and Genetics Conference, Bangkok, Thailand. December 3-4, 2001; Lampang Hospital, Lampang, Thailand, December 2, 2001; Prince of Songkla University, Songkla, Thailand, November 30, 2001
137. “Chlamydia pneumoniae-biology clinical associations, epidemiology and diagnostic overview.” Chlamydia Workshop, University of Malaya, Kuala Lumpur, Malaysia, August 14, 2001
138. “The Epidemiology of Chlamydia pneumoniae with respect to lung cancer.” Australian Society for Microbiology, Cairns, Australia, July 13, 2000
139. “Epidemiology of Chlamydia pneumoniae infections.” Annual Microbiology Meeting, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, March 22, 2000
140. “Prevalence and Risk Factors for Herpes Simplex Virus II Infections in Brazil.” Herpes Management Forum Satellite Symposium, Salvador, Brazil, September 10, 1999; Rio de Janeiro, September 8, 1999
141. “Investigating Herpes Simplex Virus in the Etiology of Cervical Cancer.” Symposium on Chlamydia and Herpes Simplex Virus Infections, Inselspital, Bern, Switzerland, April 29, 1999
142. “Epidemiology of HPV Infection and Cervical Cancer: A European Perspective.” 3M Consultants Meeting, Amsterdam, the Netherlands, April 17, 1999
143. “Herpes Simplex Virus-2 in the Etiology of Cervical Cancer.” Chlamydia pneumoniae/HSV serology, University of Birmingham, AL, October 13, 1998
144. “Infectious Cofactors of Human Papillomavirus in the Etiology of Cervical Cancer” 3M consultants meeting, Minneapolis, MN, September 14, 1998
145. “Chlamydia Trachomatis and Herpes Simplex Virus-2 in the Etiology of Cervical Cancer.” Clinical Microbiology Conference, London, June 12, 1998
146. “HPV and other STDs in Cervical Cancer: A Worldwide Perspective.” Symposium Chlamydia-Lyme, MRL Forlab, Bruxelles, March 12, 1998

TEACHING RECORD

UNC Class Lectures

Class	Years	Number of Classes	Number of students
<u>Completed</u>			
Vaccine Epidemiology (799C)- primary instructor	2015	13	14
	2016	14	10

Epidemiology. Cancer Epi and Pathogenesis (770)	2016	1	30-40
	2015	1	30-40
	2013	1	30-40
	2012	1	30-40
	2011	1	30-40
	2009	1	20-30
	2008	1	20-30
Global Non-communicable Diseases (PUBH 510), Gillings Global Health	2015	1	30-40
	2014	1	30-40
	2013	1	30-40
	2012	1	30-40
Maternal and Child Health (730) Control of Infectious Diseases in Developing Countries (756)	2010	1	15-20
	2009	1	30-40
	2008	1	30-40
	2007	1	30-40
	2006	1	40-50
	2005	1	40-50
Microbiology: Recent advances in Virology (711)	2009	1	15-20
Perinatal Epidemiology (851)	2016	1	10-15
	2008	1	20-30
	2007	1	20-30
	2006	1	20-30
Epidemiology of Sexually Transmitted Infections (141)	2006	1	20-30
Cancer Prevention and Control, HPAA/HBHE/EPID (290)	2006	1	15-20
	2005		30-40
Epidemiological Research Methods (201)	2004	1	20

Teaching Assistant

“Sexually Transmitted Infections”, Johns Hopkins School of Public Health, 1995-1997

±Indicates primary advisor

PhD Advisor

Current

Committee Chair: Adodele Gomih Alakija±, UNC Department of Epidemiology, September 2014-present

Committee Chair: Jessica Islam±, UNC Department of Epidemiology, September 2014- present

Committee Chair. Nadja Vielot±, UNC Department of Epidemiology, December 2014- present

Nidia Rodriguez±, UNC Department of Epidemiology, September 2015-present

Sinead Isaccson±, UNC Department of Epidemiology, September 2015-present

Jonathan Fix±, UNC Department of Epidemiology, incoming student, September 2016-present

PhD Dissertation Thesis Committees

Student Name	Year Graduated	Dept.	Topic	Role
Jessica Islam	In process	EPI	Assessing clinical validity of cervical cancer self-screening methods	Chair
Nadja Vielot	In process	EPI	Assessing human papillomavirus vaccine safety using commercial insurance claims	Chair
Adodele Gomih Alakija	In process	EPI	The role of HPV, DNA methylation, and other risk factors in the progression of cervical dysplasia	Chair
Kristin Moore	2015	EPI	Sexually transmitted infections and uterine fibroids	Chair
Virginia Senkomago	2013	EPI	Viral Load in penile HPV infections and its association with circumcision in Kenyan Men	Chair
Jie Ting	2013	EPI	Validation of self-collection for HPV detection among high-risk women in Nairobi, Kenya	Chair
Christina Ludema	2013	EPI	Structural models to untangle triggers of ocular/nonocular herpesvirus recurrence	Member
Cicely Michel	2011	BIOS	Semi Markov Multistate Modeling of HPV Infection	Member
Anne Fortino Rositch	2011	EPI	Human papillomavirus type competition and the associations between HPV types and future HPV acquisition in men	Chair
Danielle Backes	2010	EPI	Natural history of human papillomavirus infection among young men from Kisumu, Kenya	Chair
Julius Atashilli	2010	EPI	Cervical Precancerous Lesions in Women Initiating Antiretroviral Therapy in Cameroon: Prevalence, Severity, Predictors and Potential Impact of Screening	Member
Linda Kalalini	2007	EPI	Malaria in Pregnancy and Drug Therapies in Malawi	Member
Suzanne Belinson	2007	EPI	Reproductive health factors as HPV cofactors in the etiology of cervical intra-epithelial lesions in China	Member

Jill Koshiol	2006	EPI	Effect of smoking and human papillomavirus (HPV) type on time to clearance of HPV infection among HIV-seropositive and HIV-seronegative women	Member
--------------	------	-----	---	--------

MPH/MSPH Advisor

Student Name	Year Graduated	Dept.	Title	Reader
Lavanya Gupta	2016	MCH	Understanding reactions to results of a self-sampling HPV test among white and black women infrequently screened for cervical cancer in North Carolina	Secondary Primary
Raquel Burger-Calderon	2015	EPI	Oral health outcomes in relation to time since HIV diagnosis	
Nadja Vielot	2014	EPI	The Role of Sexually Transmitted Infections in High-Risk Human Papillomavirus Persistence among Female Sex Workers	Primary
Ayodele Gomih Alakija	2012	EPI	Risk factors for Mycoplasma genitalium among a cohort of female sex workers in Nairobi, Kenya	Primary
Alicea Mingo	2012	EPI	Cervical Cancer Awareness and Screening in Botswana	Secondary
Christine L. Schuler	2010	EPI	HPV Vaccine and Behavioral Disinhibition	Primary
Sheri Denslow	2010	EPI	Bacterial vaginosis as a risk factor for high-grade cervical lesions and cancer in HIV-seropositive women	Primary
Eric Lofgren	2009	EPI	Herpes Simplex Virus Type-1 Seroprevalence in Lampang and Songkhla, Thailand	Primary
Vinita Goyal	2009	EPI	Uterine Rupture in Mid-Trimester Misoprostol-Induced Abortion after Cesarean Delivery: A Systematic Review	Primary
Yuli Chang	2008	HBHE	Evaluating HPV vaccine effectiveness at the population level	Secondary
Jessica Hughes	2008	HBHE	How are parents of adolescent girls learning about the HPV vaccine	Secondary
Katie Keating	2008	HBHE	Potential barriers to HPV vaccine provision among medical practices in an area with high rates of cervical cancer	Secondary
Karah Fazekas	2007	HBHE	HPV vaccine acceptability among women in the rural South	Secondary
Amy Melendy	2007	EPI	Systematic review on the role of local cervical cytokines on the risk of HPV infection and the development of cervical neoplasia	Primary
Brooke Hoots	2007	EPI	Herpes Simplex virus Type 2 on the progression of HIV infection	Primary

Post-Doctoral Advisor

Student Name	Time Period	Dept.	Mentor Role	Current Position of Past Trainees
Virginia Senkomago	2013-2014	EPI	Primary	Research Fellow Office of International Cancer Control, CDC, Atlanta, GA
Jie Ting	2012-2014	EPI	Primary	Postdoctoral Scholar Biogen Idec Fellowship in Outcomes & Pharmacoeconomic Research, UCSF, San Francisco, CA
Tabatha Offutt-Powell	2011-2012	EPI	Primary	Chief, Data and Informatics Section Division of Public Health, Delaware Health and Social Services, Dover, DE
Danielle Backes	2010-2012	EPI	Primary	Research Associate, Center for Population Health & Clinic Epidemiology, Brown University, Providence, RI
Sheri Denslow	2010-2011	EPI	Primary	Public Health Epidemiologist Mission Hospital, Asheville, NC
Paul Reiter	2009-2010	HBHE	Secondary	Assistant Professor, Ohio State University
Alice Richman	2008-2010	HBHE	Secondary	Associate Professor, East Carolina University

Fogarty Fellowship Advisor, CICAMS, Cancer Center in Beijing

Student Name	Fellowship Period	Current Position of Past Trainees
Margaret Wang	2015-2016	University of Chicago
Hunter Holt	2014-2015	RUSH University Medical Cent
Priya G. Sivasubramaniam	2013-2014	University of Vanderbilt
Irene Chang	2012-2013	University of Miami
Evelyn Hsieh	2012-2013	Yale University, 2012-2013
Gordon Shen	2012-2013	University of Berkeley
Danny Colombara	2011-2012	University of Washington
Adam Lewkowitz	2010-2011	Mont Sinai Medical School
Sarah Tiggelaar	2010-2011	University of Kentucky Medical School
Margaret Lin	2009-2010	University of Washington
Philip Song	2009-2010	Johns Hopkins University
Jia Ji	2008-2009	University of Ohio

PharmD Advisor

Jake Chung, UNC Eshelman School of Pharmacy, 2011-2012

K Award Preparation Faculty Advisory Committee Member

Sylvia Becker-Dreps, UNC Department of Medicine, 2009, Current K award grantee

Assistant Professor Collaborator/Advisor:

Dr. Stephanie Wheeler, Health Policy and Management, 2012-present

Dr. Lisa Rahangdale, Department of Obstetrics and Gynecology, 2009-2012

Adwards won by Advisees

Nidia Rodriguez Ormaza, MD, MPH

2015, James Imhotep Irving Public Service Scholarship, UNC Gillings School of Public Health.

2015, Moulton-Wong Scholarship in Public Health, UNC Gillings School of Public Health.

2015, Gillings Merit award, UNC Gillings School of Global Public Health.

Jessica Y. Islam, MPH

2015, Koch Travel Award, UNC Gillings School of Global Public Health

2014, Student Travel Award, Epidemiology Department, UNC Gillings School of Global Public Health

2014, University Cancer Research Fund Grant, UNC Lineberger Comprehensive Cancer Center

2014, Annual Fund Scholarship, UNC Gillings School of Global Public Health

2014, Mary S. Thompson Scholarship, UNC Gillings School of Global Public Health

Nadja Vielot, MSPH

2015, UNC Lineberger Comprehensive Cancer Center (LCCC) Cancer Outcomes Research Program

Student Travel Award

2015, UNC Gillings Koch Travel Award

2014, Department of Epidemiology Student Travel Award

2013, UNC Gillings Koch Travel Award

Ayodele Gomih, MSPH

2015, Ruth L. Kirschstein National Service Awards for Training in Sexually Transmitted Diseases and HIV (2T32AI007001-39).

2015, Student Travel Award, UNC Department of Epidemiology

Raquel Burger-Calderon, PhD (MPH Track)

2015, ImPACT Award, UNC Training Initiatives in Biomedical and Biological Sciences (TIBBS)

2014, Merit Assistantship Award, UNC Gillings School of Global Public Health

Kristen R. Moore, MSPH

2015, 1st Place Poster Award, Society for Epidemiologic Research Annual Meeting
2015, UNC Department of Epidemiology Travel Award (\$500)
2014, NIEHS Epidemiology Branch Trainee Research Award (~\$100,000)
2013-Present, NIEHS Minority Intramural Research Training Award Fellow
2008-2009, Alpha Lambda Delta Graduate Fellowship
2007-2008, UNC Graduate School Merit Assistantship

Virginia Senkomago, PhD, MPH

2015, International Cancer Screening Network Travel Scholarship, Rotterdam, The Netherlands
2014, Second Place for Poster Presentation, 9th Annual UNC Lineberger Scientific Retreat, NC
2009-2013, Tellus Educational Foundation Doctoral Scholarship, UNC School of Public Health
2012, International Papillomavirus Society Travel Award, San Juan, Puerto Rico
2009, Winstanly Scholarship, UNC School of Public Health

Jie Ting, PhD

2009, International Papillomavirus Travel Award, Malmo, Sweden
2012, Gillings School of Global Public Health Poster Award
2012, UNC Lineberger Poster Award (Clinical/Translational)
2013, Biogen-UCSF Postdoctoral Fellowship in Health Economics and Outcomes Research
2012, Gillings School of Global Public Health Poster Award

Sheri Denslow, PhD, MPH

2009, Gillings School of Global Public Health Travel Award, University of North Carolina

Anne F. Rositch, PhD, MSPH

2013, Young Investigator Award, 20th Conference on Retroviruses and Opportunistic Infections
(CROI), Atlanta, GA
2012, National Cancer Institute Conference Award, 28th International Papillomavirus Society
Conference, San Juan, Puerto Rico
2012, Delta Omega Public Health Honorary Society, Theta Chapter, University of North Carolina
2011, Fogarty Scholar Alumni Fund Award, Fogarty International Center, NIH
2011, Rebecca James Baker Memorial Scholarship, Department of Epidemiology, UNC
2010, Infectious Disease Epidemiology Pre-doctoral Training Fellowship (T32 P.I.: Dr. Steve

Meshnick), University of North Carolina

2012, Cancer Epidemiology Pre-doctoral Training Fellowship (Declined; T32 P.I.: Dr. Andy Olshan),
University of North Carolina

2009, NIH Fogarty International Clinical Research Scholar in Nairobi, Kenya, 2009-2010. “A nested
cohort study on HPV and cervical precancerous lesions among women in HIV-discordant
couples” (Mentors: Drs. Carey Farquhar, Jennifer Smith, and James Kiarie)

2009, Graduate Tuition Incentive Award (full academic scholarship), The Graduate School, UNC

2009, Cancer Control Education Program Pre-doctoral Training Fellowship (Declined; T32 P.I.: Dr.
Michael O’Malley), Lineberger Cancer Center, University of North Carolina

Brooke Hoots, PhD

2011, Impact Award, UNC Graduate School for research of exceptional benefit to North Carolina

2009-11, Infectious Diseases Training Grant, UNC School of Medicine

2007, International Papillomavirus Society Travel Award

Suha Patel, MD

2009, Research Training Fellowship, Medical Students Program, Howard Hughes Medical Institute

Danielle Backes, PhD

2011, Delta Omega

2008, University of North Carolina, Department of Epidemiology, Cancer Training Grant

2006, 2007 IPV Society Travel Award 2006 (Prague Conference), 2007 (Beijing Conference)

Jill Koshiol, PhD

2010, NCI Earl Stadtman (Tenure-Track) Investigator

2008, Scholar-in-Training Award, American Association for Cancer Research, Infection
and Cancer: Biology, Therapeutics, and Prevention Meeting, Hong Kong, China.

2008, DCEG Fellows Award for Research Excellence (FARE) 2008 travel award, NIH,
Bethesda, MD

2008, NIH Group Merit Award for the DCEG Upper Gastrointestinal Tract Cancers
Research Group, NIH, Bethesda, MD

2008, Scholar-in-Training Award, American Association for Cancer Research, Annual
Meeting, San Diego, CA

2008, Fellows Award for Research Excellence (FARE) travel award, NIH, Bethesda, MD

GRANTS

Current

Principal Investigator, “Effect of HPV Self-Collection on Cervical Cancer Screening in High Risk Women” NIH NCI R01 CA183891, 4/1/2015-3/31/2020. \$3,012,099

Principal Investigator, “Improving testing, triage, and follow-up for cervical cancer screening in medically underserved women”, LCCC-NCCU U54, NC CA156735. 9/1/2015-8/31/2018. \$953,500

Co-Investigator, “Evaluating a community-driven cervical cancer prevention model in western Kenya”, RO1 CA188328, NIH via University of California at San Francisco (UNC subcontract), 7/1/2014 – 6/30/2019. \$154,362

Co-Principal Investigator (Sharpless, PI, LCCC), “Cancer Center Core – Enhancing Cervical Cancer Pathology Capacity in Kenya”, Administrative supplement to P30 Cancer Centers Support Grants to Stimulate Collaborative HPV Malignancy Research in Low to Middle-Income Countries, 9/1/2015- 8/31/2016. \$199,999

Principal Investigator, "Validation of a novel low-cost colposcope to improve cervical cancer screening," UNC Lineberger Developmental Funding Program, Tier 1 Pilot, 1/1/2016-12/31/2016, \$50,000.

Principal Investigator, “Self-collection to increase access to cervical cancer screening and reduce health disparities in Kenya”, Gillings Innovation Laboratory, University of North Carolina, Chapel Hill, North Carolina, 1/1/2015-12/31/2016, \$99,991.

Co-Principal Investigator, “Cytology-free POC Cervical Cancer Diagnostics for Global Health”, UH2/3, 9/1/2015-8/31/2020, \$1,373,985.

Pending

Principal Investigator, “Strengthening and Implementing Cervical Cancer Control and Public Health Research in Kenya”, Center for Disease Control, Center for Global Health Extramural Research Program Office, Conducting Public Health Research in Kenya, RFA-GH-16-006. 8/15/2016-8/14/2021, \$11,666,665.

Completed

Co-Investigator (Hoyo, NC State, PI), NCI R01CA142983, “Disparities in cervical cancer precursors and deregulation of imprinted regulatory elements”, NCI via NC State (UNC subcontract) 05/01/14- 04/30/16. \$114,706

Project leader (Sharpless, PI, LCCC), "North Carolina State-Level Partnership to Increase HPV Vaccination for Cancer Prevention", P30CA016086, Administrative supplement for NCI-designated cancer centers to support collaborations with existing state and local coalitions and HPV immunization programs, with a focus on HPV vaccination in pediatric care settings, 9/10/2014 - 01/30/2016, \$149,896

Principal Investigator, "Overcoming barriers to adolescent vaccination: vaccine champions’

perspectives" Merck Corporation, 10/27/2014-10/31/2015. \$168,945

Principal Investigator, "Evaluation of a Self-Screening Cervical Cancer Test by Mail" U54 CA156735 NCCU-LCCC Partnership in Cancer Research, Smith (UNC LCCC), Charles (NCCU), 9/28/2010-08/31/2015. \$791,000

Principal Investigator, "Issues in Implementation of Adolescent Vaccination in Schools" Agency for Healthcare Research & Quality, 9/30/2013-9/29/2014. \$34,984

Principal Investigator, "Opportunities and challenges associated with administering adolescent vaccination within pharmacies in six partner states." Merck Corporation, 11/25/2013-1/24/2015. \$126,046

Principal Investigator, "Multi-Site HPV vaccine acceptability study" GlaxoSmithKline, 5/1/2013-02/15/2015. \$508,761

Principal Investigator, "Cervical cancer demonstration project for self-sampling and dual HPV/cytological testing of Latina women in North Carolina" UNC Lineberger University Cancer Research Fund, 7/1/2012-6/30/2014. \$197,727

Principal Investigator, "Increasing Knowledge and Implementation of Evidence- Based Practices to Increase HPV Vaccination" JBS International, 1/21/2013-9/13/2013. \$10,000.

Co-Investigator (Cole, UNC, PI), "Structural models to untangle triggers of ocular/nonocular herpesvirus recurrence", NIH R21, 9/1/2011-8/31/2013. \$363,511

Principal Investigator, "Cervical Cancer Free Initiative" Four State Initiative to reduce cervical cancer among high-risk women, www.cervicalcancerfreeinitiative.org, Co-Principal Investigator, Noel Brewer, GlaxoSmithKline, 1/1/2010-12/31/2013 \$2,500,000 in Year 1 \$1,000,000 in Year 2, \$241,000 in Year 3.

Principal Investigator, "The Interdisciplinary Cervical Cancer Research Working Group." UNC Center for Global Initiatives, 1/4/2013-7/31/2013. \$4,000

Co-Investigator (Jong, WITS University, South Africa, PI), IRIDA/R01, "The prevalence and natural history of anal dysplasia in HIV-infected men and women" 6/1/2011- 7/31/2013. \$20,000

Principal Investigator, "HPV Natural History in High-risk women in Nairobi, Kenya" Gen-Probe, 4/15/2010-4/14/2013. \$120,235

Principal Investigator, "Effect of Male Circumcision on Penile Human Papillomavirus Infection" Administrative Supplement for R01 CA114773-01, 8/1/2009-7/31/2012. \$301,957

Principal Investigator, "Effect of Male Circumcision on Penile Human Papillomavirus Infection in Men" National Cancer Institute (R01 CA114773-01), 9/12/2005-6/30/2012. \$1,838,875

Principal Investigator, "Study of acceptability of HPV screening using self- collected samples." "Jennifer Smith, Co-PI, Allen Rinas, Co-PI, (Noel Brewer, I), Kate B. Reynolds Foundation, 8/1/2008-1/31/2011 \$250,000

Co-Investigator, “Acceptability of HPV vaccination to prevent anal and oral cancers” Noel Brewer, PI, Merck Corporation, 9/15/2008-9/14/2009 \$103,031

Principal Investigator, Collaborative meta-analyses on HPV research topics for UNC doctoral students, GlaxoSmithKline, 2006-8/2009. \$50,000

Co-Investigator, “Ensuring HPV Vaccine Coverage among Rural and African American Female Adolescents”, Center Disease Control, 10/1/2006- 6/30/2009: \$487,895 (S3715-25/25)

Co-Principal Investigator, “North Carolina Cervical Cancer Outreach Screening Project.” Allen Rinas, PI, American Society of Cytopathology Foundation Patient Advocacy Grant. 10/23/2008. \$5,000.00

Principal Investigator, “SPOOCS-3 Survey of Human Papillomavirus Infection and Cervical Neoplasia in China” Cleveland Clinic Foundation, Merck sponsored study, 7/2006-2/2008. \$50,000

Principal Investigator, “HPV Type-Distribution in Cervical Cancer in China: A Multi-Center Hospital-Based Study” GlaxoSmithKline, 2/1/2007-2/1/2008. \$17,874

Principal Investigator, “Effect of Female Diaphragm on Female Human Papillomavirus Infection and Cervical Neoplasia.” UNC Center for AIDS Research, \$17,730, 2005; University Research Council Research, \$4,000, 2006; UNC Young Faculty Development Award, \$7,500, 2006.

Principal Investigator, “Investigation of the natural history of HPV DNA and cervical neoplasia in a cohort of sex workers in Nairobi, Kenya” GlaxoSmithKline, 12/16/2004-12/15/2006. \$31,546

Co-Investigator, “Investigation of HPV cofactors in the etiology of invasive cervical cancer” World Health Organization Department of Human Reproduction, 9/2004-9/2005. \$66,874

Principal Investigator, “The Shanxi Province Cervical Cancer Screening I Follow- Up Study” UNC Lineberger Comprehensive Cancer Center, University of North Carolina, 2004 \$20,000

Principal Investigator, “International Herpes Seroprevalence Survey” at International Agency for Research on Cancer, GlaxoSmithKline, 2001-2002. \$240,000

Co-Investigator, “Evaluation of HPV cofactors in the etiology of invasive cervical cancer” Rockefeller Foundation, 9/1998-9/1999. \$50,000

Principal Investigator, “International Prevalence Surveys of Sexually Transmitted Infections” World Health Organization Department of Human Reproduction, 1998. \$119,000

Principal Investigator, Research related to HPV and cervical cancer, 3M Pharmaceuticals Unrestricted, 1987-1990. \$105,000

Co-Investigator, “Epidemiologic and Biologic factors associated with cervical dysplasia and cancer” University Research Council small grants program, \$5,000, 2010.

Co-Investigator, “A Cohort Study on the Role of Hormonal Contraception in the Natural History of HPV Infection and CIN Lesions” World Health Organization Department of Human Reproduction, \$80,916, 2002.

SERVICE

University

Fogarty Global Health Fellows Faculty Mentor, Cancer Site, Cancer Institute and Hospital, Chinese Academy of Medical Sciences, Beijing, China, 2008 to present

Epidemiology Admissions Committee, January 2014-present

Protocol Review Committee (PRC), Social Science Review, Lineberger Cancer Center, October 2014-present

Member, the Global and Territorial Health Research Network (GTHRN), January 2015-present

Member, UNC Cancer Prevention and Control Research Network (CPCRN), January 2015-present

Member, UNC-South China STD Research Training Center Organizing Committee, D43, Dr. Tucker, PI (UNC), Guangzhou, China, 2013-present

Mentor, Training in Infectious Disease Epidemiology (TIDE), Meshnick (PI), UNC

Mentor, HIV/STI STD/HIV T32, Miller (PI), UNC

Mentor, the Cancer Control Education Program, UNC Lineberger Comprehensive Cancer Center

Mentor, T32, UNC Global Women’s Health Fellowship, Chi (PI), UNC, 2013-present

Gillings Global Gateway Faculty, 2014-present

Clerkship Elective, UNC School of Medicine, 1 student, Spring 2015

Chair, UNC Working Group on HPV-Associated Cancers, April 2013-present

Affiliate Member, Curriculum in International and Area Studies, Department of Political Science, UNC

Department of Epidemiology Comprehensive Exams: Assisted with Writing and Grading, 2012-3; 2015

National/International

Associate Editor, *Sexually Transmitted Infections*, 2009 to present

Member of the Editorial Board, *Sexually Transmitted Diseases*, 2009 to present

Director, Cervical Cancer Free Coalition, www.cervicalcancerfreecoalition.org
January 2009 to present

Advisory Board Member, Global Coalition Against Cervical Cancer, January 2013- present

Board of Directors, Women Against Cervical Cancer (WACC) International Foundation, April 2011 to present

Pan American Health Organization, Temporary Advisor, HPV -Associated Oropharyngeal Cancer, 7/27-28/2015.

Member of President's Cancer Panel, attended three discussions nationally: July 24, 2012 San Francisco, CA; September 13, 2012: Arlington, VA; November 16, 2012: Chicago, IL; April 23-24, 2013: Miami, FL. and presented on a panel at the AACR meeting in San Diego, April 5-9, 2014

Testified to the FDA Microbiology Devices Panel of the Medical Devices Advisory Committee, Washington, D.C., March 12, 2014

Committee Member of ASHA advisory group on trichomonas infections, March 2013-present
Advisory Committee, Cervical Cancer/HPV Project, California Medical Association Foundation, April 2011 to present

Member of Expert Panel for HPV Prophylactic Vaccines, Kaiser-Permanente USA, June 2006-present

Member, Steering Committee, Preventive Oncology International, Cleveland, Ohio, 2004-present

Specialist Panel Member on Epidemiological Research in Reproductive Health for the World Health Organization Special Programme of Research, Development, and Research Training in Reproduction

Adviser, World Health Organization Expert Working Group to update the Medical Eligibility Criteria for Contraceptive Use

Member, President's Cancer Panel, July 12, 2012; September 12, 2012
Member of the Organizing Committee and Session Chair, Eurogin, Prague, May 2012

Member of the Organizing Committee and Session Chair, 25th International Papillomavirus Conference, Puerto Rico, 2012

California Medical Association Foundation: Cervical Cancer & HPV Project, Advisory Committee Meeting, Sacramento, CA, July 2011

Member of the Organizing Committee and Session Chair, Eurogin, Portugal, May 2011

Economic Work Group Advisory Board, Chicago, Illinois November 16-18, 2010

Chair for Fogarty Global Health Clinical Research Alumni Symposium 2010, “Perspectives and Issues on Human Papillomavirus,” September 2010

HPV Leadership Reception, Montreal International Papillomavirus Meeting, Montreal, Canada, Tuesday, July 18, 2010

Member of the Organizing Committee and Session Chair, 24th International Papillomavirus Conference, Montreal, Canada, July 2010

Member of the Organizing Committee and Session Chair, Eurogin, Monaco, February 2010

Member of the Organizing Committee, Committee Scientifique, PROGIN, France February 2010

Member of the Organizing Committee and Session Chair, 23rd International Papillomavirus Conference, Malmo, Sweden, May 2009

Cervical Cancer Screening Advisory Forum, Chicago, Illinois, May 1-2, 2009

Cervical Cancer Prevention National Advisory Board, New York City, New York April 24-25, 2009

Expert panel meeting on HPV exposure, New York City, New York, March 28-29, 2009

Member of the Organizing Committee and Session Chair, Eurogin, Nice, France, November 2008

Expert Panel Meeting on HPV Diagnostics, Marbella, Spain, Marbella, Spain, March 3-5, 2008

Expert peer review meeting, Human Papillomavirus (HPV) & Genital Cancer Prevention Monograph Program. Regional Reports for Latin America & Asia-Pacific regions, Sitges (Catalonia, Spain), February 7-9, 2008

Co-Guest Editor, *Journal of Adolescent Health*, Supplement on HPV Vaccines, 2008

Member of the Organizing Committee and Session Chair, 22nd International Papillomavirus Conference, Beijing, China, Planned, November 2007

Male Vaccination Expert Working Group, Beijing, China, November 7, 2007

Member of the Organizing Committee, Session Chair, and Session Co-Chair, Eurogin, October 2007

Member of the Organizing Committee and Session Chair, Eurogin, April 2006, October 2007

Burden of Disease: Epidemiology of Cervical Cancer, Health Economics Special Issues Board for Cervical Cancer, invited speaker, Atlanta, Georgia, September 29, 2007

Session Chair, “Up to dating Forum on Precursor Lesions of Cervical Cancer and Colposcopy”, International Experts Congress on Lower Genital Tract Diseases an Colposcopy-2007, Porto Alegre, Brazil, August 30-31, 2007

OB/GYN Publication Advisory Board for Cervical Cancer, Newport Beach, CA, June 15-16, 2007

Cervical Cancer Prevention Advisory Board, Dallas, Texas, June 8-10, 2007

Epidemiology of Cervical Cancer, Cervical Cancer Working Expert Panel, Dallas, Texas, June 7-8, 2007

Economic Working Expert Panel, Boston, MA, April 25-27, 2007

Member of the Organizing Committee and Session Chair, 21st International Papillomavirus Conference, Prague, September 2006

Informal Consultation on Drafting WHO Guidelines to Assure the Quality, Safety, and Efficacy of Recombinant Human Papillomavirus Vaccines, World Health Organization, Geneva, Switzerland, August 28-30, 2006

Gen-Probe Human Papillomavirus Advisory Panel Meeting, San Diego, California, June 23-24, 2005

WHO Technical Consultation on HSV-2 Vaccines, World Health Organization, Geneva, Switzerland, September 5-6, 2002

International Agency for Research on Cancer Monograph on the Evaluation of Carcinogenic Risks to Humans: Smoking and Cancer, International Agency for Research on Cancer, Lyon, France, June 11-18, 2002

WHO Specialist Panel on Epidemiological Research in Reproductive Health, World Health Organization, Geneva, Switzerland, March 12-15, 2002

WHO Workshop on Key Issues in the Design of HPV Vaccine Trials in Developing Countries, World Health Organization, Geneva, Switzerland, November 1, 2001

Session Chair, 19th International Papillomavirus Conference, Florianopolis, Brazil, September 2001

International Course on Infections that Increase the Risk of Cancer, International Agency for Research on Cancer, Foundation Marcel Merieux, Veyrier-du-Lac, France, attendee, December 13-18, 1998, and April 20-22, 2001

WHO Consultation of Cervical Cancer Screening, World Health Organization, Geneva,

Switzerland, March 27-30, 2001

IARC Monograph on the Evaluation of Carcinogenic Risks to Humans: Hormonal Contraception and Post-Menopausal Hormonal Therapy, Lyon, France, June 2-9, 1999

Grant Review

Spring 2016 LCCC Developmental Award Review Meeting, June 8, 2016, UNC Lineberger Cancer Center

SIP 16-005 Health Promotion and Disease Prevention Centers: Special Interest Project Competitive Supplements: Multi-Level Communication Strategies to Promote Human Papillomavirus (HPV) Vaccination Uptake, April 19, 2016.

NCI Community-Level Health Promotion (CLHP) Study Section, Bethesda, Maryland, October 19-20, 2015.

NIH Grant Review NCI Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) – Revision to Enhance the Collection of Cervical Cancer Screening Data (U54), March 26, 2014

NIH Grant Review, IRAP study section, Population Sciences and Epidemiology (PSE) Integrated Review Group Center for Scientific Review, February 19, 2014

Pennsylvania Final Performance Review, January 2013

Gates Foundation, Global Health Program, Neglected Infectious Diseases, July 2012

Health and Health Services Research Fund of the Food and Health Bureau under the Hong Kong SAR Government, February 2012

HPV Vaccine Trial Special Emphasis Panel, Special Review and Logistics Branch, Division of Extramural Activities, National Cancer Institute, by teleconference, December 2011

Infectious Diseases, Reproductive Health, Asthma and Pulmonary Conditions Study Section, 2010/01 IRAP, Chicago, Illinois, June 3-4, 2010

Infectious Diseases, Reproductive Health, Asthma and Pulmonary Conditions Study Section, 2010/01 IRAP, Baltimore, MD, October 1-2, 2009

NIH Revision Application Review 2010/01 ZRG1 PSE-A (95), Baltimore, MD, October 1, 2009

Challenge Grants, American Recovery & Reinvestment Act of 2009 (ARRA) funding opportunities National Institutes of Health, June 2009

National Institute of Allergy and Infectious Diseases Special Emphasis Panel National Institute of Allergy and Infectious Diseases ZAI1 MMT-M (M1), U19 grant applications RFA-AI-08-004, Sexually Transmitted Infections Cooperative Research Centers, March 3-5, 2009

Epidemiology and Genetics of Cancer, 2008/10 Council ZRG1 HOP-T 02 M, May 16, 2008

CDC Grants for Public Health Dissertation Research (R36) peer review panel, July 25-26, 2007

Reviewer for Professional Journals

Member of Editorial Board:

Sexually Transmitted Infections (2004:1, 2008:1, 2009:1, 2012:1, 2013:2; 2014:4; Associate Editor 2009-present)

Sexually Transmitted Diseases (2005:3, 2006:1, 2007:2, 2008:2, 2009:8, 2010:3, 2011:10, 2012:9, 2013:4; 2014:4; Member of Editorial Board 2009-present)

Journal reviewer:

American Journal of Preventive Medicine (2011:1)

Biomedical Central Infectious Diseases: (2006:1, 2007:1, 2009:1)

British Journal of Cancer (2004:1)

Cancer Research (2006:1)

Cancer Epidemiology Biomarkers and Prevention (2006:1, 2008:2)

Epidemiology (2003:1; 2015:1)

Journal of Adolescent Health (2009:1, 2011:1)

Journal of Clinical Virology (2009:1, 2010:1)

Journal of the American Medical Foundation (2006:1)

Journal of Infectious Diseases (2003:1, 2007:1, 2009:1, 2012:1; 2014:1)

Journal of Medical Economics (2008:1)

Journal of the National Cancer Institute: (2012:1; 2013:1; 2014:1)

Infectious Diseases in Obstetrics and Gynecology (2011:1)

International Journal of Cancer (2003:2, 2004:6, 2005:4, 2006:9, 2007:1, 2008:5, 2009:2, 2010:1, 2011:1, 2012:3, 2013:1; 2014:1; 2015:1)

PLoS One (2012:1; 2014:1)

Vaccine (2008:1)